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Abstract 
 
Guanylate binding proteins (GBPs) are large GTPases that are substantially 
upregulated by interferons during infection. The human genome consists of seven 
GBP family members with high sequence identity. GBPs have been implicated to 
confer host resistance to a number of pathogens across several species. In mice, 
specific GBP family members are responsible for host defence mechanisms, 
including the induction of inflammasome responses during bacterial infections, and 
the disruption of pathogen vacuoles leading to effective protection against the 
parasite Toxoplasma gondii, and the bacteria Salmonella enterica typhimurium and 
Chlamydia trachomatis. Toxoplasma is an apicomplexan intracellular parasite that 
resides within a parasitophorous vacuole (PV), and can cause severe 
complications and even death in humans and other animals. The aim of this project 
was to analyse the characteristics and roles of individual human GBP family 
members in cells at steady state and in Toxoplasma infected cells. The first step 
was to develop tools to study the proteins, including producing and characterising 
specific antibodies, establishing cell overexpression systems and characterising 
cells deficient in certain GBPs. Using these tools, the subcellular localisations of 
GBP1 and GBP4 were determined to the cytoplasm and nucleus respectively. It 
was concluded that during type I and II Toxoplasma infection GBP1 and 4 are not 
recruited to the PV like in the mouse. Despite this, in human epithelial cells, GBP1 
plays an important and specific role in the restriction of Toxoplasma replication. It 
was deduced that GBP4 protein levels are dramatically reduced during infection 
with the type I, but not the type II strain of Toxoplasma. GBP4 protein levels could 
be stabilised during type I Toxoplasma infection with an inhibitor of cysteine, serine 
and threonine proteases. Using an antibody specific for GBP1 and 2, a large 
dataset of potential interaction partners in a Toxoplasma strain-specific fashion was 
generated. The tools produced, specifically the GBP-specific antibodies, provide a 
valuable resource that can be used by other lab members and collaborators to 
more fully understand the functions of these interesting and important large 
GTPases.   
 
 4 
 
Acknowledgements 
 
First and foremost I would like to thank Eva Frickel, for giving me the opportunity to 
work on this project. Even though I was straight from my undergraduate degree, 
she trusted me with a brand new project, and I hope her trust has been rewarded 
over the course of my PhD. She allowed me to work independently and to find my 
own way, but gave help and advice generously when it was needed.  
 Thank you to Drs Fiona Tomley and Avinash Shenoy for taking the time to 
study my thesis and examine me on the contents. We were able to spark 
interesting discussion and I enjoyed the debate. I am glad I was able to defend my 
work and achieve my award. 
I would like to acknowledge next the other Frickel lab members, both past 
and present. The hours of discussions, troubleshooting and conversations were 
greatly appreciated, and I hope I was able to help you all out as much as you 
helped me. With regards to lab members, I need to specifically highlight Barbara 
Clough, who worked with me from day one to teach me everything I know. Every 
single piece of help and guidance, and every cup of tea were hugely appreciated- I 
couldn’t have done it without you. I want to thank my thesis committee- Tony 
Holder, Andreas Wack and Greg Elgar who provided so much valuable advice and 
who helped keep my project on track over all these years. I also want to 
acknowledge the Medical Research Council, who funded my four years and 
allowed me to have such a productive project. 
The Francis Crick Institute (formally the National Institute for Medical 
Research) is a truly excellent place to work. I am so lucky to have been surrounded 
with the best scientists who have added richly to my work throughout, and whom I 
would like to thank. The Microscopy Facility at Francis Crick, Kate Sullivan and 
Donald Bell who were always around to train me up and to help with the numerous 
emergencies. To Annemarthe van der Veen, who provided the reagents required 
for viral transduction techniques along with invaluable advice. To Jason Mercer, for 
the help with the Vaccinia viral protein overexpression system (and the excellent 
chef skills on lab retreat). Bram Snijders and Vesela Encheva, for running the mass 
spectrometry analysis and providing me with everything I needed to take it to the 
next step. The Flow cytometry facility, without whom I could not have done my 
 5 
 
invasion assays. To Rachel Chung and Alana Sargent who kept everything running 
smoothly. To David Bacon for the word-processing training, without whom this 
thesis would be hand-written with the figures glued in. To everyone in the (former) 
Parasitology division and everyone who joined me in all the seminars over the 
years, where I learnt so much. I would like to add thanks to Jörn Coers and his lab 
at Duke University, who we worked with to generate tools and with whom we 
published the GBP1 paper in Cellular Microbiology. 
I want to thank Rachel Lawrence, my first ever mentor. Without her I would 
not have gained the knowledge or enthusiasm on which to base my post-grad 
career and I would not have been so fortunate to claim my place in the Frickel lab.  
I need to say thank you to my nearest and dearest. To my family, who have 
supported me in every way during this project- my wonderful parents who inspire 
me everyday to be the best that I can. To all my siblings and siblings-in-law who 
have always presented someone to look up to and aspirations to reach towards - 
particularly Alistair who has provided me with a home over all these years. To my 
friends (you all know who you are!) who have suffered my whinging and 
complaining- with whom I have celebrated and commiserated in equal measures. I 
look forward to having more time to spend with you all! 
Last, and most certainly not least, I want to thank my Luke Moss. You have 
been there to push me to keep working when I could do more, and to tell me to 
sleep when no more work could be done. You have been my rock, ensuring that 
I’m fed and kept in clean clothes while working and writing. Your calmness and 
reason kept me grounded through this whole process, I couldn’t have done it 
without you. 
 
 6 
 
Table of Contents 
 
Abstract ................................................................................................................ 3	  
Acknowledgements ............................................................................................. 4	  
Table of Contents ................................................................................................. 6	  
Table of figures .................................................................................................... 8	  
List of tables ...................................................................................................... 10	  
Abbreviations .................................................................................................... 11	  
Chapter 1.	   Introduction .................................................................................. 13	  
1.1	   IFNγ driven host response ................................................................... 13	  
1.2	   Guanylate Binding Proteins ................................................................. 13	  
1.2.1	   GBP discovery .................................................................................. 14	  
1.2.2	   GBP structure and biophysical properties ......................................... 15	  
1.2.3	   GBPs as host defence proteins ........................................................ 17	  
1.3	   Toxoplasma gondii ............................................................................... 18	  
1.3.1	   Toxoplasma characteristics and lifecycle .......................................... 18	  
1.3.2	   Host responses against Toxoplasma ................................................ 23	  
1.3.3	   IFNγ effector mechanisms against Toxoplasma ............................... 25	  
1.3.4	   Toxoplasma and GBPs ..................................................................... 27	  
1.4	   GBPs, bacteria and the inflammasome ............................................... 28	  
1.5	   The aim of this thesis ........................................................................... 30	  
Chapter 2.	   Materials & Methods .................................................................... 32	  
2.1	   Tissue Culture ....................................................................................... 32	  
2.1.1	   Cell culture ........................................................................................ 32	  
2.1.2	   Culture of Toxoplasma gondii ........................................................... 33	  
2.1.3	   Infection of cells with Toxoplasma gondii ......................................... 33	  
2.1.4	   Toxoplasma irradiation ...................................................................... 33	  
2.2	   Protein Biochemistry ............................................................................ 33	  
2.2.1	   Cell lysis ............................................................................................ 33	  
2.2.2	   SDS-PAGE and Immunoblot ............................................................. 34	  
2.2.3	   Immunoprecipitation .......................................................................... 35	  
2.2.4	   Immunofluorescence ......................................................................... 35	  
2.2.5	   Confocal microscopy and image analysis ......................................... 36	  
2.2.6	   Subcellular fractionation .................................................................... 36	  
2.2.7	   Protein degradation inhibition ........................................................... 37	  
2.3	   Overexpression and cell cloning ......................................................... 38	  
2.3.1	   Cell transfection with TransIT 2020 .................................................. 38	  
2.3.2	   Cell transfection with FuGeneHD ...................................................... 38	  
2.3.3	   Generation of TAP, mCherry and GFP tagged constructs for GBP 
overexpression ............................................................................................ 38	  
2.3.4	   GeneSwitch driven overexpression of GBPs .................................... 39	  
2.3.5	   Vaccinia virus driven overexpression of GFP-GBP4 ........................ 40	  
2.3.6	   Inducible lentiviral driven overexpression of GFP-GBP4 .................. 40	  
2.4	   Antibody production ............................................................................. 41	  
2.4.1	   Antigenic peptide design for antibody production ............................. 41	  
2.5	   Toxoplasma/ Host interaction assays ................................................. 42	  
2.5.1	   FACS for invasion assay ................................................................... 42	  
 7 
 
2.5.2	   Plaque assay .................................................................................... 43	  
2.5.3	   Assessing parasite vacuolar replication ............................................ 43	  
2.5.4	   Statistical analysis ............................................................................. 44	  
Chapter 3.	   Generation and characterisation of molecular tools and 
techniques to study hGBPs ............................................................................. 45	  
3.1	   Results ................................................................................................... 45	  
3.1.1	   Generation and characterisation of molecular tools and techniques 
to study hGBPs ............................................................................................ 45	  
3.1.1	   Overexpression of human GBPs in mammalian cells ....................... 60	  
3.1.2	   Optimisation of techniques to evaluate Toxoplasma infection 
characteristics .............................................................................................. 68	  
3.2	   Discussion ............................................................................................. 71	  
3.2.1	   Tool characterisation ......................................................................... 71	  
3.2.2	   Optimisation of experiments ............................................................. 79	  
Chapter 4.	   The impact of human Guanylate Binding Proteins on 
Toxoplasma gondii infection ........................................................................... 82	  
4.1	   Results ................................................................................................... 82	  
4.1.1	   GBP1 ................................................................................................ 82	  
4.1.2	   GBP4 ................................................................................................ 92	  
4.2	   Discussion ........................................................................................... 100	  
Chapter 5.	   Results gathered to be used for continuation of GBP work in 
the Frickel Lab ................................................................................................. 119	  
5.1	   Results ................................................................................................. 119	  
5.1.1	   Protein interaction partners of GBP2 .............................................. 119	  
5.2	   Discussion ........................................................................................... 125	  
Chapter 6.	   Conclusion ................................................................................. 129	  
Chapter 7.	   Appendix .................................................................................... 130	  
Chapter 8.	   Publications ............................................................................... 141	  
Rights and Permissions ................................................................................. 150	  
Reference List ................................................................................................. 162	  
 8 
 
Table of figures 
 
Figure 1 Tertiary Structure of GBP1 ....................................................................... 16	  
Figure 2 Genomic arrangements of GBPs ............................................................. 17	  
Figure 3 Lifecycle and hosts of Toxoplasma .......................................................... 21	  
Figure 4 Mouse GBP dependent induction of inflammasome responses ............... 30	  
Figure 5 Alignment of GBP C-termini and peptides for antibody production .......... 47	  
Figure 6 Characterisation of anti-GBP1 polyclonal antibody .................................. 56	  
Figure 7 GBP2 antibody characterisation ............................................................... 58	  
Figure 8 GBP4 antibody characterisation ............................................................... 59	  
Figure 9 pan-GBP antibody characterisation .......................................................... 60	  
Figure 10 Expression of GBP1, 2 and 4 in A549 cells ............................................ 65	  
Figure 11 Expression of GBP1, 2 and 4 in THP-1 macrophages ........................... 66	  
Figure 12 Characterisation of ∆GBP1 cells ............................................................ 67	  
Figure 13 Invasion capacity of Toxoplasma in A549 cells ...................................... 68	  
Figure 14 Replication of Toxoplasma in A549 cells ................................................ 69	  
Figure 15 Indirect plaque assay showing Toxoplasma survival in A549 cells ........ 70	  
Figure 16 GBP1 is a cytoplasmically localised protein ........................................... 83	  
Figure 17 GBP1 does not recruit to the Toxoplasma parasitophorous vacuole in 
A549 cells ............................................................................................................... 85	  
Figure 18 GBP1 does not recruit to the Toxoplasma parasitophorous vacuole in 
THP-1 macrophages .............................................................................................. 86	  
Figure 19 GBP1 can restrict the growth of type II Toxoplasma in A549 cells, but not 
type I ....................................................................................................................... 88	  
Figure 20 Complementation of GBP1 rescues control of Toxoplasma growth ....... 89	  
Figure 21 Invasion capacity of Toxoplasma in the absence of GBP1 .................... 91	  
Figure 22 GBP1 restricts replication of Toxoplasma in A549 cells ......................... 92	  
Figure 23 GBP4 is a nuclear protein in THP-1 macrophages ................................ 93	  
Figure 24 Type-I, but not type-II Toxoplasma alters protein expression of GBP4 in 
THP-1 macrophages .............................................................................................. 94	  
Figure 25 Effect of increasing type I Toxoplasma MOI on GBP4 protein expression
 ................................................................................................................................ 95	  
Figure 26 Density of GBP4 protein bands .............................................................. 96	  
 9 
 
Figure 27 GBP4 is not recruited to the PV of Toxoplasma, and protein expression is 
lost during infection with type I parasites ................................................................ 97	  
Figure 28 Staining of GBP4 protein is lost across the cell population upon infection 
with type I Toxoplasma but not type II .................................................................... 98	  
Figure 29 GBP4 protein can be accumulated by using protein degradation inhibitors
 .............................................................................................................................. 100	  
Figure 30 Predicted nuclear localisation signals within GBP4 amino acid sequence
 .............................................................................................................................. 110	  
Figure 31 The phylogenetic tree showing distribution of GBP family members ... 113	  
Figure 32 mCherry-C1 vector map ....................................................................... 133	  
Figure 33 eGFP-C1 vector map ........................................................................... 134	  
Figure 34 pGene vector map ................................................................................ 135	  
Figure 35 pJS4 vector map .................................................................................. 136	  
Figure 36 pLVX-Tight-Puro vector map ................................................................ 137	  
 
 10 
 
List of tables 
 
Table 1 Protein degradation inhibitors .................................................................... 37	  
Table 2 Screening of polyclonal antibody sera for specific bands in immunoblot .. 48	  
Table 3 Candidates for monoclonal GBP2 antibody production from fusion of 
mouse ‘R’ ................................................................................................................ 49	  
Table 4 Candidates for monoclonal GBP2 antibody production from fusion of mice 
'V' and 'N' ................................................................................................................ 51	  
Table 5 Candidates for monoclonal GBP4 antibody production from fusion of 
mouse 'N' ................................................................................................................ 53	  
Table 6 Candidates for monoclonal GBP4 antibody production from fusion of 
mouse 'R' ................................................................................................................ 54	  
Table 7 Protein interaction candidates for GBP1 and 2 identified in a Toxoplasma 
strain-dependent manner ..................................................................................... 123	  
Table 8 Protein interaction candidates of GBP1 and 2 that implicate roles in 
translation. ............................................................................................................ 124	  
Table 9 Primer lists for GBP cloning ..................................................................... 130	  
Table 10 PCR Amplification of GBP4 for C1/ pcDNA3/ pGene vectors ............... 131	  
Table 11 PCR amplification of GBP4 for pJS4 and pLVX-Tight-Puro .................. 132	  
Table 12 Peptide sequences for polyclonal antibody production ......................... 138	  
Table 13 Peptide sequences for monoclonal antibody production ....................... 138	  
Table 14 GBP antibodies produced ...................................................................... 139	  
 
 11 
 
 Abbreviations 
 
AIM2   Absent in melanoma 2 protein 
ALR   Absent in melanoma 2-like receptor 
Atg3   Autophagy protein 3 
Atg5   Autophagy protein 5 
Bcl-2   B cell lymphoma 2 
BID   BH3 interacting-domain death agonist 
BMDM  Bone marrow-derived macrophage 
DAMPs  Danger-associated molecular patterns 
DC   Dendritic cell 
DMEM  Dulbecco’s modified Eagle medium 
ELISA   Enzyme-linked immunosorbent assay 
FBS   Foetal bovine serum 
GAP   GTPase activating protein 
GBP   Guanylate Binding Protein  
GKS   Glycine-Leucine-Serine 
GRA15  Dense granule protein 15 
GTP   Guanosine triphosphate 
HAP1   Human haploid cell  
HFF   Human foreskin fibroblasts 
HUVEC  Human umbilical vein endothelial cell 
IDO   Indolamine-2,3-dioxygenase 
IFN   Interferon  
IFNγ    Interferon-gamma 
IL-12   Interleukin-12 
IL-1β   Interleukin-1-beta 
iPSCs   Induced pluripotent stem cells 
IRF1   Interferon regulating factor 1 
IRG   Immunity related GTPases 
IRGM   Immunity related GTPase family M 
LPS   Lipopolysaccharide 
MEF   Mouse embryonic fibroblast 
 12 
 
mGBP   Murine guanylate binding protein 
MOI   Multiplicity of infection 
MVP   Major vault protein 
Mx   Myxovirus resistant protein 
NK   Natural killer 
NKG2D  Natural-killer group 2 member D protein 
NLR Nucleotide-binding domain, leucine rich repeat containing 
receptor 
NO   Nitric oxide 
PAMPs  Pathogen-associated molecular patterns 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PCV   Pathogen-containing vacuole 
PFA   Paraformaldehyde  
PIKE   PI-3Kinase Enhancer 
PMA   Phorbol myristate 
Pru   Prugniaud 
PV   Parasitophorous vacuole 
RFLP   Restriction fragment length polymorphism 
ROP16  Rhoptry protein 16 
ROP18  Rhoptry protein 18 
RPMI   Roswell Park Memorial Institute 
RRBP1  Ribosome binding protein 1 
SDS-PAGE  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
TAE   Tris-acetate-EDTA 
TLR   Toll-like receptor 
TMEM109  Transmembrane protein 109 
TMEM214  Transmembrane protein 214 
TMEM33  Transmembrane protein 33 
TNFα   Tumour necrosis factor-alpha 
VMA21  Vacuolar ATPase assembly integral membrane protein 21 
Introduction 
13 
 
Chapter 1. Introduction 
1.1 IFNγ driven host response 
Interferons are cytokines made in and secreted from host cells in response to a 
vast array of pathogens. They play a vital role in inhibiting the replication and 
spread of viral, bacterial and parasitic pathogens (de Veer et al., 2001). It is now 
also clear that they play much wider roles encompassing the regulation of cell 
proliferation, differentiation, survival and death (Samarajiwa et al., 2009).  
 There are 3 types of interferons, types I, II and III. All three types are 
responsible for activating multiple signal pathways that in turn lead to 
transcriptional activation of many interferon regulated genes (Samarajiwa et al., 
2009). As a result, mice with an interrupted receptor for type I or type II interferons 
are exceptionally susceptible to viral infections and exhibit multiple defects in host 
defence (de Veer et al., 2001).  
There is much debate and uncertainty over how many genes are 
upregulated by interferons, with estimates ranging from 500 genes (Boehm et al., 
1997) to >1300 genes by IFNγ alone (MacMicking, 2004). But it is certain that of 
the genes upregulated by these cytokines, only a tiny fraction of their protein 
products have been identified and characterised.  
1.2 Guanylate Binding Proteins 
In 1983, Cheng et al. treated human fibroblasts with interferons and analysed the 
proteins that were synthesised. They identified a protein that could bind guanylate 
agarose columns. This 67kDa protein was induced in both human and mouse 
fibroblasts, and could not be detected in unstimulated cells (Cheng et al., 1983). 
The same group went on to identify at least two genes encoding the 67kDa IFNγ-
induced protein. Furthermore they show that one of these ‘Guanylate Binding 
Proteins’ (GBPs) had the capacity to bind GMP as well as GDP and GTP, likely 
due to a missing N(T)KXD consensus motif that would confer guanine specificity 
(Cheng et al., 1991).  As a result, GBP1 was identified as a GTPase that converts 
GTP to GMP, a unique characteristic among GTPases. 
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1.2.1 GBP discovery 
As characterisation of GBP1 continued, sequence analysis of GBP1 determined 
that it could be isoprenylated (Nantais et al., 1996). Isoprenylation of a protein 
involves the attachment of a farnesyl or geranyl-geranyl lipid moiety to a C-terminal 
CaaX motif. This addition is important in targeting proteins to intracellular 
membranes or for facilitating protein/protein interactions. In the case of GBP1, a 
farnesyl modification was identified when a decrease in incorporation of [3H]-
mevalonate was observed upon addition of a farnesyl transferase inhibitor (Nantais 
et al., 1996). Isoprenylation of GBP1 enables its localisation to the Golgi apparatus, 
but only in the presence of IFNγ and when aluminum fluoride is added to mimic the 
GTP bound state (Modiano et al., 2005).  
 During the study mapping GBP1 to chromosome 1, a large number of 
bands were recognised on a Southern blot using a GBP1 cDNA probe - indicating 
that there were other closely related genes to be discovered (Strehlow et al., 1994), 
and so began the search for more GBP family members. 
GBPs 2, 3 and 4 were identified (Strehlow et al., 1994, Luan et al., 2002, 
Olszewski et al., 2006) and found to have a strikingly high level of identity to GBP1 
(77%, 88% and 56% respectively). GBP2 was shown to have an isoprenylation site, 
although this time it was a geranyl-geranyl motif (Britzen-Laurent et al., 2010). A 
further protein with very high homology to the known GBPs was discovered, and 
was defined as GBP5. This family member had the ability to be transcribed into at 
least 3 splice variants, from which 2 different proteins were produced. GBP5 was 
also found to be isoprenylated with a geranyl-geranyl motif (Vestal and Jeyaratnam, 
2011). Interestingly, one of the GBP5 splice variants is tumour-specific and is 
truncated by 97 amino acids at the C-terminus, losing its isoprenylation motif 
(Fellenberg et al., 2004, Wehner and Herrmann, 2010). In 2006 all of the human 
GBPs currently known were finally identified, defining seven GBPs and one 
pseudogene to be present (Olszewski et al., 2006). All seven members are highly 
similar and are located on chromosome 1 (Boehm et al., 1997), however they are 
induced differentially. GBPs 1, 2 and 3 are upregulated in endothelial cells by IFNγ, 
tumour necrosis factor-alpha (TNFα) and interleukin-1-Beta (IL-1β), whereas GBPs 
4 and 5 are upregulated only by IFNγ. These cells did not express GBPs 6 or 7 
(Guenzi et al., 2001, Tripal et al., 2007). The same study looked at the subcellular 
Introduction 
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localisation of GBPs 1-5 by overexpression of fluorescently tagged proteins. GBPs 
1, 3 and 5 were shown to have a cytoplasmic localisation, and GBPs 2 and 4 
appeared nucleocytoplasmic. Although the GBPs show such a remarkably high 
identity to one another, these differences in induction and localisation indicate that 
they might have different cellular functions (Tripal et al., 2007).  
 
1.2.2 GBP structure and biophysical properties 
The biochemical and biophysical properties of GBP1 have been much studied over 
the last 3 decades. In 2004, the residues that were crucial for nucleotide binding 
and for cooperative GTP hydrolysis were determined (Praefcke et al., 2004). On 
this basis, point mutants were produced that could mimic GBP1 in either its 
nucleotide free form (K51A) or in its GTP bound form (R48A) (Praefcke et al., 
2004).  An external GTPase activating protein (GAP) is not required, as GBP1 
contains an internal GAP (Abdullah et al., 2009). Consequently, as the 
concentration of GBP1 increases, a higher specific GTP hydrolysis activity occurs, 
with the protein forming homo-oligomers which in turn leads to catalytic activation 
of the GTPase (Kunzelmann et al., 2005). The G-domain of GBP1 can cleave GDP 
directly, which leads to a conformational change, positioning the protein in order to 
cleave GDP (Ghosh et al., 2006) thus allowing the unique ability to hydrolyse GTP 
to GMP. 
The crystal structure of full length GBP1 was solved in 2000 (Prakash et al., 
2000). It was seen that the N-terminal 278 residues consisted of a modified G-
domain (Figure 1). The C-terminal was found to form an extended helical domain 
that also has unique features, comprising two three-helix bundles, the core of which 
was formed by hydrophobic residues that are connected by only one hydrogen 
bond and instead is stabilised by water-mediated contacts (Prakash et al., 2000). 
The structure clearly implicated GBP1 as part of the same large-GTPase group that 
includes Mx-proteins and dynamin, and from this it was suggested GBP1 had the 
ability to form oligomers. 
Introduction 
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Figure 1 Tertiary Structure of GBP1 
Structure of human guanylate binding protein 1 representing a unique class of 
GTP-binding proteins, (Prakash et al., 2000), Nature 403, 567-571. 
 
Oligomerisation of proteins can regulate their subcellular localisation. 
Britzen-Laurent et al. showed that GBPs do homodimerise in vivo and that 
membrane association of the isoprenylated family members is a dependent factor 
(Britzen-Laurent et al., 2010). The K51A mutant, which represents nucleotide free 
GBP1, was not able to form dimers in vitro, indicating that GTP binding is required 
for this characteristic. The dimerisation and substrate binding occurs quickly with a 
rapid burst of phosphate ions before a steady state stage is reached. It is thought 
that the irreversible dissociation of the substrate acts as a rate-limiting step 
(Kunzelmann et al., 2005). Furthermore, GBP1 is not able to produce GMP if 
dimerisation does not take place, showing the allosteric step required is triggered 
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by dimerisation (Abdullah et al., 2010). Moreover, GBPs can heterodimerise in vivo 
in a hierarchical manner, resulting in the potential for membrane association of 
non-prenylated GBPs (Britzen-Laurent et al., 2010). The identification and 
characterisation of 11 murine GBPs (mGBPs) and 2 pseudogenes (Staeheli et al., 
1984, Vestal et al., 1998, Han et al., 1998, Anderson et al., 1999b, Nguyen et al., 
2002, Olszewski et al., 2006, Degrandi et al., 2007, Konermann et al., 2007) 
demonstrated that there was a high level of similarity between the human and the 
murine GBPs and showed that the proteins are well conserved across species 
(Degrandi et al., 2007). The mGBPs are found in clusters over two chromosomes, 
chromosome 3 containing mGBPs 1, 2, 3, 5, 7 and chromosome 5 containing 
mGBPs 4, 6, 8, 9, 10 and 11 (Kresse et al., 2008) (Figure 2). 
 
 
Figure 2 Genomic arrangements of GBPs 
Schematic representation of the genomic arrangement of human and mouse 
GBPs. Red box denotes presumed pseudogenes. Yellow box denotes genes 
unrelated to GBPs. Adapted from (Shenoy et al., 2007), Immunobiology Volume 
212, Issues 9–10. 
 
1.2.3 GBPs as host defence proteins  
The fact that these proteins are well conserved and are so highly upregulated in 
response to inflammatory cytokines would hint at a function involved in host 
response to pathogens. In both human and mouse, there is evidence that GBPs 
play an anti-viral role. Expression of GBP1 resulted in lower titres and reduced viral 
progeny of vesicular-stomatitis-virus and encephalomyocarditis virus in human cells 
(Anderson et al., 1999a). Restriction of the same two viruses was shown by 
mGBP2, the closest ortholog to human GBP1 (Carter et al., 2005). In 2007, 
Degrandi et al. characterised the molecular functions of mGBPs 1-10 (Degrandi et 
Introduction 
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al., 2007). C57Bl/6 mice were infected with either Listeria monocytogenes or 
Toxoplasma gondii before levels of mGBP induction were measured by either real 
time-PCR or mRNA expression patterns as detected on a gene chip array. All 
mGBPs were induced in vivo by these infections. Furthermore, the study defined 
the subcellular localisation of these GTPases during infection with Toxoplasma 
gondii. Interestingly, they showed that the parasitophorous vacuoles (PVs) of a 
strain of Toxoplasma considered to be non-virulent in mice were decorated with 
mGBPs 1, 2, 3, 6, 7 and 9 from just 30 minutes post infection in IFNγ-stimulated 
cells. Furthermore, infection with a virulent strain of Toxoplasma resulted in barely 
any mGBP decoration of the PVs (Degrandi et al., 2007). Human GBPs were also 
recruited to the PV, although in much lower amounts (Ohshima et al., 2014). The 
recruitment of GBPs to the PV of Toxoplasma in a virulence-strain dependent 
manner strongly suggested that these GTPases are an important set of host 
defence molecules.  
 
1.3 Toxoplasma gondii  
1.3.1 Toxoplasma characteristics and lifecycle 
Toxoplasma gondii is an obligate intracellular parasite that resides within a 
parasitophorous vacuole and infects any nucleated cell type. While the definitive 
host is the feline, in which the sexual stage of the life cycle occurs, any warm-
blooded animal can become an intermediate host. A succinct review of the first 100 
years of Toxoplasma research was produced by Jitender Dubey in 2008 (Dubey, 
2008). 
Toxoplasma was first isolated in 1908 from the rodent Ctenodactylus gundi 
(Nicolle and Manceaux, 1908), where it was recognised as a new organism and 
named for it’s shape (toxo – toxon Greek for arc) and the creature from which it 
was isolated (gundi) (Nicolle and Manceaux, 1909). While Toxoplasma was 
recognised within many animal samples over several decades it was not 
successfully isolated in a viable form until 1937, after which the isolates from 
humans and animals were proven to be the same species (Sabin and Olitsky, 
1937). Studies on worldwide isolates of Toxoplasma found genetic variability 
(Pfefferkorn and Pfefferkorn, 1980, Dardé et al., 1987, Howe and Sibley, 1995, 
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Tibayrenc et al., 1991, Sibley and Boothroyd, 1992), with different strains 
demonstrating different levels of virulence in mice (Dubey, 2002, Lehmann et al., 
2006). Molecular epidemiological and population biology studies first inclined that 
there were only three clonal lineages that result in the differing virulence and 
pathogenicity phenotypes (Sibley et al., 2009). 
The parasites can be grouped into ‘virulent’ (type I), and ‘avirulent’ (types II 
and III). The virulent Toxoplasma are highly pathogenic and display very limited 
genetic diversity. The avirulent strains are further grouped into two distinct clonal 
lineages (Darde, 1996).  These type II and III strains are the strains that have been 
isolated from AIDS patients and widespread outbreaks, and from agricultural 
animals (Belfort-Neto et al., 2007, Ferreira et al., 2008, Miller et al., 2004, Conrad 
et al., 2005, Demar et al., 2007, Demar et al., 2008). While the large majority of 
North American strains fall into these three recently derived lineages, the strains 
from South America have been shown to be more genetically diverse, falling into 
distinct genotypes (Sibley et al., 2009). These distinguished groups are shaped by 
biological geographic factors, population sweeps and infrequent sexual 
recombination.  
There are several methods by which Toxoplasma has been genotyped. 
They include multi-locus enzyme electrophoresis, which was used in early studies 
on strain variation. This method was used to define several polymorphic enzymes 
and thus characterise isolates into three major zymodemes (Darde et al., 1992). 
Later, techniques focussed on identifying microsatellite markers. These are short, 
repeated segments of DNA that are frequently located in regions of non-coding 
DNA and was a successful method to use for high-throughput analyses (Ajzenberg 
et al., 2002b, Ajzenberg et al., 2002a). Restriction fragment length polymorphism 
(RFLP) was widely used as the method to genotype specific genetic loci, allowing 
for high-throughput analysis via PCR, restriction digest and gel electrophoresis, 
and was used to group types I, II and III (Sibley and Boothroyd, 1992). Direct 
sequencing of genomic regions using single nucleotide polymorphisms, insertions 
and deletions eventually revealed complete genetic diversity; for example 
highlighting the high diversity in the GRA6 locus (Sibley et al., 2009). This is the 
method that provides the best approach for detecting polymorphisms in new 
isolates. With direct sequencing it could then be shown that the predominant clonal 
lineages varied by only 1-2% at the nucleotide level (Grigg et al., 2001) and 
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subsequent coalescence analysis supports a model by which the so-thought three 
linages evolve from a common ancestor in the last 10,000 years (Su et al., 2003), 
corresponding to the same time-frame when animals underwent domestication. 
It was hypothesised that the divergence of isolates from South America was 
due not to differences in host range, but instead was due to geographical variations 
and recombinants of the genotypes prevalent in the north (Khan et al., 2006, 
Ferreira et al., 2008). However, when isolates from various regions were analysed 
in comparison to previously characterised North American samples there were in 
fact four ancestral lineages reconstructed. This shows that while South and North 
American Toxoplasma share a common ancestry, they are reproductively isolated 
(Khan et al., 2007); perhaps as a result of cats migrating over the Panamanian 
land-bridge (Johnson et al., 2006, Khan et al., 2007). 
The lifecycle of Toxoplasma takes place in a number of hosts. The sexual 
stage of the lifecycle occurs in the intestine enterocytes of felines. Felines ingest an 
infected animal containing dormant parasite cysts and upon reaching the 
epithelium villi shizogonic and gametogonic stages develop within vacuoles 
situated alongside the brush border of the cell near the nucleus. These two stages 
are observed together in no particular sequence or preferred location along the 
entire villus epithelium (Hutchison et al., 1971). After a short incubation period of as 
little as 5 to 10 days, the felines release numerous diploid oocysts into the 
environment via their faeces (Dubey et al., 1972). The next stage of the 
Toxoplasma lifecycle takes place inside an intermediate host, which could be any 
warm-blooded animal. Ingested oocysts will develop into fast replicating haploid 
tachyzoites that multiply intracellularly by endodyogeny and disseminate 
throughout its host (Goldman et al., 1958, Frenkel and Dubey, 1973). Host death 
would occur if this stage continued indefinitely. Therefore, upon immune pressure 
from the host, the parasite slows its replication and develops into a haploid 
bradyzoite that will persist as tissue cysts in immune-privileged areas, like deep 
tissue and in the brain (including astrocytes, microglia and neurons), for the rest of 
the host’s life (Jacobs et al., 1960a, Halonen et al., 1996, Fischer et al., 1997, 
Halonen et al., 1998, Freund et al., 2001, Schluter et al., 2001). Humans can 
become host to Toxoplasma in a number of different ways. One route is via the 
ingestion of undercooked meat that contains tissue cysts (Jacobs et al., 1960b, 
Desmonts et al., 1965). Humans can ingest oocysts that have been shed from 
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felines (Hutchison, 1965), by directly handling the faeces, from contaminated fruits 
and vegetables that are unwashed, or from a contaminated water supply 
(Benenson et al., 1982, Bowie et al., 1997, de Moura et al., 2006, Teutsch et al., 
1979) (Figure 3). 
 
Figure 3 Lifecycle and hosts of Toxoplasma 
Felines are the definitive host of Toxoplasma, and from cats parasite oocysts are 
shed in the faeces. These oocysts are ingested by intermediate hosts, in which the 
parasite develops first into tachyzoites, then dormant bradyzoites within cysts in 
immune-privileged sites. While most infections persist without the host being 
aware, complications can occur in immunocompromised hosts and pregnant 
females. 
 
Once a human becomes infected, they can spend their whole life completely 
unaware of their Toxoplasma companion as the immune system keeps the parasite 
at bay. This results in a chronic infection that is not cleared (Johnson, 1992, Weiss 
et al., 2009). However, problems can arise under specific circumstances. If a 
woman becomes infected with the parasite during pregnancy, congenital 
Foetal abnormalities
Ocular toxoplasmosis
Toxoplasmic encephalitis
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transmission and disease characterised by encephalomyelitis can occur that may 
lead to either abortion or severe foetal abnormality (Wolf et al., 1939, Sabin and 
Ruchman, 1942, Couvreur and Desmonts, 1962, Havelaar et al., 2007). 
Furthermore, a host who is immunocompromised, for example an AIDS patient or a 
patient undergoing immunosuppressive therapy, can die from toxoplasmosis of the 
brain when a lift of immune pressure causes Toxoplasma to revert back to its fast-
replicating tachyzoite stage (Luft et al., 1983, Israelski et al., 1988). Before the 
AIDS epidemic neurological toxoplasmosis was rare, however during this time the 
level of acquired infection became apparent. Without treatment, Toxoplasma 
reactivation was fatal and even with treatment still carried a 10-30% mortality rate 
(Luft et al., 1983, Luft and Remington, 1992). Complications also arise in the form 
of ocular disease caused by Toxoplasma-driven inflammation and formation of 
lesions in the eye (Wilder, 1952, Grigg et al., 2001, Park and Nam, 2013). Although 
these occurrences of eye disease and severe ocular inflammation are relatively 
regularly observed outcomes of an infection (Janku, 1923, Wilder, 1952), studies 
within Brazil have shown an increased prevalence of ocular toxoplasmosis in this 
location. This variation in disease phenotype in acquired infection would suggest 
that in humans some strains may be more pathogenic that others (Silveira et al., 
1988, Glasner et al., 1992).  
Toxoplasma can cause severe disease and death in humans, but it is also a 
large problem in the animal world. This parasite has been responsible for 
innumerable abortions in sheep and thus has a high economic impact (Hartley and 
Marshall, 1957, Beverley, 1961, Dubey and Welcome, 1988). Toxoplasma 
demonstrated its parasitic success by causing widespread fatality in sea otters, fur 
seals and endangered monk seals when oocysts contaminated marine waters 
(Holshuh et al., 1985, Honnold et al., 2005, Conrad et al., 2005). For these reasons, 
it is important that this parasite is studied and understood further, to find effective 
treatments and vaccines to control it. Further, understanding the effects different 
strains produce will allow a more targeted approach for therapy.  
The Toxoplasma strains that exist are the same species, however the 
polymorphic effector genes allow for varied responses. Virulence factors, including 
rhoptry protein 16 (ROP 16) and dense granule protein 15 (GRA 15) play key 
strain-dependent roles in host response to infection. While both type I (RH) and II 
(Prugniaud) parasites harbour GRA15 genes, the polymorphic nature of these 
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genes allows for different effector mechanisms, with type II able to manipulate the 
NFΚB signalling pathway much more significantly than type I (Rosowski and Saeij, 
2012). This same effector in type I is responsible for inhibiting interferon regulating 
factor 3, a proinflammatory transcription factor, (Rosowski and Saeij, 2012) as well 
as protecting the PV from host protection mechanisms (Virreira Winter et al., 2011) 
(discussed further later) while playing little effect in these manners in type II 
parasites. The ROP16 kinase in type I Toxoplasma plays an important role by 
phosphorylating STAT1 into a non-transcriptionally active form, successfully down-
regulating IFNγ-signalling pathways. However, while type II does not show this 
effect, the same phenotype is produced when a type I copy of the gene is 
ectopically expressed (Rosowski and Saeij, 2012). The need to understand how 
different strains affect pathology will be important in understanding how to 
recognise and control infection. 
1.3.2 Host responses against Toxoplasma 
The immune response against Toxoplasma has been widely studied with many 
different aspects being highlighted as important for infection control. Dupont et al. 
elegantly reviewed the immune reactions to this parasite, emphasising the varied 
models by which a host controls this infection (Dupont et al., 2012). Toxoplasma is 
capable of infecting any nucleated cell type, with a slight preference for 
macrophages reported (Zhao et al., 2014). The active invasion of Toxoplasma into 
a cell requires the secretion of three waves of proteins. These proteins are made 
up of micronemes, dense granules and rhoptry proteins, and can modify the host 
cell behaviour and can inhibit immune responses (Lim et al., 2012). The parasite 
moves into the cell surrounded by host lipid membrane, which it can then modify to 
become it’s safe-haven, the PV. Toxoplasma appears to hide from the immune 
system within the PV, so questions are raised as to how the host immune system 
interacts with the parasite.  
Monocytes, neutrophils, dendritic cells (DCs) have all been implicated in 
orchestrating protection against Toxoplasma. It is true that one of the critical 
functions of these cells in the response to Toxoplasma is the production of 
interleukin-12 (IL-12). This in turn stimulates the production of IFNγ from natural 
killer (NK) cells and T cells (Gazzinelli et al., 1993, Gazzinelli et al., 1994, Hunter et 
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al., 1994). It is acknowledged that IFNγ is the main mediator of resistance to 
Toxoplasma since it is responsible for promoting a large array of killing 
mechanisms (Suzuki et al., 1988). A TH1 immune response ensues, which is 
characteristic of many intracellular pathogen infections. Mice that are deficient in 
either IL-12 or IFNγ cannot control infection and succumb shortly after challenge 
(Suzuki et al., 1988, Hunter et al., 1993, Gazzinelli et al., 1994). The role of toll-like 
receptors (TLRs) is important in host defence, as they are responsible for the initial 
sensing of parasite products. A range of TLRs, including TLR2, TLR4 and TLR11, 
respond to Toxoplasma profilin or to glycosylphophatidylinositols that are found on 
the parasite surface (Yarovinsky et al., 2005, Debierre-Grockiego et al., 2007). 
TLRs are also responsible for sensing the insult on the host that occurs as the 
tachyzoites translocate from the gut (Benson et al., 2009).  
As IL-12 is a vital first step in the attack against Toxoplasma, numerous 
studies have been conducted to identify the primary cell types that are responsible 
for the release of this cytokine in vivo. Many sources have been identified, including 
neutrophils, inflammatory monocytes, macrophages and DCs (Gazzinelli et al., 
1996, Bliss et al., 1999, Bliss et al., 2000, Scanga et al., 2002, Mordue and Sibley, 
2003, Whitmarsh et al., 2011). CD8+ DCs were defined as the prominent cell type 
releasing IL-12 in vivo (Reis e Sousa et al., 1997). Furthermore, in mice deficient in 
the transcription factor Batf3, a lack of CD8+ DCs resulted in a severe IL-12 defect 
and reduced CD8+ T cell responses; a consequence of which was increased 
parasite load and death of the host (Mashayekhi et al., 2011). Monocytes also play 
a role in resistance, showing an increased susceptibility to infection when the 
recruitment chemokine receptor, CCR2, is lacking in mice (Robben et al., 2005, 
Benevides et al., 2008, Dunay et al., 2010). One reason for their importance could 
be the role monocytes play in the production of nitric oxide (NO) (Dunay et al., 
2010). This direct control mechanism has been shown to decrease parasite 
replication, with NO-deficient mice dying during Toxoplasma challenge (Benevides 
et al., 2008). While the function of NO in parasite control has to be fully elucidated, 
there is evidence that NO could stimulate early egress of tachyzoites from 
macrophages and by inhibiting reactivation of parasites to tachyzoites in the brain 
(Gazzinelli et al., 1993, Khan et al., 1997, Schluter et al., 1999, Yan et al., 2015). 
NK cells play an important role in the production of IFNγ (Denkers et al., 1993, 
Sher et al., 1993, Johnson et al., 1993, Hunter et al., 1994) and also promote the 
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adaptive immune responses with CD8+ T cells via interactions with natural-killer 
group 2, member D protein (NKG2D) that is expressed on both cell types (Guan et 
al., 2007).  
Adaptive immune responses are an important part of the defence of a host 
against Toxoplasma. Mice deficient in B cells or CD4+ T cells survive the acute 
phase of infection and have normal IFNγ responses, but ultimately succumb to the 
disease as a result of increased parasite burden in the central nervous system 
(Denkers et al., 1997, Kang et al., 2000, Johnson and Sayles, 2002). CD8+ T cells 
play a necessary role in both the acute and chronic infection. Mice lacking Batf3 
transcription factor have severely depleted CD8+ are significantly more susceptible 
to Toxoplasma and do not survive the acute phase of infection (Mashayekhi et al., 
2011). Furthermore, when CD8+ T cells are depleted in mice that are chronically 
infected, the parasite cysts are significantly increased in size, with an upset in the 
amount of cytokines being produced, as well as a loss of vaccine-induced immunity 
(Gazzinelli et al., 1991, Guiton et al., 2009). Therefore, in the host defence 
mechanism against Toxoplasma, both the innate and adaptive immune responses 
are crucial, with IL-12 and CD8+ cells proving vital for host survival. 
 
1.3.3 IFNγ effector mechanisms against Toxoplasma  
There are a number of Toxoplasma killing mechanisms that are driven by the 
cytokine IFNγ. One of the mechanisms is the upregulation of indolamine-2,3-
dioxygenase (IDO) 1 and 2. This enzyme is responsible for catalysing the 
degradation of tryptophan (Murray et al., 1989, Prendergast, 2008) in many cell 
types, including fibroblasts, macrophages and brain cells (Pfefferkorn, 1984, 
Murray et al., 1989, Daubener et al., 1996, Daubener et al., 2001). As Toxoplasma 
is an auxotroph for tryptophan, the IFNγ-meditated reduction of the amino acid 
results in inhibition of parasite growth. Mice that have been treated with IDO 1 and 
2 inhibitors during a Toxoplasma challenge have much increased susceptibility to 
disease and significantly increased parasite burdens (Divanovic et al., 2012). 
In mice, IFNγ is also responsible for the upregulation of a family of p47 large 
GTPases, the immunity related GTPases (IRGs). Mice that are deficient in Irgm3 
exhibit normal IFNγ responses, but soon die due to increased parasite burden 
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(Taylor et al., 2000). As studies progressed, it became clear that other family 
members are involved in host response to Toxoplasma, and a similar susceptibility 
was seen in mice lacking Irgm1, Irgd, Irga6 or Irgb6 (Collazo et al., 2001, Zhao et 
al., 2009b, Fentress et al., 2010, Pawlowski et al., 2011). IRGs are actively co-
localised to the PV of Toxoplasma, resulting in the PV forming a tight-fitting 
morphology around the parasite. After this recruitment, the PV membrane blebs 
and ruffles and finally lyses, and is stripped away (Martens et al., 2005, Ling et al., 
2006, Hunn et al., 2008, Zhao et al., 2009a, Zhao et al., 2009b, Zhao et al., 2010, 
Khaminets et al., 2010, Steinfeldt et al., 2010). The result of this action is that the 
parasite is no longer in its safe-haven, and is free in the cytoplasm where it 
undergoes permeabilisation and is killed (Melzer et al., 2008).  
Guanylate binding proteins also make up an important arm of the IFNγ host 
response against Toxoplasma. As mentioned earlier, mGBPs are recruited around 
the PV of type II ‘avirulent’ Toxoplasma, and can be manipulated to be inactive by 
the type I ‘virulent’ strain. It was hypothesised after this observation that GBPs 
were important anti-microbial effectors mechanisms.  
As IRGs had been shown to have such an important function during 
Toxoplasma infection, it seemed likely that GBPs, which surrounded the PV in a 
similar manner, were also vital to host response. Mice deficient in the cluster of 
GBPs found on chromosome 3 (GBPchr3-/-) were engineered by targeted 
chromosome deletion and infected with Toxoplasma. These mice showed 
significantly increased susceptibility to infection, attributed to a much increased 
parasite load throughout the animal (Yamamoto et al., 2012). Furthermore, it was 
identified that in bone marrow derived macrophages (BMDMs) from GBPchr3-/- mice, 
the recruitment of the IRGs is negatively affected. The result of the loss of 
recruitment of these effector molecules is a lack of blebbing and ruffling of the 
Toxoplasma PV in GBPchr3-/- BMDMs. When the GBPs were complemented back 
into the macrophages, IFNγ-meditated protection was restored (Yamamoto et al., 
2012).  
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1.3.4 Toxoplasma and GBPs 
In 2011, Virreira Winter et al. successfully confirmed that IFNγ-dependent 
relocalisation of mGBPs around the Toxoplasma PV correlated with the virulence 
type of the parasite. They identified three specific parasitic factors that determined 
the difference in virulence types between parasite strains. These were ROP16, 
rhoptry protein 18 (ROP18) and GRA15. Therefore, it was suggested that the 
virulence of Toxoplasma depended on the recognition of GBPs. A mass 
spectrometric analysis of mGBP1 isolated from an infected cell culture identified 
mGBPs 2, 4 and 5 as its binding partners, indicating that these large GTPases are 
brought the to PV as part of a large multimeric structure (Virreira Winter et al., 
2011). How either GBPs or IRGs can recognise the PV of Toxoplasma is an 
interesting question. The parasite survives inside the cell protected by a vacuole 
composed of host cell membrane that keeps it largely invisible to host defence 
mechanisms. So how do these large GTPases recruit to the PV so efficiently? In 
2013, it was shown that the targeting of these GTPases requires the formation of 
higher-order protein oligomers, and that this was regulated by the immunity related 
GTPase family M (IRGM) (Haldar et al., 2013). Irgm1 and Irgm3 proteins do not 
localise to the pathogen vacuoles, but instead reside on self-organelles. As a result, 
the organelles are guarded against an association with GBPs and IRGs. By 
inference, GBPs and IRGs were located upon the entities in the cell that are 
missing the ‘self’ IRGM proteins (Haldar et al., 2013). 
The recruitment of mGBPs and mouse IRGs to the vacuole of Toxoplasma 
is dependent on the autophagy protein 5 (Atg5). Atg5 is part of a complex that 
facilitates the transfer of an ubiquitin-like protein from autophagy-related protein 8 
(Atg8) to the lipid phosphatidylethanolamine, and a role in the activation of the 
GTPase activity of large GTPases is hypothesised (Haldar et al., 2013). Further 
investigation of the function of autophagy proteins in cell-autonomous responses 
against Toxoplasma showed that, in mouse, IFNγ-dependent suppression and 
GTPase recruitment was significantly reduced when Atg7 or Atg16L1 were not 
present (Ohshima et al., 2014). However, interestingly, when either Atg16L1 or all 
of the GBPs were knocked out in human cells, the IFNγ-dependent response was 
not affected (Ohshima et al., 2014). Deposition of mGBPs is shown not only to be 
dependent on autophagy proteins, but also on wider ubiquitination systems, with 
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the E3 ligase TRAF6 regulating association of mGBPs with the PV (Haldar et al., 
2015).  
Specifically, mouse GBP1 is implicated in contribution to cell-autonomous 
immunity against Toxoplasma (Selleck et al., 2013). The ability of this family 
member to recruit around the PV is mediated by ROP18, the pseudogene ROP5 or 
an active threonine kinase. When these virulence factors were knocked out, 
parasite clearance in BMDMs was possible in the presence of IFNγ. Mice deficient 
in mGBP1 showed an increased susceptibility even to type II ‘avirulent’ 
Toxoplasma. However, this susceptibility was reversed when the infecting strain 
was a ∆ROP18 mutant (Selleck et al., 2013). Mouse GBP2 also plays a role in 
defence against Toxoplasma, with BMDMs from mGBP2-deficient mice being 
unable to control the replication of the parasite (Degrandi et al., 2013). 
 
1.4 GBPs, bacteria and the inflammasome 
As the roles played by the GBPs against Toxoplasma gondii are becoming clearer, 
so are the roles played against other pathogens. Toxoplasma is an intracellular 
pathogen that resides inside a vacuole, as is Chlamydia trachomatis. When HeLa 
cells were infected with C. trachomatis, it was observed that GBPs 1 and 2 
localised to the vacuole, or inclusion, of this bacteria. Moreover, when these same 
GBPs were knocked down using silencing RNA, the inclusion sizes were 
significantly larger, indicating enhanced bacterial replication. The opposite result 
was observed when GBP1 or 2 were overexpressed in the same cells (Tietzel et al., 
2009, Al-Zeer et al., 2013). A strain of C. trachomatis that was hyper-virulent, due 
to presence of a putative cytotoxin gene, was not affected by GBP overexpression 
(Tietzel et al., 2009). The inclusions decorated with GBPs were targeted for 
autophagic destruction (Al-Zeer et al., 2013), thereby implicating GBPs in functions 
related to autophagy. It was shown that Atg5 and 3 play vital roles in successful 
decoration of the pathogen vacuole with GBPs during a Toxoplasma infection, and 
the same is true for C. trachomatis (Haldar et al., 2014).  
 The mechanisms by which GBPs exert their functions have only been begun 
to unravel over the last four or so years. Inflammasomes are complexes 
responsible for sensing and altering the immune system to danger such as 
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infection or tissue damage. They are activated by nucleotide-binding domain, 
leucine rich repeat containing receptor (NLR) proteins and absent in melanoma 20-
like receptor (ALR) proteins to activate the cleavage of caspase-1, which in turn 
upregulates IL-1β and IL-18 secretion as well as cleavage of gasdermin protein to 
induce pyroptosis (Guo et al., 2015). Shenoy et al. were able to demonstrate that 
GBP5 was a non-NLR or -ALR protein that could stimulate inflammasome 
assembly. Furthermore, in response to lipopolysaccharide (LPS), Listeria 
monocytogenes or Salmonella enterica typhimurium GBP5 selectively promoted 
NLRP3 inflammasome responses. BMDM from mice that were deficient in GBP5 
had significant defects in their ability to cleave caspase-1, IL-1β and IL-18 in vitro 
indicating an important role in these events (Figure 4). In vivo, the GBP5-deficient 
mice had impaired defence and inflammasome assembly against a L. 
monocytogenes infection (Shenoy et al., 2012). Furthermore, mGBPs were 
implicated in the activation of the non-canonical inflammasome in caspase-11-
dependent host defence against gram-negative bacteria (Pilla et al., 2014, Meunier 
et al., 2014) (Figure 4). Legionella pneumophila and C. trachomatis infection trigger 
pyroptosis in IFNγ-activated macrophages, however induction of this response is 
lost when mGBPchr3-/- macrophages are used (Pilla et al., 2014, Finethy et al., 
2015). Additionally, the mGBP cluster on chromosome 3 is responsible for a 
pyroptosis reaction to the LPS from L. pneumophila or S. enterica typhimurium, 
suggesting a role for GBPs in cytosol sensing of bacteria (Pilla et al., 2014). GBPs 
are recruited to the pathogen-containing vacuoles of these bacteria and are 
necessary for the breakage of said vacuoles. The lysis of these safe-havens 
releases LPS in to the cytosol, where it is detected, allowing the host to mount a full 
response (Meunier et al., 2014). A second consequence of vacuole breakage is the 
recognition by galectin 8 of previously unexposed host glycans, which in turn leads 
to recruitment of nuclear dot protein 52 (NDP52) and the uptake of bacteria into 
autophagosomes (Thurston et al., 2012, Meunier et al., 2014). 
 The absent in melanoma 2 (AIM2) inflammasome response detects double-
stranded DNA in the cytosol and mounts the appropriate host defence. The mGBPs 
2 and 5 play a role in activation of this system during infection with the cytosolic 
bacteria Francisella novicida (Man et al., 2015, Meunier et al., 2015). After initial 
detection of the pathogen, IFNs upregulate interferon regulatory factor (IRF) 1, 
which in turn induces expression of mGBPs. Mouse GBPs 2 and 5 recruit to the 
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bacteria and promote bacteriolysis, DNA release, and therefore bacteria killing 
(Man et al., 2015, Meunier et al., 2015) (Figure 4). 
 The renewed interest in GBPs has shown them to be powerful responders 
to bacterial infections, reacting by inducing the inflammasome via a number of 
different pathways. It will be fascinating to see if this response is consistent for 
different pathogens, including Toxoplasma gondii.  
 
Figure 4 Mouse GBP dependent induction of inflammasome responses 
Mouse GBPs have been implicated in both the canonical and non-canonical 
activation of inflammasomes. Adapted from (Kim et al., 2016), Nature Immunology 
17, 481–489. 
  
1.5 The aim of this thesis 
As the roles that are dependent on GBPs become more unravelled and the 
mechanisms by which they work are becoming clearer, it is apparent they are a 
very important family of antimicrobial effectors. The mechanistic work so far 
regarding the inflammasome has been carried out in a murine species. Similarly, all 
but one study regarding GBPs and Toxoplasma infection focuses on mice 
(Ohshima et al., 2014). As GBPs have been shown to work so coherently with 
IRGs in a number of settings, it is important to move these studies into a human 
system. Humans only contain 2 IRG proteins; one is damaged in many ways and is 
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no longer IFN-inducible, and the other has only the G domain transcribed. As a 
result both versions are indicated to be non-functional in the conventional manner 
(Kim et al., 2012). While the GBPs are well conserved between species, there may 
be a vast difference in their modes of action as a result of the evolutionary 
pressures and the loss of a group of significant interaction partners.  
The aim of this thesis is to study GBPs in a human system, while focussing 
on a Toxoplasma gondii infection model. The first step will be to develop the 
necessary tools for functional characterisation of GBPs, including producing 
antibodies and characterising mutant cells. As the GBP family members show such 
a high level of identity between family members, developing reagents that are 
specific for one family member is important to ensure the definite allocation of 
functions. Secondly, I will establish stable and reliable overexpression of these 
proteins in an appropriate cell type. While there have been overexpression models 
published in the literature, I, and others, have observed that no one has published 
systems that are consistently used. I will move to create these systems to enable 
the study of this group of large GTPases.  
Using the reagents I will produce, I will study the subcellular localisation of 
individual GBPs both in a steady state cell and on the context of a Toxoplasma 
infection. I will determine whether or not GBPs recruit to the PV and how infection 
may change the location of individual family members. Furthermore, I will use these 
systems to study the effects of these proteins on the replication and survival of 
Toxoplasma. I will work to develop appropriate survival and invasion protocols in 
order to reliably assess the parasites viability.  
 I will begin to unravel the characteristics and functions of these intriguing 
proteins, but I also want to develop tools and protocols that will provide others, both 
within the lab and those who are collaborators, with a solid ground on which to 
further our knowledge of guanylate binding proteins.
Materials & Methods 
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Chapter 2. Materials & Methods 
2.1 Tissue Culture 
2.1.1 Cell culture 
All cells were cultured at 37˚C in 5% CO2. Human foreskin fibroblasts (HFFs) 
(ATCC #CRL-2429) were cultured in Dulbecco's Modified Eagle Medium (DMEM) + 
GlutaMax (Thermo Fisher Scientific #10566016) supplemented with 10% heat-
inactivated foetal bovine serum (FBS) (Life Technologies #10500064). The cells 
were passed 1:10 when confluency was reached. A549 cells (ATCC #CCL-185) 
were cultured in DMEM + GlutaMax supplemented with 10% FBS and were passed 
1:5 when 80% confluency was reached. Human umbilical vein endothelial cells 
(HUVECs) (Promocell #C12203) were cultured in M199 medium (Life Technologies 
#11043023) supplemented with 20% FBS, 10U/ml heparin (Sigma #H-3149) and 
30mg/ml endothelial cell growth supplement (Upstate 02-102). HUVECS were 
allowed to reach 70% confluency before being passed 1:4, these cells were not 
used beyond passage 10. THP-1 monocytes (ATCC #TIB-202) were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium +L-glutamine (Gibco 
#11875093) supplemented with 10% FBS. These suspension cells were passed 
1:4 when they reached 1X106 cells/ml. To differentiate into macrophages, the cells 
with stimulated with 1µM phorbol myristate acetate (PMA) (Sigma #P8139) for 3 
days. HEK293T cells, human kidney cells commonly used for retroviral vector 
production, (ATCC #CRL-3216) were cultured in DMEM + GlutaMax supplemented 
with 10% FBS, and were passed 1:5 when 70% confluency was reached. 3T3 
fibroblasts (kind gift from Jonathan Howard) were cultured in DMEM +GlutaMax 
supplemented with 10% FBS and were passed 1:8 when 80% confluency was 
reached. When appropriate, the cells were stimulated for induction of protein 
expression by adding 1nM mifepristone hormone (Invitrogen #H110-1) and 
incubating for 24 hours at 37˚C in 5% CO2. Where IFNγ stimulation was required, 
10U/ml IFNγ (Promega #FHC24802) was added to the culture media and 
incubated for the appropriate time. 
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2.1.2 Culture of Toxoplasma gondii 
Parasites expressing eGFP/luciferase or tdTomato, strains type I RH and type II 
Prugniaud (Pru) were maintained on a monolayer of HFFs in T25 culture flasks 
(Corning #CLS3289), with the cells cultured as described above. Once the 
Toxoplasma had exhausted the feeder cell supply, the monolayer was scraped and 
the parasites freed by syringe lysis using a 25-gauge needle, before 200µl type I or 
500µl type II suspensions were reseeded onto fresh HFFs.  
 
2.1.3 Infection of cells with Toxoplasma gondii 
Cells were cultured as appropriate before the layer was scraped mechanically, with 
the resulting suspension was passed through a 25-gauge needle thereby liberating 
Toxoplasma from vacuoles by syringe-lysis. The Toxoplasma were counted on a 
haemocytometer and the appropriate multiplicity of infection (MOI) was seeded 
upon the cell monolayer. To ensure simultaneous invasion of cells, the cultures 
were then centrifuged for 5 minutes at 200xg at room temperature. The infection 
was allowed to persist for the appropriate length of time at 37˚C in 5% CO2. 
 
2.1.4 Toxoplasma irradiation 
Where appropriate, the Toxoplasma were γ-irradiated in HFF cells with 15000 rad 
using a Gammacell 40 137Caesium Irradiator before following the infection protocol 
as described above. 
 
2.2 Protein Biochemistry 
2.2.1 Cell lysis 
For adherent cells: the media was aspirated and the cell layer was washed 2 times 
by covering in ice-cold phosphate buffered saline (PBS) (Sigma #D8537). Ice-cold 
lysis buffer was added and the cell layer was scraped before the suspension was 
collected into an eppendorf tube and stored on ice. For suspension cells: the cells 
were centrifuged for 6 minutes at 300xg, the supernatant was discarded and the 
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cell pellet was resuspended in ice-cold PBS. The cells were centrifuged at 4˚C for 6 
minutes at 300xg to wash them, and then the process was repeated. After the 
supernatant was aspirated following the second wash, ice-cold lysis buffer was 
added to the pellet, and it was resuspended by flicking the tube. The tubes were 
vortexed briefly to ensure lysis of the nuclei, before being incubated on an end-over 
shaker at 4˚C for 1 hour. The suspension was centrifuged at 12000xg for 15 
minutes at 4˚C, after which the total soluble lysate was collected. The protein 
concentration was calculated using Bio Rad Protein assay dye reagent (Bio Rad 
#5000006). 100µl of reagent was added to 400µl PBS. 2.5µl of lysate was added to 
the mixture, followed by 500µl PBS. The mixture was incubated at room 
temperature for 10 minutes after which the absorbance (A) was quantified by a 
spectrometer at OD595. The protein concentration in mg/ml was calculated using 
the equation (A*14.44)/2.5. 
 
2.2.2 SDS-PAGE and Immunoblot 
Protein expression was analysed by separation with sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) followed by identification using 
antibodies in immunoblot. Cell lysates were produced as described. 10µg of protein 
denatured in Laemmli sample buffer containing dithiothreitol as reducing agent 
(NEB) was loaded into a precast 4-12% Bis/Tris NuPage gel (Thermo Fisher 
Scientific #NW0412) to be run on the Invitrogen Gel System, with a lane dedicated 
to the pre-stained protein standard ladder Novex Sharp (Thermo Fisher Scientific 
#LC5800). The gels were run using 200V until the dye front reached the bottom of 
the gel. The gel was transferred onto nitrocellulose membranes using the iBlot dry 
blotting system as described by the manufacturer (Thermo Fisher Scientific 
#IB21001) before staining with Ponceau-S solution (Sigma Aldrich #P7170-1L) to 
visualise protein. The membranes were blocked in Blotto solution (5% non fat milk 
in PBS + 0.05% Tween 20 with 0.02% sodium azide as preservative) for 1 hour 
with shaking at room temperature before probing with a primary antibody for the 
appropriate time on an orbital shaker. All commercial antibodies were diluted in 
buffers to manufacturer specification. The polyclonal anti GBP and 2 antibodies 
were diluted in 5% non fat milk in PBS + 0.05% Tween 20 with 0.02% sodium azide 
Materials & Methods 
 
35 
 
as preservative, the polyclonal anti-GBP4 antibody was diluted in 1% BSA in PBS + 
0.05% Tween 20 with 0.02% sodium azide, the monoclonal antibodies were not 
diluted. The membranes were washed 3 times for 5 minutes each in PBS 0.05% 
Tween 20 before being probed with the appropriate secondary antibody on an 
orbital shaker. After the membranes were washed 3 times for 5 minutes with PBS 
0.5% Tween 20, they were incubated with Immobilion Western Chemiluminescent 
HRP substrate (Merck Millipore #WBKLS0100) for 5 minutes at room temperature, 
with shaking. The membranes were then exposed to x-ray film before developing 
the film and visualisation.  
 
2.2.3 Immunoprecipitation 
Cell lysates were prepared as stated, using buffer containing 0.5% NP-40 
detergent. An appropriate volume of primary antibody was added to 0.5mg of the 
protein sample, which was mixed well and incubated for 30 minutes at 4˚C on an 
end-over shaker. At the same time, 50µl of Protein-G-sepharose beads (AbCam 
#ab193259) were prewashed in dolphin tubes (Sigma Aldrich, #Z717533) by 
centrifugation for 2 minutes at 1800xg 3 times using lysis buffer. The cell lysate 
was added to the beads and mixed well. The suspension was incubated for 1 hour 
at 4˚C on an end-over shaker. Centrifugation of the suspension at 4˚C for 2 
minutes at 1800xg followed, the supernatant was removed and the beads were 
washed 3 times in lysis buffer by centrifugation. The washed beads were 
resuspended in 1x-SDS sample buffer and the sample was boiled for 5 minutes to 
remove the sample from the beads. The beads were pelleted by centrifugation in a 
microfuge at full speed (1200xg) for 30 seconds, and the supernatant was loaded 
onto a gel for SDS-PAGE and analysis. 
 
2.2.4 Immunofluorescence 
Cells were cultured on 9mm glass coverslips (Gerhard Menzel GMBH 
#LDRND9/1.5). When the cells reached confluency the media was aspirated and 
the cells were washed twice in PBS. The coverslips were incubated with 3% 
paraformaldehyde (PFA) for 15 minutes at room temperature, following which they 
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were washed once with Perm Quench buffer. The wash was replaced with fresh 
Perm Quench and the coverslips were incubated for 10 minutes at room 
temperature. The Perm Quench was aspirated and PGAS buffer was added, with 
the cells incubating for at least 5 minutes. The primary antibody was diluted at an 
appropriate concentration in PGAS. The coverslips were placed cell side down onto 
a 50µl drop of antibody solution and were incubated for 1 hour at room temperature 
in a humidified chamber. The coverslips were washed 3 times in PGAS before the 
incubation process was repeated, in the dark, with the appropriate fluorescent 
secondary antibody diluted in PGAS. The coverslips were subjected to 3 washes in 
PGAS, followed by 3 washes in PBS. The final PBS wash contained 1:10,000 
dilution of Hoechst DNA stain (Thermo Fisher Scientific #H3570). The coverslips 
were rinsed twice in dH2O before being mounted onto glass slides (Thermo 
Scientific Superfrost Plus #J1800AMNZ) using Mowiol-488 polymer (Sigma Aldrich 
#81381). The slides were incubated overnight in the dark at room temperature to 
ensure adhesion before being visualised on a bright-field or confocal microscope. 
Buffer recipes can be found in Appendix. 
 
2.2.5 Confocal microscopy and image analysis 
Slides were viewed using a Zeiss 510 Inverted Microscope with a x100 lens, and 
were analysed using Zen Blue software or were imaged on a Leica SP5-invert 
Confocal microscope using x100 objective and analysed using LAS-AF software. 
Further image formatting was done using Image J software.  
 
2.2.6 Subcellular fractionation 
Subcellular fractionation was carried out using the Qiagen Qproteome Cell 
Compartment Kit, #37502. This is a proprietary kit in which the buffer components 
are kept confidential. The protocol was followed as per manufacturer instructions. 
Briefly, 5x106 cells were harvested, washed twice in ice-cold PBS by centrifugation 
for 5 minutes at 300xg. The cells were lysed in CE1 buffer by incubating on an end-
over shaker at 4˚C for 10 minutes. The lysate was centrifuged at 4˚C for 10 minutes 
at 1000xg, with the resulting supernatant containing the cytosolic protein fraction. 
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This fraction was stored on ice, and the pellet was resuspended in CE2 buffer by 
pipetting up and down. The suspension was incubated for 30 minutes on the end-
over shaker at 4˚C before centrifuging at 6000xg for 10 minutes at 4˚C. The 
resulting supernatant contains the membranous protein fraction; this was aspirated 
and stored on ice. The pellet was resuspended in 7µl manufacturers benzonase 
nuclease mixed with 13µl distilled water, and incubated for 25 minutes at room 
temperature. CE3 buffer was added to the mixture, and the suspension was 
incubated for 10 minutes at 4˚C on an end-over shaker. The sample was then 
pelleted by centrifugation at 6800xg at 4˚C for 10 minutes, with the resulting 
supernatant forming the nuclear protein fraction. This fraction was removed and 
stored on ice. The pellet comprises the cytoskeletal proteins, and was resuspended 
in buffer CE4. The samples were then precipitated with ice-cold acetone, before 
being resuspended in distilled water and quantified using the Bio Rad protein assay 
dye as described above. 
 
2.2.7 Protein degradation inhibition 
Cells were grown to 90% confluency, and were treated with the appropriate 
degradation inhibitor for 60 minutes. Type II Toxoplasma were used to infect the 
cells at an MOI of 3, with the infection being allowed to persist for 2 hours before 
the cells were harvested and lysed as described above for protein expression 
analysis. See Table 1 for information on usage and source of each component. 
 
Table 1 Protein degradation inhibitors 
Inhibitor Manufacturer Usage 
MG132 Cambridge BioScience 
# CAY10012628-5 
10µM 
Leupeptin Enzo Life Sciences 
#ALX-260-009 
10µg/ml  
Calpastatin Cambridge BioScience 
#16501-100-CAY 
10µM 
Lactacystin Cayman 
#19680219 
40nM 
Z-VAD-FMK Invivogen 
#ABE266 
4µg/ml 
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2.3 Overexpression and cell cloning 
2.3.1 Cell transfection with TransIT 2020  
TransIT 2020 lipid transfection reagent was purchased from Mirus (#MIR5404) and 
the protocol was carried out as per manufacturers instructions. Briefly, adherent 
cells were grown in 6 well plates, and were allowed to reach 80% confluency. 
Suspension cells were also plated in 6 well plates, and used at a density of 
5x105/ml. The reagent was warmed to room temperature before mixing gently by 
vortexing. 2.5µg DNA was added to 250µl of Opti-MEM serum free medium 
(Thermo Fisher Scientific #31985062) and mixed gently by pipetting. Then, 7.5µl of 
the TransIT reagent was added, mixing gently with pipetting, before incubating at 
room temperature for 15-30 minutes. The transfection mixture was added dropwise 
into the wells of cells and the plate was rocked gently. The cells were incubated at 
37˚C in 5% CO2 for 24 hours before being analysed for protein expression. 
 
2.3.2 Cell transfection with FuGeneHD 
FuGeneHD lipid transfection reagent was purchased from Promega, #E2311. 
Adherent cells were allowed to grow to 80% confluency in a 24-well plate. The 
reagent was warmed to room temperature, before vortexing gently to mix. 2µg of 
DNA was added to 100µl Opti-MEM serum free media, after which 6µl of the 
transfection reagent was added and was mixed gently by pipetting. The mixture 
was incubated at room temperature for up to 15 minutes, after which the mixture 
was added dropwise on top of the cells. The plate was rocked gently and was 
incubated for 24 hours at 37˚C in 5% CO2 before the cells were analysed for 
protein expression. 
 
2.3.3 Generation of TAP, mCherry and GFP tagged constructs for GBP 
overexpression 
Coding sequences of hGBP3, hGBP4, hGBP5, hGBP6 and hGBP7 were amplified 
by PCR, using Fermentas PCR Master Mix (Thermo Fisher Scientific Inc) 
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according to manufacturer’s protocol (Table 3). Primers were purchased from 
Sigma-Aldrich and were used to integrate appropriate sites for recognition by 
restriction endonucleases as well as to introduce HA, FLAG, mCherry or GFP 
epitope tags. The two restriction sites are not complementary to provide control 
over the inserted PCR product’s orientation and to prevent re-ligation of the vector 
to form transformable circular DNA. To enable a higher level of efficiency of linear 
DNA cutting by the enzymes, short overhangs were placed 5’ to the restriction sites. 
All primers with their tags and restriction sites are listed in the Appendix. 
Both the PCR product and appropriate vectors were double digested for 1 
hour at 37˚C as indicated in Appendix, Table 10. Successful digestion was verified 
by electrophoresis on a 1% agarose gel containing Gel Red (Biotium, #41003-BT) 
in 1X Tris-Acetate-EDTA (TAE) buffer at 100V until migration was complete. The 
samples were visualised under UV light. The bands were excised and the DNA was 
extracted using Qiagen Quick Gel Extraction kit (#28704). C1 vectors and the insert 
were ligated using a fast ligation protocol (Thermo Fisher Scientific #K1422), to the 
values as indicated in Table 10 with an incubation of 15 minutes at room 
temperature. 
For each transformation, 3µl of the ligated vector preparation was added to 
One Shot Mach-1 E. coli competent cells (Life Technologies, # C862003). After 30 
minutes incubation on ice, the cell suspension was subjected to heat shock at 42˚C 
for 30 seconds, before being returned to ice for 2 minutes. Following this, cells 
were recovered in 250µl SOC and shaken for 1 hour at 37˚C. The transformed cells 
were spread on agar plates containing the appropriate antibiotic selection and 
allowed to form colonies overnight at 37˚C. DNA constructs were harvested from 
transformed Mach-1 cells using the Qiagen Quicklyse Miniprep kit, # 27405, and 
DNA was quantified on a NanoDrop spectrophotometer.  
 
2.3.4 GeneSwitch driven overexpression of GBPs 
DNA from GBP image clones was amplified by PCR from the C1 and pcDNA3 
constructs to include appropriate restriction sites for cloning into the pGene vector 
primers and restriction sites can be found in the Appendix. The plasmid and GBP 
DNA underwent restriction digest before ligation using a fast ligation protocol 
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(Thermo Fisher Scientific #K1422). The product was run on an electrophoresis gel, 
with the bands being visualised using UV light before excision. The constructs were 
extracted as above. 3T3 fibroblasts that stably express the pSwitch plasmid were 
obtained as a kind gift from Jonathan Howard. These cells were grown to 70% 
confluency before being transfected with the individual pGene-GBP constructs 
using the TransIT 2020 transfection reagent as described. 24 hours after 
transfection the media was replaced with complete media, and selection with 
50µg/ml zeocin (Invivogen #ant-zn-1) began in order to produce stable clones. To 
induce protein overexpression, mifepristone was added and incubated with cells for 
24 hours before experimentation or protein analysis. 
 
2.3.5 Vaccinia virus driven overexpression of GFP-GBP4 
GFP-GBP4 was amplified from the pGene-GFP-GBP4 plasmid including restriction 
sites for AscI and PacI, primer sequences are included in the Appendix. The 
product was run on an electrophoresis gel as described, before the correct bands 
were visualised using UV light, and excised and extracted as above. 
 The pJS4 plasmid for this system was a kind gift from Jason Mercer (UCL). 
The plasmid and DNA underwent a restriction digest with AscI and PacI enzymes 
(Thermo Fisher Scientific #FD1894/ #FD2204) using the Thermo Fast Digest 
system (#FD1894/ FD2204). The vector and insert were ligated using a fast ligation 
protocol before transformation into competent cells as described above. THP-1 
monocytes and HUVECs were grown to 5x105 cells/ml or 80% confluency 
respectively before being infected with Vaccinia virus by Jason Mercer. One hour 
post infection, the cells were transfected with the pJS4-GFPGBP4 construct using 
the TransIT 2020 reagent as described. The cells were incubated at 37˚C in 5% 
CO2, with cells being lysed for protein expression analysis at specific time points.  
 
2.3.6 Inducible lentiviral driven overexpression of GFP-GBP4 
GFP-GBP4 was amplified from the pGene-GFP-GBP4 plasmid including restriction 
sites for MluI and NotI, primer sequences and PCR protocol are included in the 
Appendix. The product was run on an electrophoresis gel as described before the 
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correct bands were visualised using UV light, and excised and extracted as above. 
The pLVX-Tight-Puro, Tet-On-Adv, ∆8.9 and VSV-G plasmids were a kind gift from 
Annemarthe van der Veen and Caetano Reis e Sousa. A pLVX-mCherry plasmid 
was received as a kind gift from Rhiannon White. The pLVX-Tight-Puro plasmid 
and GFP-GBP4 DNA underwent restriction digest with the appropriate enzymes 
using the Thermo Fast Digest system (#FD0564/ # FD0593). The vector and insert 
were ligated using a fast ligation protocol (Thermo Fisher Scientific #K1422) before 
transformation into competent cells as described.  
HEK293T wells were grown to 70% confluency before transfection with the 
VSV-G and ∆8.9 packaging plasmids along with either Tet-On-Adv, pLVX-mCherry 
or PLVX-TP-GFPGBP4 plasmids. Supernatant from the cells containing the viruses 
were collected at both 24 and 48 hours post-transfection. The samples underwent 
ultra-centrifugation for 90 minutes at 4˚C at 20,000g before being flash frozen and 
stored at -80˚C. THP-1 monocytes were grown to 5x105 cells/ml before 
transduction with the viruses. The pLVX-mCherry or pLVX-TP-GFPGBP4 viruses 
were added to the cells, along with the Tet-On-Adv virus and 8µg/ml Polybrene. 
The cultures were centrifuged at room temperature for 90 minutes at 1200xg to 
ensure infection of cells, before being incubated at 37˚C in 5% CO2. The media 
was changed on the cells 6 hours after transduction and replaced with complete 
media. After 48 hours the cells were selected on 4µg/ml Puromycin (Thermo Fisher 
Scientific #A1113802) and 500µg/ml G418 (Thermo Fisher Scientific #11811098). 
To induce the expression of the protein of interest, the cells were treated with 
1µg/ml doxycycline (Sigma # D9891) and the cells were studied from 4 to 24 hours 
to analyse protein expression. 
 
2.4 Antibody production 
2.4.1 Antigenic peptide design for antibody production 
In order to produce rabbit polyclonal peptide antibodies against all 7 hGBPs, I first 
aligned the protein sequences before selecting a unique sequence for each hGBP. 
The specific peptide sequences and alignment across the family can be found in 
Figure 5. The peptides were ordered from BioMatik Corporation, Canada. The 
sequences were initially chosen from homologs to mGBP peptides (Degrandi et al., 
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2007) and were then further designed according to specificity ensuring there was 
as little similarity across the selected sequences as possible. Immunogenicity was 
also checked using software available online (Thermo Scientific, Pierce Antibodies, 
Antigen Profiler Peptide Tool). BioMatik conjugated the peptides to keyhole limpet 
haemocyanin in order to improve immunogenicity. The company Antibody 
Production Services proceeded to inject these immunogens into rabbits. A pre-
bleed and subsequent test bleeds at 3 intervals were taken before the final bleed.  
For the production of mouse monoclonal antibodies, the peptide sequences 
for GBP2 and 4 were elongated (Figure 5). Covalab Biotechnology Company 
produced the peptides, before immunising four mice per peptide. The preimmune 
sera were tested for background reactivity before immunisation. Hybridomas were 
produced up to 192 days post-inoculation; the supernatant was preliminary tested 
by enzyme-linked immunosorbent assay (ELISA) for reactivity against the peptide 
by the company. After reactive candidates were identified, I tested the supernatants 
by immunoblotting for specificity against lysates of mouse fibroblasts that inducibly 
overexpress TAP-tagged GBP family members. Three mice underwent fusion for 
the anti-GBP2 antibody. Of these, one mouse yielded no reactive hybridomas while 
the second and third mice produced a total of two reactive hybridomas. These were 
cloned to produce a total of four reactive antibodies (Table 3 and 4). In this project, 
monoclonal anti-GBP2 clone 9E12c1 was used. Two mice underwent fusion to 
produce hybridomas for monoclonal anti-GBP4 antibody production. From these, 
one of the fusion events produced no reactive hybridomas. The second fusion 
event yielded two reactive hybridomas, which were cloned and then subcloned to 
produce four reactive antibodies (Tables 5 and 6). In this project, monoclonal anti-
GBP4 clone 9A12c6d3 was used. 
 
2.5 Toxoplasma/ Host interaction assays 
2.5.1 FACS for invasion assay 
Cells were grown to 80% confluency and were infected with irradiated Toxoplasma 
as described above. After 1 hour of infection, the cells were incubated with 2x 0.5% 
Trypsin +EDTA (Life Technologies #15400-054) at 37˚C to allow the cells to detach 
from the culture plate. The reaction was quenched with warmed DMEM media 
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containing 10% FBS, and the cells were transferred into a 15ml Falcon tube to be 
pelleted by centrifugation at 300xg for 5 minutes. The media was aspirated and the 
cells were washed twice in ice cold PBS by centrifugation at 37˚C at 300xg. After 
the supernatant was aspirated following the final wash, the cells were resuspended 
in ice-cold 4% PFA and transferred to a well of a round-bottomed 96-well plate to 
be incubated on ice for 20 minutes. PBA was added on top and the plate was 
centrifuged at 450xg for 3 minutes to pellet the cells. The supernatant was removed 
by gently inverting the plate, after which the cells were resuspended in PBA and 
transferred to a FACS tube ready for analysis on a BD LSR-II flow cytometer. 
 
2.5.2 Plaque assay  
A549 cells were allowed to grow to confluency in a 24-well plate before being 
infected with either 300 type I or 600 type II Toxoplasma. The infection was allowed 
to persist for the desired length of time, before the cell layer was scraped and the 
parasites released by syringe lysis using a 25-gauge needle. This suspension was 
then plated onto unstimulated, confluent HFFs in 1:2 serial dilutions. The infection 
persisted for 4 days at 37˚C in 5% CO2 after which plaques were counted using a 
microscope.   
 
2.5.3 Assessing parasite vacuolar replication  
Cells were grown on glass coverslips until confluency. They were infected with 
eGFP expressing Toxoplasma at an MOI of 0.5, and the infection was allowed to 
persist for the desired length of time. The cells on coverslips were washed 
extensively to ensure all parasites that had not invaded were removed, after which 
they were fixed, permeabilised and blocked as above. The coverslips were washed 
3 times in PGAS, followed by 3 washes in PBS, with 1:10,000 Hoechst DNA stain 
contained in the last wash. They were then mounted on glass slides as described 
above. The slides were viewed on a bright-field microscope and the number of 
parasites per vacuole were counted using x63 lens. A minimum of 100 vacuoles 
was counted, with each sample produced in triplicate. 
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2.5.4 Statistical analysis 
Parasite replication assays were carried out in triplicate and at least twice. For 
these two independent variables (time and parasite number) are compared and so 
a 2-way ANOVA statistical analysis was carried out to determine significance. 
Plaque assays were carried out in triplicated and at least twice. The plaque assay 
in Figure 15 was normalised to 100% growth in wild type unstimulated cells, thus in 
this experiment, a paired t-test was used to calculate significance. In plaque assays 
comparing growth between cell types as well as IFNγ-stimulation, experiments, two 
independent variables are compared (IFNγ-stimulation and cell type) and so a 2-
way ANOVA was carried out to determine significance. When calculating the 
statistical significance between the densities of bands on an immunoblot or the 
intensity of fluorescence staining in immunofluorescence images an unpaired t-test 
was utilised due to the comparison of two independent groups. 
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Chapter 3. Generation and characterisation of 
molecular tools and techniques to study hGBPs 
3.1 Results 
3.1.1 Generation and characterisation of molecular tools and techniques to 
study hGBPs 
3.1.1.1 Antibodies 
As the seven GBPs have such a high level of identity across the family, obtaining 
antibodies that are specific is not trivial. Consequently, there is a lack of 
commercial antibodies available, with no guarantee of specificity for individual 
family members. To ensure I had antibodies that were directed to specific regions 
of the protein, thereby increasing the probability of specificity for each GBP, it was 
decided to produce antibodies with which to carry out this project. There are a 
number of options when producing bespoke antibodies. While it was necessary to 
obtain the best tools possible, cost considerations had to be taken into account. 
Therefore, I proceeded with a mixture of polyclonal and monoclonal antibody 
production. Unique peptide sequences were chosen for each family member, 
ensuring that each one had a high immunogenic capacity using an online software 
tool from Thermo Scientific (https://www.thermofisher.com/uk/en/home/life-
science/antibodies/custom-antibodies/custom-antibody-production/antigen-profiler-
antigen-preparation.html#). The peptides designed for the polyclonal antibody 
production ranged from 13 to 16 amino acids in length and were selected from the 
C-terminal of the protein sequence. This is because the C-terminus has the highest 
level of sequence variability, giving an increased likelihood of making antibodies 
that are family member specific (Figure 5). One rabbit per human GBP was 
inoculated with the appropriate peptide before test-bleeds were harvested at three 
time points after infection, prior to the final bleed. The sera from these bleeds were 
screened for reactivity in immunoblot against mouse fibroblasts that inducibly 
overexpressed the respective human GBP. Table 2 demonstrates the candidate 
polyclonal antibodies and their reactivity in immunoblot. 
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 Furthermore, two of the unique peptide sequences were elongated in order 
to produce monoclonal antibodies. From the literature, it had been reported that 
GBPs 2 and 4 could be found in the nucleus under certain conditions (Tripal et al., 
2007). With the exception of nuclear trafficking Ran proteins, human GTPases 
have had limited function reported in the nucleus, so these two candidates 
appeared very interesting. On the basis of this, monoclonal antibodies were 
produced to GBP2 and GBP4 (Figure 5). Tables 3-6 demonstrate the candidates 
for GBP2 and GBP4 monoclonal antibody production. Four mice per GBP were 
inoculated with specific antibody. The company determined levels of antibody via 
ELISA and the animals with high antibody titre underwent fusion. The resulting 
hybridoma supernatants were analysed by the company via ELISA against the 
inoculating peptide. After reactive candidates were identified, I tested the 
supernatants by immunoblotting for specificity against lysates of mouse fibroblasts 
that inducibly overexpress TAP-tagged GBP family members. Three mice 
underwent fusion in order to produce the anti-GBP2 antibody. Of these, one mouse 
yielded no reactive hybridomas while the second and third mice produced a total of 
two reactive hybridomas. These were cloned to produce a total of four reactive 
antibodies (Table 3 and 4). In this project, monoclonal anti-GBP2 clone 9E12c1 
was used. Two mice underwent fusion to produce hybridomas for monoclonal anti-
GBP4 antibody production. From these, one of the fusion events produced no 
reactive hybridomas. The second fusion event yielded two reactive hybridomas, 
which were cloned and then sub-cloned to produce four reactive antibodies (Tables 
5 and 6). In this project, monoclonal anti-GBP4 clone 9A12c6d3 was used. 
 A polyclonal antibody had been made previously using full-length 
recombinant GBP1. However, it had never been properly characterised in regard to 
specificity and cross-reactivity to other family members, and therefore was not 
being used either reliably or to its full potential. This antibody was added to the 
repertoire requiring testing. 
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Figure 5 Alignment of GBP C-termini and peptides for antibody production 
Sequences were aligned using Clustal Omega Multiple Sequence Alignment tool.  
Blue indicates peptides for polyclonal antibody production. The yellow section 
represents the additional amino acids that were selected in addition to the blue 
peptide sequence; this extended peptide was used for monoclonal antibody 
production for GBP2 and GBP4. 
  
  
GBP5      AVKQGIYSKPGGHNLFIQKTEELKAKYYREPRKGIQAEEVLQKYLKSKESVSHAILQTDQ 
GBP2      DVKQGTFSKPGGYRLFTQKLQELKNKYYQVPRKGIQAKEVLKKYLESKEDVADALLQTDQ 
GBP1      EVKAGIYSKPGGYRLFVQKLQDLKKKYYEEPRKGIQAEEILQTYLKSKESMTDAILQTDQ 
GBP3      EVKAGIYSKPGGYCLFIQKLQDLEKKYYEEPRKGIQAEEILQTYLKSKESVTDAILQTDQ 
GBP6      SISAGSFSVPGGHKLYMETKERIEQDYWQVPRKGVKAKEVFQRFLESQMVIEESILQSDK 
GBP4      SILRGIFSVPGGHNLYLEEKKQVEWDYKLVPRKGVKANEVLQNFLQSQVVVEESILQSDK 
GBP7      SISRGTFFVPGGHNIYLEAKKKIEQDYTLVPRKGVKADEVLQSFLQSQVVIEESILQSDK 
           :  * :  ***: :: :  : :: .*   ****::*.*::: :*:*:  : .::**:*: 
 
GBP5      ALTETEKKKKEAQVKAEAEKAEAQRLAAIQRQNEQMMQERERLHQEQVRQME----IAKQ 
GBP2      SLSEKEKAIEVERIKAESAEAAKKMLEEIQKKNEEMMEQKEKSYQEHVKQLTEKMERDRA 
GBP1      TLTEKEKEIEVERVKAESAQASAKMLQEMQRKNEQMMEQKERSYQEHLKQLTEKMENDRV 
GBP3      ILTEKEKEIEVECVKAESAQASAKMVEEMQIKYQQMMEEKEKSYQEHVKQLTEKMERERA 
GBP6      ALTDREKAVAVDRAKKEAAEKEQELLKQKLQEQQQQMEAQVKSRKENIAQLKEKLQMERE 
GBP4      ALTAGEKSIAAERAMKEAAEKEQELLREKQKEQQQMMEAQERSFQEYMAQMEKKLEEERE 
GBP7      ALTAGEKAIAAKQAKKEAAEKEQELLRQKQKEQQQMMEAQERSFQENIAQLKKKMERERE 
           *:  **         *: :   : :     : :: *: : :  :* : *:       :  
 
GBP5      NWLAEQQKMQEQQMQEQAAQLSTTFQAQNRSLLSELQHAQRTVNNDDP--CVLL------ 
GBP2      QLMAEQEKTLALKLQEQERLLKEGFENESKRLQKDIWDIQMRSKSLEP--ICNIL----- 
GBP1      QLLKEQERTLALKLQEQEQLLKEGFQKESRIMKNEIQDLQTKMRRRK---ACTIS----- 
GBP3      QLLEEQEKTLTSKLQEQARVLKERCQGESTQLQNEIQKLQKTLKKKT---KRYMSHKLKI 
GBP6      HLLREQIMMLEHTQKVQNDWLHEGFKKKYEEMNAEISQFKRMIDTTKNDDTPWIARTLDN 
GBP4      NLLREHERLLKHKLKVQEEMLKEEFQKKSEQLNKEINQLKEKIESTKNEQLR-LLKILDM 
GBP7      NYMRELRKMLSHKMKVLEELLTEGFKEIFESLNEEINRLKEQIEAAENEEPSVFSQILDV 
          . : *         :     *    :     :  ::   :             :       
 
GBP5      --------------------------------------- 
GBP2      --------------------------------------- 
GBP1      --------------------------------------- 
GBP3      --------------------------------------- 
GBP6      LADELTAILSAPAKLIGHGVKGVSSLFKKHKLPF----- 
GBP4      ASNIMIVTLPGASKLLGVGTKYLGSRI------------ 
GBP7      AGSIFIAALPGAAKLVDLGMKILSSLCNRLRNPGKKIIS 
                                                 !
Peptide selected for polyclonal antibody production
592
595
591
586
633
640
638
Peptide selected for monoclonal antibody production
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Table 2 Screening of polyclonal antibody sera for specific bands in immunoblot 
GBP Test bleed 1 Test bleed 2 Test bleed 3 Final bleed 
1 P P P  P 
2 P P P P 
3   P  
4 P P P P 
5 P    
6     
7 P P P P 
 
One rabbit per human GBP family member was inoculated with the appropriate 
peptide. Test bleeds were taken at 3 intervals before a final bleed. Where ticks are 
shown, a band for the individual GBP was observed in immunoblot. Where blank, 
no signal was observed.  
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Table 3 Candidates for monoclonal GBP2 antibody production from fusion of 
mouse ‘R’ 
 Monoclonal human GBP2 
4 mice immunised; V, B, R, N 
 Fusion of mouse R Day 66 
Hybridoma Signal observed 
by ELISA 
Signal observed 
in IB after ELISA 
ID of clones with signal 
observed in IB 
1D3    
1A5    
1B5    
1A7    
1E9 P   
1E10    
1G11    
2G2    
2F3    
2H3    
2D6    
2C8 P   
2A10    
2F10    
2B11    
2A12    
2C12    
3B2    
3G3    
3C5    
3D7    
3C9    
3G9    
3D10    
3C11    
3H11    
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Continued…  
 Monoclonal human GBP2 
4 mice immunised; V, B, R, N 
 Fusion of mouse R Day 66 
Hybridoma Signal observed 
by ELISA 
Signal observed 
in IB after ELISA 
ID of clones with 
signal observed in IB 
4C1    
4G1    
4B2    
4B3    
4A4    
4C8    
5H2    
5B4    
5E4    
5B5    
5G5    
5E7    
5G10    
5G11    
5C12    
6F2    
6D3    
6H4    
6C5    
6E5    
6F6 P   
6D7    
6F8    
 
A tick represents a signal in ELISA or a specific band in immunoblot. All candidates 
that demonstrated a signal in ELISA underwent testing in IB. Where blank, no 
signal was observed when screened in ELISA and/or immunoblot. 
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Table 4 Candidates for monoclonal GBP2 antibody production from fusion of 
mice 'V' and 'N' 
 Monoclonal human GBP2 
4 mice immunised; V, B, R, N 
 Fusion of mice V and N after Day 192 
Hybridoma Signal observed 
by ELISA 
Signal observed 
in IB after ELISA 
ID of clones with 
signal observed in IB 
1A6 P P 1A6d6 
1A6g2 
1G12 P   
2F4    
2H11 P   
3H1 P   
3F2 P   
3B7    
5H12    
6A1 P   
6B6 P   
6H6 P   
6D9 P   
6G12    
7D1 P   
7A5    
7A4 P   
7G7    
7A12    
7G12    
8H1 P   
8G9    
9F1    
9E3 P   
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Continued… 
 Monoclonal human GBP2 
4 mice immunised; V, B, R, N 
 Fusion of mice V and N after Day 192 
Hybridoma Signal observed 
by ELISA 
Signal observed 
in IB after ELISA 
ID of clones with 
signal observed in IB 
9B8    
9H9 P   
9E12 P P 9E12b2 
9E12c1 
10F1    
10H3 P   
10C4    
10C5    
10G8    
11F6 P   
13A3    
13D3    
13B10    
13D11 P   
13C12    
 
A tick represents a signal in ELISA or a specific band in immunoblot. All candidates 
that demonstrated a signal in ELISA underwent testing in IB. Where blank, no 
signal was observed when screened in ELISA and/or immunoblot. 
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Table 5 Candidates for monoclonal GBP4 antibody production from fusion of 
mouse 'N' 
 Monoclonal human GBP4 
4 mice immunised; V, B, R, N 
 Fusion of mouse N Day 129 
Hybridoma Signal observed 
by ELISA 
Signal observed 
in IB after ELISA 
ID of clones with 
signal observed in IB 
1C2    
1D8    
4A4    
4H12    
6B9    
7E1    
9H6    
9C12    
 
A tick represents a signal in ELISA or a specific band in immunoblot. All candidates 
that demonstrated a signal in ELISA underwent testing in IB. Where blank, no 
signal was observed when screened in ELISA and/or immunoblot. 
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Table 6 Candidates for monoclonal GBP4 antibody production from fusion of 
mouse 'R' 
 Monoclonal human GBP4 
4 mice immunised; V, B, R, N 
 Fusion of mouse R Day 173 
Hybridoma Signal observed 
by ELISA 
Signal observed in 
IB after ELISA 
ID of clones/ sub-
clones with signal 
observed in IB 
2A8     
3F9     
4A7     
4E9 P    
5E1 P P 5E1d1 
5E1g1 
 
5F9     
5C10 P    
6C6     
6D10     
6H11     
9D5 P    
9A12 P P 9A12c6 9A12c6f8 
9A12c6d3 
10D2 P    
10D3     
10H8     
 
A tick represents a specific band in immunoblot. All candidates that demonstrated a 
signal in ELISA underwent testing in IB. Where blank, no signal was observed 
when screened in ELISA and/or immunoblot. 
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All candidate antibodies were tested to ensure a band of the correct size 
could be detected in other cells via immunoblot using HUVEC lysates, with the best 
candidates taken forward for full characterisation. First, a polyclonal antibody 
produced against the GBP1 peptide was characterised. I, and others, have 
developed mouse 3T3 fibroblasts that inducibly overexpress tagged individual 
family members, which will be described later in this chapter. Using lysates from 
these cells I showed that the polyclonal antibody was specific for this GBP family 
member in immunoblotting (Figure 6A). Furthermore, a band of the correct size 
was detectable in immunoblots of A549 cell lysates that was subsequently lost 
when probing lysates from A549 cells deficient in GBP1 (made by Barbara Clough) 
(Figure 12). Using lysates from the same GBP-overexpressing 3T3 fibroblast cells, 
it was shown that this antibody reacts with both GBPs 1 and 2 in 
immunoprecipitation, but does not cross react with GBP3 (Figure 6B). 
Immunoprecipitation characterisation was limited to GBP1, 2 and 3 due to the 
highest level of identity being present between these family members. It was shown 
that the same antibody was specific to GBP1 in immunofluorescence by lack of 
staining in A549 cells that were deficient in GBP1 protein expression as compared 
to wild type cells (Figure 6C).  
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Figure 6 Characterisation of anti-GBP1 polyclonal antibody 
Immunoblot showing anti-GBP1 antibody reactivity in 3T3 fibroblasts 
overexpressing individual TAP-tagged GBP family members. 10µg of protein was 
loaded into each lane for SDS-PAGE. The same membrane was probed with anti-
Flag to show TAP (HA-Flag) was present (A). Immunoblot showing the 
immunoprecipitation capacity of anti-GBP1 antibody in 3T3 fibroblasts over 
expressing GFP-tagged GBP1, 2 or 3. 40µl of antibody was used to 
immunoprecipitate from 500µg of total lysate. 35µl of immunoprecipitated end 
product was loaded in each lane for SDS-PAGE (B). Immunofluorescence images 
showing staining with anti-GBP1 in A549 WT cells as compared to A549 ∆GBP1 
cells. Scale bars 10µM. Cells were stimulated or not for 18 hours with 10U/ml IFNγ  
(C). Each representative of 3 independent experiments.  
WT +IFNγWT -IFNγ
∆GBP1 +IFNγ∆GBP1 -IFNγ
GBP1 GBP1
GBP1 GBP1
C
A
110-
80-
60-
50-
40-
1 G
FP
2 G
FP
3 G
FP
3T3 GBP-
IB-
IP- α-GBP1
α-GFP
93 kDa
B
110-
80-
60-
50-
40-
3T3 TAP-GBP- 1 2 3 4 5 6 7
α-GBP1
80-
60-
α-Flag
Tool generation and characterisation 
 
57 
 
As mentioned above, it was previously reported that GBP2 and 4 could be 
found in the nucleus (Tripal et al., 2007), therefore these family members were 
used in both polyclonal and monoclonal antibody production. In the process of 
choosing suitable hybridoma clones to take forward, a monoclonal antibody specific 
to GBP2 was identified by immunoblot (Figure 7A). For the polyclonal antibody, a 
number of rabbits were immunised with peptide against GBP2, however none of 
the resulting candidates obtained showed any signal in an immunoblot. Once 
candidates had been selected, further characterisation showed that both 
monoclonal and polyclonal antibodies had a capacity for immunoprecipitation, 
however neither antibody was specific. The anti-GBP2 polyclonal antibody also has 
the capacity to immunoprecipitate GBP1 protein (Figure 7B) and the monoclonal 
antibody retrieves at least GBP1 and GBP3 in an unspecific manner (Figure 7C).  
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Figure 7 GBP2 antibody characterisation 
Immunoblot showing reactivity of the monoclonal anti-GBP2 antibody in 3T3 mouse 
fibroblasts overexpressing individual TAP-tagged human GBPs. 10µg of total 
protein was loaded into each lane for SDS-PAGE. The same membrane was 
probed with anti-Flag to show TAP (HA-Flag) was present (A). Immunoblot showing 
the immunoprecipitation capacity of monoclonal anti-GBP2 antibody (B) and the 
polyclonal anti-GBP2 antibody (C) in 3T3 fibroblasts overexpressing TAP-tagged 
GBP1, 2 or 3. 35µl of immunoprecipitated end product was loaded in each lane for 
SDS-PAGE.10µl of antibody was used to IP from 500µg of total lysate in (B). 40µl 
of antibody was used to IP from 500µg of total lysate in (C). Each representative of 
3 independent experiments. 
 
When characterising the anti-GBP4 antibodies, a rabbit polyclonal antibody proved 
specific in immunoblots (Figure 8A). The monoclonal antibodies that were raised 
against GBP4 were tested in immunoblots against lysates from 3T3 fibroblasts 
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overexpressing individual GBPs. None were found to produce any signal in this 
application. However, upon further testing, it was shown that an anti-GBP4 
monoclonal antibody could specifically retrieve GBP4 by immunoprecipitation 
(Figure 8B). 
 
Figure 8 GBP4 antibody characterisation 
Immunoblot showing reactivity of anti-GBP4 polyclonal antibody in 3T3 fibroblasts 
overexpressing individual TAP-tagged GBPs. 10µg of total protein was loaded into 
each lane for SDS-PAGE. The same membrane was probed with anti-Flag to show 
TAP (HA-Flag) was present (A). Immunoblot showing immunoprecipitation capacity 
of anti-GBP4 monoclonal antibody in 3T3 fibroblasts overexpressing GFP-tagged 
GBP4. 65µl of antibody was used to IP from 500µg of total lysate. 35µl of 
immunoprecipitated end product was loaded in each lane for SDS-PAGE (B). Each 
representative of 2 independent experiments.  
 
 A polyclonal antibody against GBP1 had previously been produced in rabbit 
by Sebastian Virreira Winter and Eva Frickel by using full-length recombinant 
protein. Due to the very high levels of identity between the seven GBP family 
members, it was important to fully characterise this antibody and determine its 
specificity. Lysates from 3T3 fibroblasts overexpressing individual GBP family 
members were probed with this recombinant protein antibody. It became clear that 
although the antibody recognised GBP1 protein, it was cross-reactive with GBPs 2, 
3 and 6 as well (Figure 9). Therefore it has been labelled as an anti-pan-GBP 
antibody, and will be referred to as such from this point onwards.  
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Figure 9 pan-GBP antibody characterisation 
Immunoblot showing the reactivity of the anti-pan-GBP in 3T3 fibroblasts 
overexpressing individual TAP-tagged GBPs. 10µg of protein loaded into each lane 
for SDS-PAGE. The same membrane was probed to show that TAP (HA-Flag) was 
present. Representative of 3 independent experiments. 
  
3.1.1 Overexpression of human GBPs in mammalian cells 
In order to assess the function of the GBPs in the context of a Toxoplasma gondii 
infection, I planned to overexpress each family member in a variety of human cells. 
These cells would be infected with Toxoplasma before evaluating how parasite 
survival and replication would be affected. Within the literature, a number of 
techniques for overexpression of human GBPs have been demonstrated (Modiano 
et al., 2005, Pammer et al., 2006, Duan et al., 2006, Tripal et al., 2007, Schnoor et 
al., 2009, Tietzel et al., 2009, Al-Zeer et al., 2013, Forster et al., 2014, Ostler et al., 
2014, Blondel et al., 2015, Li et al., 2015). At the same time, there are variations 
within even single laboratories in the methods used to overexpress this family of 
proteins. Therefore, to establish this technique, a number of transfection methods 
were employed in order to find the most efficient and least toxic approach. 
First, I used a lipid based transfection method to transiently overexpress 
human GBPs. All seven of the individual GBP family members were cloned into C1 
and pcDNA3 vector plasmids with either a mCherry- or GFP-N-terminus tag. This 
was a large undertaking that was done in collaboration with a lab at Duke 
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University, and with another member of the Frickel lab. GBP1 and 2, with both GFP 
and mCherry tags were produced by the Coers lab. GBPs 3-6 with a GFP tag were 
produced by Barbara Clough. I produced GFP-GBP7 and mCherry-tagged GBPs 3-
7. These were then employed to transiently transfect a variety of human cell types 
with Mirus TransIT 2020 lipid transfection reagents. It became apparent that after 
transfection, the cells began to look very sickly. While fluorescent cells were 
observed (data not shown), after only a few hours of this transfection the cells died. 
Hence, these results imply that the cells did not tolerate the overexpression of 
these proteins. With an expression window of less than 12 hours before the cells 
succumbed, it was not possible to carry out an infection and viability assay with 
Toxoplasma gondii. Hence, transient overexpression was not a feasible method 
with which to study GBPs.  
Following this, a ‘Tet-On’ inducible lentiviral method of transduction 
technique was employed. THP-1 monocytes would be stably transduced before 
differentiation into macrophages. The expression of tagged-GBPs is then inducible 
with the addition of doxycycline. Lentiviral transduction generally allows for a higher 
efficiency due to the advantage of it being able to transfect both dividing and non-
dividing cells. Furthermore, with an inducible system, the transduced cells only 
have the protein expression upregulated when doxycycline treatment is applied. In 
order to stop the virus from recombining inside the cell, the genes necessary to 
package and assemble the virus are contained in separate vectors. To test the 
system, I cloned GBP4 into the pLVX-Tight-Puro-Vector. The pLVX-Tight-Puro 
plasmid containing GBP4 was transfected using TransIT 2020 into HEK293T cells 
along with the two plasmids containing the packaging components. At the same 
time, a separate population of HEK293T cells were transduced with the Tet-On-Adv, 
the lentiviral vector for producing a doxycycline-activated transactivator for this 
system, containing plasmid and the separate packaging plasmids. A control 
lentivirus was produced also by using a pLVX-mCherry vector transfected with the 
packaging plasmids. This would result in a non-inducible overexpression and will 
demonstrate whether the production of virus was effective by analysing the 
resulting transduction. The lentivirus produced was harvested at both 24 and 48 
hours before being pooled, filtered, centrifuged and flash frozen, ready for 
transduction into THP-1 monocytes.   
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 To transduce THP-1 monocytes, cells were incubated either with the 
mCherry-lentivirus or with a combination of the Tet-On-Adv and pLVX-GBP4 viral 
stocks. Polybrene was added to aid the reaction as it is a cationic polymer that can 
neutralise charge repulsion between the virions and sialic acid- allowing greater 
adsorption on to the cell surface (Hunn et al., 2008). The transduction was allowed 
to persist for 6 hours after which the media was changed and selection with G418 
and Puromycin for doubly transduced cells began. The mCherry-expressing cells 
were viewed 24 hours post-transduction, with a high level of fluorescence being 
observed. Before inducing expression of GBP4, the THP-1 monocytes were 
differentiated into macrophages. They were then incubated with doxycycline for 24 
hours to allow the protein to accumulate. After approximately 12 hours, the cells 
looked unhealthy and began to detach from the wells. By 24 hours the cells had 
almost completely ceded to the consequences of transduction of GBPs, when 
compared with control-transduced cells.  
 Another classically used viral-mediated method of transient protein 
overexpression employs Vaccinia virus (Falkner et al., 1992). This system has 
been used in cases of toxic protein expression as it can lead to very rapid 
production of the protein of choice due to its capacity to transcribe DNA in the 
cytoplasm. Conveniently, Vaccinia virus is able to infect any cell type. If GBPs 
could be overexpressed very quickly without a gradual accumulation of protein, the 
cells could be used for a short infection time point experiment before the cells were 
affected by the potential toxicity. Again, GBP4 was used to test the system, this 
time with a GFP-tag at the N-terminal. GFP-GBP4 was cloned into the pJS4 vector 
under a Vaccinia e/l promoter and this was transfected into unstimulated A549 cells, 
THP-1 monocytes and HUVECs that had been infected with Vaccinia virus 1 hour 
prior by Dr Jason Mercer (UCL). Lysates were made of each cell type at time points 
ranging from 4 to 24 hours post transfection. A very low expression was seen at 
time points after 4 hours post transduction in THP-1 monocytes, which could be 
due to the low transfection capacity of these cells. At 4 hours post transduction 
expression of GFP was visible in HUVECs. The HUVECs were visibly unhealthy 
from 8 hours post transduction, and the majority were non viable by the 12 hour 
post transduction time point. Immunoblotting of these lysates with the anti-GBP4 
polyclonal peptide antibody demonstrated that GBP4 protein could be detected 
from 6 hours in HUVECs, and this increased significantly until 12 hours, after which 
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expression was lost- likely due to the cells being dead. What was interesting was 
the lack of GFP-tagged GBP4 expression in these cells. Potentially, the presence 
of the Vaccinia virus in the cell could itself begin to induce endogenous GBP4 
expression in HUVECs. However, when the blots were reprobed, GFP could be 
detected in samples from 8 to 10 hours post infection suggesting that, in fact, the 
tag was being cleaved from the N-terminus of GBP4. It was decided that this was 
not an appropriate method to overexpress GBPs due to the fact Vaccinia may be 
inducing its own GBP response. Although I decided not to continue with this 
Vaccina driven method, I learned that tags may not be stable when expressed at 
the N-terminus of GBP4 and any constructs designed in the future must have tags 
inserted C-terminus instead.  
 While it was becoming increasingly clear that overexpression of GBPs was 
not a suitable method to study their function, it was possible that some inducible 
methods of overexpression could be used as a tool to characterise the bespoke 
antibodies. GeneSwitch is a system sold by Invitrogen that allows for mifepristone 
inducible expression of protein of choice. A hormone expression system is a more 
desirable one than a doxycycline inducible system, as antibiotics may affect 
responses of cells and thus potentially affect the Toxoplasma infection. The basis 
of the system is that a ‘pSwitch’ regulatory plasmid is stably transfected into the cell 
line of choice. After this, the ‘pGene’ plasmid containing the gene of interest is 
stably transfected into the cells with pSwitch. The pSwitch plasmid is responsible 
for expressing low levels of the GeneSwitch protein. This protein is dimerised upon 
treatment with mifepristone, following which it binds with the promoter in the pGene 
plasmid- thus inducing expressing of the protein of choice.  
 It was attempted to stably transfect HFFs with the first plasmid, pSwitch. 
However it was never possible to introduce this plasmid into the HFFs, therefore 
using this system in human cells was not continued. Correspondence with another 
lab revealed they too had problems with this system (Marianne Schmidt, personal 
communication). Shortly after beginning this endeavour, Invitrogen discontinued 
the system.  
Mouse 3T3 fibroblasts that were stably expressing the pSwitch plasmid 
were obtained as a kind gift from Jonathan Howard (Hunn et al., 2008). GFP- and 
TAP-tagged GBPs were cloned into the pGene vector as a joint effort between 
myself, Barbara Clough and the Coers lab at Duke University. GFP- or TAP-GBP1 
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and 2 were cloned by our collaborators at Duke. Barbara Clough produced GFP-
tagged GBPs 3-6. I produced GFP-tagged GBP6 and TAP-tagged GBPs 3-7. 
Sharing the work equally, Barbara Clough and I used these constructs to transfect 
3T3 cells before selecting for successfully transfected cells with antibiotics. The 
cells were incubated with mifepristone for 24 hours before lysing and assessing 
GBP expression with the appropriate antibodies. It was clear that these cells could 
withstand the toxicity of GBP plasmid transfection and protein overexpression, with 
sustained and robust expression possible. Perhaps as the cells are from mouse 
origin, the interacting partners or pathways responsible for toxicity in human cells 
may be missing or incompatible. It should also be noted that these cells were not 
IFNγ inducible, therefore could not be a valid tool for studying GBP function.  
3.1.1.1 Cell Characterisation 
It is important that the study of human GBPs is carried out in an appropriate cell 
type. This means that the protein must be expressed, as well as demonstrating 
they are IFNγ sensitive within the particular cell type. For this project, GBPs were 
characterised first in A549 lung epithelial cells. These cells are robust cells that are 
widely accepted for biochemical analysis experiments, and have been utilised in a 
number of immune response studies, particularly in cancer studies (Brichory et al., 
2001, Hartman et al., 2007, Hawdon et al., 2010, Li et al., 2012, Guitierrez et al., 
2016). A549s were plated and allowed to adhere before stimulating with IFNγ 
overnight. Following this stimulation the cells were lysed and run on SDS-PAGE 
before being transferred to nitrocellulose membrane. The membranes were probed 
with the anti -pan-GBP, -GBP1, -GBP2 and -GBP4 antibodies. It was clear that all 
of the tested GBPs were substantially expressed in these A549 cells (Figure 10 A, 
B & C). They all demonstrated sensitivity to IFNγ, however interestingly GBP1 
expression was also detected at basal level (Figure 10A), a result that will be 
confirmed by qPCR. 
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Figure 10 Expression of GBP1, 2 and 4 in A549 cells 
Immunoblots showing levels of protein expression of GBP1 (A), GBP2 (B) and 
GBP4 (C) in A549 cells. GBP1 and GBP4 polyclonal antibodies were used, and 
GBP2 monoclonal antibody was used. 10µg of protein was added to each lane for 
SDS-PAGE. Cells were stimulated or not for 18 hours with 10U/ml IFNγ. Arrows 
represent GBP band. Each representative of 3 independent experiments. 
 
 THP-1 macrophages were characterised for GBP expression next. It is 
widely reported in the literature that macrophages are the frontline of defence to 
Toxoplasma (Dupont et al., 2012). The THP-1 cells were differentiated into 
monocytes before stimulating overnight with IFNγ. The macrophages were lysed 
and the lysates run on SDS-PAGE before being transferred to nitrocellulose 
membrane. These membranes, as above, were probed with anti –pan-GBP, -GBP1, 
-GBP2 and –GBP4 antibodies. Again, in this cell type GBPs were all well 
expressed in the cells induced with IFNγ (Figure 11 A, B & C). From the results of 
the characterisation of GBPs in A549 and THP-1 cells signified it was clear that 
these were suitable cells in which to study GBPs both in steady state and in 
Toxoplasma infected cells. 
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Figure 11 Expression of GBP1, 2 and 4 in THP-1 macrophages 
Immunoblots showing the protein expression levels of GBP1 (A), GBP2 (B) and 
GBP4 (C) in THP-1 macrophages. GBP1 and GBP4 polyclonal antibodies were 
used, and GBP2 monoclonal antibody was used. 10µg of protein was added to 
each lane for SDS-PAGE. Cells were stimulated or not for 18 hours with 10U/ml 
IFNγ. Each representative of 3 independent experiments.  
  
 Production of knock out cells using the CRISPR-Cas9 genome editing 
technique spells great advances in cell biology. It is important however, that the 
cells are well characterised to ensure they are reliable. GBP1 knock out cells, using 
CRISPR-Cas9, were generated in A549 cells by Barbara Clough. Before they were 
implemented in studies using Toxoplasma, I needed to be sure that GBP1 protein 
was truly knocked out. First, a lack of GBP1 protein expression was confirmed. 
This was done by immunoblot using the specific anti-GBP1 polyclonal peptide 
antibody. It is clear that GBP1 protein cannot be detected in these cells (Figure 
12A). The peptide immunogen used for developing this antibody is in a region from 
the C-terminal of GBP1 (Figure 5). The guide RNA used to make these A549 
∆GBP1 cells was targeted to a region towards the N-terminal part of the protein, 
indicating that a mutation has been made and therefore the protein cannot be 
translated. The same membrane was reprobed with the anti-pan-GBP antibody to 
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ensure that the expression of other family members was not affected (Figure 12B). 
To confirm the mutation was in the correct position sequencing on the A549 
∆GBP1 cells was carried out by Barbara Clough, with the disruption of the DNA 
sequence being exactly where predicted within the guide RNA region. Furthermore, 
the cells were plated on coverslips and fixed in order to carry out 
immunofluorescence staining with the anti-GBP1 antibody. It was clear that the 
A549 ∆GBP1 cells had significantly lower staining than their wild-type counterpart 
(Figure 6). The addition of these cells to the repertoire of GBP tools is very valuable 
due to the fact they can be utilised to monitor GBP1 expression during a 
Toxoplasma infection.  
 
Figure 12 Characterisation of ∆GBP1 cells 
Immunoblot showing lysates from A549 cells that had GBP1 targeted for disruption 
by CRISPR, probed with the anti-GBP1 polyclonal peptide antibody. 10µg of 
protein was added to each lane for SDS-PAGE. (A). Immunoblot showing lysates 
from A549 cells that had GBP1 targeted for disruption by CRISPR, probed with the 
anti-pan-GBP polyclonal antibody against recombinant GBP1 whole protein. 10 µg 
of protein was added to each lane for SDS-PAGE (B). Cells were stimulated or not 
for 18 hours with 10U/ml IFNγ. Each representative of 3 independent experiments. 
All samples from same experiment on the same day. 
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3.1.2 Optimisation of techniques to evaluate Toxoplasma infection 
characteristics 
A large aim within this project is to determine whether or not GBPs play a role 
during infection with the parasite Toxoplasma gondii. In order to answer this 
question I require reliable methods to assess the survival and viability of parasites 
under varying conditions. In order to carry this out, I required techniques to 
determine how well the parasites were able to invade, replicate and form plaques.  
 To observe the efficiency of parasite invasion, a FACS based approach can 
be utilised. I used γ-irradiated td-Tomato parasites, which are invasion-competent 
but replication-deficient Toxoplasma, ensuring accurate assessment of parasite 
burden per cell without the confounding factor of parasite replication. These 
Toxoplasma were allowed to incubate with cells overnight before the cells were 
thoroughly washed and fixed. To analyse, cell reads were taken for the same 
length of time while gating focused on cells displaying a red fluorescence indicating 
the presence of an intracellular td-Tomato parasite. Since it was important to show 
that Toxoplasma has a capacity for invading A549 cells this method was employed. 
It was demonstrated that almost 50% of A549 cells were infected by this parasite, 
with a slight reduction of invasion efficiency seen when the cells were stimulated 
with IFNγ overnight prior to infection (Figure 13). 
 
Figure 13 Invasion capacity of Toxoplasma in A549 cells 
Graph displaying percentages of A549 cells that have been invaded by td-tomato 
type II Toxoplasma via fluorescence in the PE channel. An isotype control was 
carried out to ensure the correct peaks were observed. Cells were stimulated or not 
for 18 hours with 10U/ml IFNγ. MOI 1. Graphs representative of 3 independent 
experiments. 
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 To determine how well a parasite can replicate within a cell, 
immunofluorescence microscopy was employed. Toxoplasma gondii expressing 
GFP were seeded onto A549 cells on glass coverslips and the infection was 
allowed to persist for a specific number of hours. The cells were then washed 
thoroughly and fixed before being mounted onto slides ready for analysis under the 
microscope. At least 100 vacuoles were identified per sample at random, and 
within each of the vacuoles the number of parasites were counted. By counting 1, 2, 
4 or 8 parasites per vacuole, it was possible to calculate the number of times a 
parasite had replicated within the cell. It was necessary to show that Toxoplasma 
replicates, and can be controlled by IFNγ, in A549 cells in the way that has been 
widely described in the literature. Therefore, using this method, an IFNγ mediated 
control of Toxoplasma replication could be observed and calculated. I was able to 
show a significant reduction in parasite replication when the A549s were stimulated 
overnight with IFNγ prior to infection, this was apparent at 12 hours post-infection 
and became more striking by 18 and 24 hours post infection (Figure 14). 
 
Figure 14 Replication of Toxoplasma in A549 cells 
Graphical representation of replication of vacuolar type II Toxoplasma gondii in 
A549 cells. Cells were stimulated or not with 10U/ml IFNγ for 18 hours. N=3 
independent experiments each performed in triplicate. Significance was determined 
using 2-way ANOVA, *p<0.01, ****p<0.00001. 
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 A plaque assay is a widely accepted technique with which to determine the 
fitness of Toxoplasma gondii. The principal of this method is to seed parasites on a 
confluent layer of fibroblasts and count the resulting plaques formed after 3-5 days 
of infection. This method works well in contact inhibited cells such as HFFs. 
However there is a caveat in the fact that many other cell types do not stay 
adherent when infected with Toxoplasma gondii, as well as the fact that few cells 
are truly contact inhibited in growth. When a plaque assay was attempted with 
A549 cells, it was observed that after 24 hours of infection the cells began to lift 
meaning plaques were uncountable. In order to overcome this challenge, an 
indirect plaque assay was designed. This technique involved incubating parasites 
inside A549 cells for specific amounts of time before lysing the parasites from the 
cells and seeding the resulting numbers on a confluent monolayer of unstimulated 
HFFs in a dilution series. Plaques were then counted after the usual 3-5 days of 
growth in the HFFs. This method made it possible to move a plaque assay in to 
numerous cell types. When the plaques were counted after 3-5 days in 
unstimulated HFFs, Toxoplasma that had been incubated for 24 hours in pre-
stimulated A549 cells showed an IFNγ-dependent restriction, demonstrating that 
this indeed was a representative way of determining parasite fitness (Figure 15). 
 
Figure 15 Indirect plaque assay showing Toxoplasma survival in A549 cells 
Graph showing IFNγ-dependent restriction of type I and type II Toxoplasma as 
determined by indirect plaque assay after 24 hours of infection in A549 cells. Cells 
were stimulated or not with 10U/ml IFNγ for 18 hours. 300 type I parasites or 600 
type II parasite were used. Values were normalised to 100% growth in unstimulated 
cells. N=3 independent experiments, each carried out in triplicate. Significance was 
determined using paired t-test, *p<0.01, ***p<0.0001.  
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3.2 Discussion 
3.2.1 Tool characterisation 
GBP-specific antibodies 
One of the most important parts of a successful study is the quality of the tools at 
your disposal. In order to identify the characteristics of individual GBP family 
members, I began by ensuring I had the most reliable and well-characterised tools 
possible. The first step was to design polyclonal and monoclonal antibodies, which 
I fully analysed to be certain about the results they produced. Considering that 
GBPs were discovered over 30 years ago, the question arises why better tools are 
not more widely and commercially available. This is possibly due to the fact that the 
proteins have such a high level of identity and similarity that producing antibodies 
that are specific for individual family members is very difficult. The most widely 
used antibody directed at human GBP is one that recognises the family members 1 
to 5.  
A number of other groups have published articles using antibodies against 
both mouse and human GBPs that were produced in their respective labs. In 2002 
Lubeseder-Martellato et al. produced a monoclonal antibody in rat against 
recombinant human GBP1 that was affinity purified against recombinant human 
GBP1-His6 peptide. Two clones were produced and implemented in immunoblot, 
each reacted with both human GBP1 and GBP2 as determined by probing lysates 
from Escherichia coli that express recombinant His6-tagged GBP1 or GBP2 
(Lubeseder-Martellato et al., 2002). In 2007, Degrandi et al. produced polyclonal 
antibodies against mouse GBPs 1, 2, 3, 4, 5 and 7. This was done by immunising 
rabbits with peptides from each protein before the rabbit sera was texted against 
lysates of 293T cells that were transfected with each mouse GBP (1-10). Each 
serum was then affinity purified against the specific peptide sequence against 
which they were produced (Degrandi et al., 2007). It was from these sequences 
that I took inspiration when first identifying the specific peptides against which I 
would raise antibodies. Shenoy et al. produced a monoclonal antibody against full-
length recombinant mouse GBP5, as well as polyclonal antibodies against peptide 
sequences from human GBPs 1 to 6. These affinity purified polyclonal antibodies 
were screened in turn against E.coli lysates expressing recombinant His-6-tagged 
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individual human GBP family members to ensure there was no cross-reactivity 
(Shenoy et al., 2012). These other labs have shown it is possible to produce the 
tools required to study GBPs even though the difficulties I have outlined in this 
project exist. A monoclonal antibody is preferable in terms of longevity as the 
hybridomas can be brought back into culture to obtain more supernatant. However, 
Degrandi et al. and Shenoy et al., and now I have shown that polyclonal antibodies 
can be just as useful for making important discoveries about these proteins.  
The aim within this project was to establish antibodies with which I could 
carry out immunofluorescence, immunoblotting and immunoprecipitation. I 
successfully obtained antibodies against GBP1, GBP2 and GBP4. The polyclonal 
anti-GBP1 antibody is proficient in immunoblotting, immunofluorescence and 
immunoprecipitation, however retrieves GBP2 also during immunoprecipitation. For 
GBP2, monoclonal and polyclonal antibodies were produced. The monoclonal 
antibody performs excellently in immunoprecipitation and immunoblotting. The 
polyclonal anti-GBP2 antibody was not functional for immunoblotting or 
immunofluorescence, but did efficiently retrieve GBP2 during immunoprecipitation. 
Monoclonal and polyclonal antibodies against GBP4 were produced, with the 
polyclonal antibody performing effectively in immunoblotting while the monoclonal 
antibody could be utilised in immunoprecipitation. More antibodies have been 
produced and characterised in part, however they have not been fully optimised 
and as such provide a valuable repertoire of tools that can potentially be utilised in 
the future (Appendix). 
 Many candidate antibodies that were produced recognised bands of 65-
67kDa on an immunoblot, however on closer inspection they were not specific for 
individual family members. I was not surprised by this outcome. When protein 
family members show such a high level of identity, the cross reactivity of an epitope 
is expected. There was most cross-reactivity between GBPs 1 and 3 as these 
GBPs exhibit identity levels of 88% (Olszewski et al., 2006). In light of this, having 
produced a GBP1-specific antibody is highly valuable. The lack of specificity for 
one GBP family member was the biggest hurdle that I came upon while 
characterising these antibodies. However, this does not mean that they will not 
prove useful in the future. As mentioned above, most human GBP studies have 
published using a commercial antibody for GBP family members 1-5. Therefore, 
while we want to differentiate out the functions of the specific GBPs, we can use 
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combinations of these broad-range antibodies to determine overall expression of 
this family of large GTPases. A large problem I encountered through the process 
was the lack of signal altogether when testing for effectiveness. While I used 
software to choose the most immunogenic peptide sequence, as well as the 
company conjugating keyhole limpet haemocyanin to the peptide, in many of the 
animal subjects there was no apparent response. This could be due to an 
inaccuracy of the software predictive abilities. Perhaps the chosen immunogens 
were insufficient to produce an intense immune response to result in highly avid 
antibodies.  
 Polyclonal antibodies are relatively inexpensive to produce, but result in a 
pool of antibodies that potentially recognise a number of variations of the original 
immunogen peptide sequence. While this means there is a higher possibility of 
recognising the protein across a number of techniques, it increases the likelihood of 
an unspecific or weak reaction. Monoclonal antibodies are more costly to produce, 
and although the affinity and specificity is potentially higher for polyclonal 
antibodies, there is a higher chance that, as only one antigen sequence is 
recognised, this may not be a good candidate for target recognition. The 
monoclonal and polyclonal antibodies in this project were produced from very 
similar, but not identical, sequences. This fact together with the different natures of 
poly- and monoclonal antibodies means there is a slight discrepancy between the 
applications that were successful for the different candidates. The anti-GBP2 
monoclonal antibody performs very effectively in immunoblotting, however the 
polyclonal counterpart is completely ineffective in this regard. Perhaps the 
elongation of the peptide sequence in the designing of the monoclonal antibody 
was necessary for the recognition of an epitope that produces an efficient immune 
response. Alternatively, the other components present in the polyclonal antibody 
may dilute the effect of the antibody and a pure, concentrated product from the 
hybridomas is required. With regards to the anti-GBP4 antibodies, it is likely that 
the polyclonal antibody is unable to immunoprecipitate due to a lack of affinity. The 
process of immunoprecipitation requires a binding strength sufficient to maintain 
the antibody-epitope interaction throughout the experimental process. It is likely 
that the monoclonal antibody clone I chose to progress with reacted to an epitope 
that maintained a much stronger immune response, and thus allowed for higher 
affinity antibodies. 
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 It is becoming more apparent that each GBP family member seems to play 
a unique role, and for this reason, having the ability to separate out each GBP is 
becoming much more vital. Therefore it was imperative that I had a good tool with 
which to characterise the antibody candidates. This characterisation of the 
antibodies was only possible due the fact that a cell line that overexpressed 
individual GBP family members was made. The Coers lab at Duke University 
generously supplied the cloned constructs for GFP- and mCherry-tagged GBP1 
and GBP2 expression. I cloned the constructs to produce the GFP-GBP7 cell line, 
as well as the mCherry-tagged GBP 3-7 constructs. Barbara Clough produced the 
constructs for GFP-tagged GBP 3-6 expression. Then sharing the work equally, 
Barbara Clough and I produced mouse fibroblasts that were transfected to stably 
express the components that allowed the inducible overexpression of individual, 
tagged human GBPs. As a result, each antibody could be tested against a range of 
lysates to show exactly which family members were being recognised. Furthermore, 
as mGBPs are not present without IFNγ stimulation, there was no risk of a false 
positive occurring in the form of cross-reaction with the mouse GBP counterparts. 
Another method by which to screen each antibody for specificity would be to use 
lysates of E.coli that express recombinant protein for each individual GBP. This 
method has been used successfully in the past and would be useful to implement 
as a second protocol to confirm our findings. 
 Further to the antibody production and characterisation of all human GBP 
family members, I chose to focus on GBP1 and GBP4. For GBP1, the antibody as 
described above was specific to GBP1 and proficient in IB and IF. Additionally, 
∆GBP1 cells had been developed in the meantime (Barbara Clough, Frickel lab). 
For GBP4 I employed my specific polyclonal antibody to confirm that the protein 
was indeed a nuclear GTPase. Using these antibodies and other tools, I was able 
to outline a number of characteristics of GBPs in steady state and Toxoplasma 
infected cells. Repertoires of other antibodies, including a characterised antibody 
against GBP2, remain for others to continue this work.  
 
Heterologous GBP expression 
Protein overexpression is a technique that is classically used to study the function 
of said proteins during infection. Therefore, I wanted to develop stable 
overexpression systems in an appropriate cell type, with the intention of 
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investigating how this would affect the growth and survival of Toxoplasma. 
Unfortunately I was unable to produce human cells that reliably overexpressed any 
GBP protein. It was obvious that the cells were not able to withstand the 
introduction of additional GBPs, and I could not maintain the overexpressing cells. 
GBP1 has been implicated in basic cellular homeostatic responses, including actin 
remodelling (Ostler et al., 2014) and regulation of the epithelial barrier function 
(Schnoor et al., 2009). Perhaps when overexpression of GBP occurs, there is a 
basic cellular imbalance that causes this inability to retain the cells in a healthy 
state. 
As more literature regarding the function of GBPs is emerging it is clear that, 
in mice at least, these large GTPases are playing an important role in the induction 
of inflammasome immune responses. This is potentially a logical explanation as to 
why the overexpression of GBP protein would result in the cells dying. The 
inflammasome response is a multi-protein innate immune complex is partly 
responsible for the inflammatory reaction against microbial pathogens (Guo et al., 
2015). It assembles in the cytosol and the activation is reliant on signals in the form 
of danger-associated molecular patterns (DAMPs) or pathogen-associated 
molecular patterns (PAMPs) that are a consequence of invading pathogens 
(Martinon et al., 2002, Chen and Nunez, 2010, Lamkanfi and Dixit, 2014). The 
protein forming the scaffold of the complex defines the inflammasome type (Guo et 
al., 2015). The majority of inflammasomes are formed with Nucleotide-binding 
domain, leucine rich repeat containing receptor (NLRs). However non-NLR proteins, 
including absent in melanoma 2 (AIM2) and pyrin, can also establish an 
inflammasome (Takeuchi and Akira, 2010, Guo et al., 2015).  
In 2012, Shenoy et al. identified human GBP5 as a non-NLR promoter of 
NLRP3 inflammasome pathway in response to L. monocytogenes, S. enterica  
typhimurium or to their lipopolysaccharides (LPS). This response leads to release 
of the proinflammatory cytokines IL-β and IL-18 (Shenoy et al., 2012), which are 
upstream in the process of pyroptosis- a type of inflammatory cell death (Lamkanfi 
and Kanneganti, 2012, Strowig et al., 2012). More recently, it has been shown that 
during L. pneumophila or S. enterica typhimurium infection in mice that the GBP 
proteins clustered on chromosome 3 are essential for the activation of a non-
canonical inflammasome response and pyroptosis that is defined by activation of 
caspase-11 (Pilla et al., 2014, Meunier et al., 2014). This activation is dependent 
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on sensing the bacteria in the cytosol, and can be triggered by direct transfection of 
the LPS itself (Pilla et al., 2014). These bacterial pathogens are both contained in a 
vacuole, and in macrophages that lack the GBPchr3-/- family members there was a 
reduced staining for galectin-8, a marker for lysed vacuoles, compared to wild type. 
This indicated that these GTPases were also involved in the breakage of the 
pathogen vacuoles, allowing for inflammasome-activating sensing of the bacterial 
components (Meunier et al., 2014). The AIM2 inflammasome pathway is involved in 
induction of inflammation in response to the sensing of double-stranded DNA, and 
results in cell death by pyroptosis (Guo et al., 2015). Mouse GBP2 and GBP5 are 
implicated in the activation of this inflammasome type during infection with the 
cytosolic bacteria Francisella novicida by inducing bacterial lysis and release of 
DNA to the cytosol to be detected by the AIM2 complex (Meunier et al., 2015, Man 
et al., 2015). It would be very interesting to determine whether or not GBPs play a 
similar role during infection with Toxoplasma in both human and mouse species, 
especially as there has been no evidence published that the PV of this parasite is 
broken during infection in humans. While a secondary signal is also required for 
inflammasome induction, perhaps it is not a saturated response during upregulation 
of the endogenous protein, meaning that overexpressed GBP protein can further 
induce this defensive cell reaction. 
These large GTPases have been strongly implicated, in response to 
pathogenic invaders, to activate a number of processes that result in host cell 
pyroptosis (Pilla et al., 2014, Meunier et al., 2014, Man et al., 2015, Meunier et al., 
2015). Therefore, it would infer that the transfection of GBP DNA into a cell for 
heterologous overexpression is not tolerated as this protein family works to induce 
cell death. 
Since starting this endeavour, communication with a number of other labs 
and individuals has revealed that they also are not able to reliably overexpress 
these proteins. While overexpression has been used in a number of GBP studies, 
often these expressions are not stable. Thus, there is too short a time window 
available after heterologous GBP protein expression meaning prolonged infection 
time points are not feasible. Moreover, if a cell is already compromised, there is no 
guarantee that the host/ pathogen relationship is occurring in the most biologically 
relevant manner. This further highlights that we need to invest time in developing 
other ways with which to determine GBP function. 
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CRISPR-mediated GBP knock out cells 
To have a specific protein reliably knocked out in a cell is one of the most effective 
ways of analysing the role it plays in certain conditions. Therefore, I made sure to 
fully characterise cells that were made to be potentially deficient in GBP1 or GBP4 
using the CRISPR-Cas9 genome editing technique (CRISPR targeting performed 
by Barbara Clough, Frickel lab). I successfully identified A549 cells that did not 
express GBP1 protein on an immunoblot. After these cells were sequenced to 
show that the GBP1 sequence was efficiently disrupted, they were to be used in 
experiments to determine the protein function during a Toxoplasma infection. 
Additionally, I characterised cells that were made to be deficient in GBP4 by 
immunoblot (CRISPR targeting performed by Joseph Wright, Frickel lab, data not 
shown). It is apparent that these cells have been manipulated, but rather than 
lacking GBP4 they contained a truncated version of the protein. It will be 
fascinating to work out if this truncated protein form is still active, and whether or 
not it affects the survival and growth of Toxoplasma. 
 The new development of being able to quickly and efficiently knock out 
proteins using CRISPR-Cas9 is an invaluable tool within the entire biological 
science field. This revolution has been important in this project with GBPs. Studies 
in the past have used knock down methods to determine a functional role of these 
proteins during infections with LPS, bacterial and viral pathogens (Shenoy et al., 
2012, Pan et al., 2012, Al-Zeer et al., 2013). The method has proven useful and 
has led to breakthroughs that have been important to understanding roles that 
GBPs play. However, this is not a sustainable method of deleting a protein in order 
to understand how it functions over a long-term period. Now the advance of 
CRISPR-Cas9 offers a solution for this problem. 
The progress made in the CRISPR field has been exponential. New 
plasmids to enable cloning of the Cas9 system are emerging constantly, resulting 
in more efficient ways to insert the guide RNAs and select for successful 
transfections. Importantly, characterisation of these cells needs to be stringent and 
complete. It is vital that the deletion of the protein is not only tested for using an 
immunoblot approach. A cut and nonhomologous repair of the DNA may occur, but 
there is no guarantee that the protein is not still transcribed in a truncated form. 
Depending on the location of the antibody’s immunogen epitope, this truncated 
protein may or may not be detected by an antibody. Therefore the protein may not 
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be identified for example, but may still be fully or partly functional. For this reason, it 
is necessary to get the specific region of the DNA sequenced, and determine how 
much of the sequence has been disrupted. There is always the risk of off-target 
effects when manipulating the genome using a guide RNA that may locate to a 
gene that is not the desired one. For this reason, as well as sequencing the top 
predicted off-target regions, a second clone made using a different guide sequence 
should be used as comparison. In the case of GBP1, I ensured that there was no 
loss of staining with our pan-GBP antibody, indicating that other GBPs are still 
intact. Moreover, during the course of my project, I reinforced the results I acquired 
with a second clone (data not shown). This established that the effects I saw during 
infection with Toxoplasma were not due to an aberrant cell clone that produced 
results due to unknown genome manipulations. I was able to further confirm the 
knockout of GBP1 by complementing the protein back into the cell using a lipid 
transfection of the mCherry-GBP1 construct (produced by Coers lab). When the 
protein had been reintroduced, the cells responded like the wild type cells during 
Toxoplasma infection (see later, Chapter 4, Figure 20). Complementation is a quick 
and reliable method of confirming a phenotype is due to a real knockout rather than 
off-target effects. The next step with these cells is to sequence the regions of the 
other family members, to be sure that there is not disruption in any of those areas.  
  Research can only be as reliable as the tools we have. Therefore, the 
availability of characterised cells and antibodies is necessary to be sure of the 
outcomes of our experiments. There has been a renewed interest in studying this 
family of large GTPases lately, and to share our reagents with collaborators is a 
vital next step after the work that has been put in. Poor reagents can lead to a lack 
of data, and inconsistencies in observations. The analysis of these cells and 
antibodies engrossed a large part of my PhD project. As a result, I have an 
understanding of the difficulties in finding specific tools, and how to optimise 
processes to get the best from the product. I do believe that there needs to be 
more stringency in characterising commercially available tools, especially for 
targets that have a high level of similarity to something else. These commercial 
tools often have been produced with an immunogen that is not made publically 
known, and the analysis of these proteins for immunoblotting is frequently only the 
observation of a band of the correct size on a membrane which may or may not 
represent the correct protein. CRISPR-Cas9 presents a further opportunity for the 
Tool generation and characterisation 
 
79 
 
study of GBPs in this regard. The option of tagging the endogenous protein with an 
epitope tag is now a real possibility. To add a tag would mean that reliable 
immunoprecipitation and detection on an immunoblot or in immunofluorescence 
with very well established antibodies would become possible. This technique, while 
revolutionary cannot completely replace the need for antibodies as it is a time 
consuming process and is possible only with transfectable cells. Furthermore, even 
a small insert may affect the functions of the endogenous protein so caution should 
be taken.  
 
3.2.2 Optimisation of experiments 
Once reliable tools have been acquired, it becomes necessary to ensure that the 
techniques and methods being used are the most appropriate to answer the 
question being asked. I optimised an experiment to determine the invasive capacity 
of Toxoplasma in epithelial cells. Following this I determined both how to assess 
the replicative ability of the parasite in the vacuole and to assess the plaque 
forming ability within epithelial cells.  
For the invasion assay I used γ-irradiated parasites; this is because they 
can invade effectively but have lost the ability to replicate as a result of DNA 
damage. Since epithelial cells are non-phagocytic, this means when I detect a 
Toxoplasma within a cell, I can be certain that it is the result of direct invasion. Next, 
I ensured that I could carry out an assay to calculate the replicative ability of 
vacuolar parasites in A549 cells using microscopy. This is a generally accepted 
mechanism with which to study parasite replication, however the protocol is usually 
carried out in fibroblasts. In this case, I confirmed that A549 epithelial cells 
restricted Toxoplasma in an IFNγ dependent manner, and optimised the 
concentration of cytokine to use to ensure that the results were consistent and 
reliable. When the concentration of IFNγ was too high, the infection could not 
successfully establish and so the results were not biologically accurate. I also 
ensured I chose the correct time points at which to count the parasites. It was 
difficult to ensure that it was possible to count the parasites across the different 
conditions over a time course. In the absence of IFNγ, the parasites replicated at 
much increased speed and often resulted in vacuoles so large it was impossible to 
Tool generation and characterisation 
 
80 
 
quantify the number of parasites within. Over time, I optimised the MOI of the 
infection alongside the appropriate time points to ensure that the counting was 
carried out in a consistent and reliable manner. 
Assessing the ability of Toxoplasma to form plaques within a cell layer, and 
carrying out fitness assays is something that has been done extensively in the 
literature over the years. These assays have relied on the parasites being 
contained in fibroblasts. This is because these cells are heavily contact inhibited, 
and Toxoplasma is able to form very uniform, predictable and quantifiable plaques 
in these cells. This protocol is much more commonly implemented to assess 
parasite mutants against the wild type rather than to assess host cell factors. It has 
been used previously however to compare Toxoplasma growth in cells that have 
had host targets knocked down with siRNA, and those that had been stimulated by 
IFNγ with cells that are unstimulated (Virreira Winter et al., 2011, Niedelman et al., 
2013). When it is necessary to move the parasites to another cell type, problems 
arise when trying to determine the pathogen replicative capacity. As the infection 
progresses in these other cell types, the cells begin to grown on top of each other 
and also many lose their adhesive capacities and lift from the culture dishes. As a 
result, it becomes impossible to accurately quantify how well the parasites have 
replicated. For this reason, I designed an experiment that could establish short-
term survival of Toxoplasma in epithelial cells. This is important because it allows 
us to use pre-existing genetically modified non-fibroblast cells in Toxoplasma 
viability assays. It is time consuming to make genetically engineered cells in the 
first place, so where the mutant cell has already been produced, it would be 
undesirable to remake these genotypes in fibroblasts. Moreover there is also the 
fact that fibroblasts may not be the biologically relevant cell type to study. By 
incubating the parasites in the epithelial cells for a maximum of 24 hours before 
syringe lysing them out and plating them on the fibroblasts, the gradual lifting of the 
cells is avoided. This protocol will allow researchers to move their experiments 
between cell types, and not be restricted to fibroblasts. 
The next step with these methods is to produce a high-throughput method 
that would be useful, for example, in screening a large number of parasite mutants 
or different host cell CRISPR knock out clones. One could possibly determine 
invasion, host cell killing and/or parasite replicative defects. This could be done by 
utilising FACS, and to determine how to accurately view the number of parasites 
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within a cell, and how many times they have replicated. This is possible due the 
fact that one can expand on the method I used to assess the percentage of 
infected cells by gating on fluorescent parasites inside the cells. As the number of 
parasites inside the cells increases, the mean fluorescence intensity would also be 
expected to increase, hence allowing quantification of replicative ability. 
 The efforts taken to overexpress these large GTPases have proven that this 
is not a viable or reliable method with which to study them. The fact that the cells 
are sickly means that results could be attributed to this, rather than directly 
because of the presence of GBPs. The importance of consistent, reliable and well-
characterised tools and experimental mechanisms needs to be stressed more 
within the science community, with emphasis on analysing antibody specificity and 
cell genetic features.
GBPs and Toxoplasma gondii infection 
 
82 
 
Chapter 4. The impact of human Guanylate Binding 
Proteins on Toxoplasma gondii infection 
4.1 Results 
4.1.1 GBP1 
GBP1 has been the most intensely studied human guanylate binding protein family 
member. It has been implicated in protection against pathogens such as hepatitis C 
virus (Itsui et al., 2009), influenza A virus (Zhu et al., 2013), vesicular stomatitis 
virus (Anderson et al., 1999a) and encephalomyocarditis virus (Anderson et al., 
1999a). GBP1 also interacts with actin (Ostler et al., 2014) and plays a role in 
endothelial cell proliferation (Guenzi et al., 2001). While this GBP family member is 
believed to be relevant in pathogenic infection responses, these studies have relied 
on overexpression of GBP1, and hence we still do not understand how the 
endogenous protein acts. Considering the importance of murine GBPs in the 
context of restricting Toxoplasma infection, I decided to determine whether GBP1 
could recognise the pathogen, and therefore whether or not it plays a role in host 
response. 
The subcellular localisation of a protein often gives clues to its function. The 
literature has previously defined GBP1 as a cytosolic protein as determined by 
heterologous overexpression of the protein with a GFP-tagged GBP1 (Tripal et al., 
2007, Britzen-Laurent et al., 2010). Furthermore, it has been shown that GBP1 
localises to the golgi when treated with aluminium fluoride (AlF3), a reaction that 
causes the GTPase to mimic GTP-binding (Britzen-Laurent et al., 2010). To 
determine the localisation of endogenous GBP1 and to answer if this is affected by 
Toxoplasma, a subcellular fractionation technique followed by SDS-PAGE was 
utilised. THP-1 macrophages were stimulated or not with IFNγ overnight before 
being infected with either type I (RH) or type II (Pru) Toxoplasma. The infection was 
allowed to persist for 2 hours before the cells were lysed and subjected to 
subcellular fractionation. The resulting product was run on a gel, transferred by 
western blot before being probed with the anti-GBP1 peptide polyclonal antibody. 
GBP1 was confirmed to be a cytoplasmic protein, with the location remaining 
unchanged on infection (Figure 16). 
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Figure 16 GBP1 is a cytoplasmically localised protein 
Subcellular fractionation of THP-1 cells shows the location of GBP1 in steady state 
cells and in Toxoplasma infected cells, MOI 3. Cells were infected for 2 hours. 10µg 
of protein was added to each lane for SDS-PAGE. All samples were run on the 
same gel, blocks have been indicated for demonstration. Cells were stimulated or 
not with 10U/ml IFNγ for 18 hours. Representative of 3 independent experiments. 
Each panel indicates a separate gel, all samples from same experiment on the 
same day. 
 
It is well documented that a selection of murine GBPs localise to the 
parasitophorous vacuole during a Toxoplasma infection (Degrandi et al., 2007, 
Virreira Winter et al., 2011, Selleck et al., 2013), Low levels of recruitment of 
human GBPs have also been reported (Ohshima et al., 2014). However, the 
immunofluorescence in the Ohshima study relied on an antibody that recognised 
GBPs 1-5, resulting in the recruitment status of individual family members being 
unknown still. To determine whether or not GBP1 was recruited to the PV during 
infection, A549 epithelial cells and THP-1 macrophages that had been stimulated 
or not with IFNγ, were seeded onto coverslips before infecting with type I or type II 
Toxoplasma. The infection was allowed to persist for 1 – 12 hours, with the cells 
being fixed at a number of time points, before being stained with the anti-GBP1 
peptide polyclonal antibody and analysed by immunofluorescence microscopy. The 
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coverslips were viewed using a confocal microscope, and at no time point was 
recruitment of GBP1 to the PV observed in either cell type although a clear 
increase in cytoplasmic GBP1 expression was observed when cells were 
stimulated with IFNγ. Figures 17 and 18 show representative images of cells fixed 
at 1, 2 or 4 hours.  
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Figure 17 GBP1 does not recruit to the Toxoplasma parasitophorous vacuole in 
A549 cells 
Confocal microscopy images showing the distribution of GBP1 in Toxoplasma-
infected A549 cells over a time course. Images were viewed using 100X 
magnification. MOI 2 for type I, MOI 3 for type II. Cells were stimulated or not for 18 
hours with 10U/ml IFNγ. All scale bars 10µm. Representative images from 4 
experiments. 
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Figure 18 GBP1 does not recruit to the Toxoplasma parasitophorous vacuole in 
THP-1 macrophages 
Confocal microscopy images showing the distribution of GBP1 in Toxoplasma-
infected THP-1 macrophages over a time course. Images were viewed using 100X 
magnification. MOI 2 for type I, MOI 3 for type II. Cells were stimulated or not for 18 
hours with 10U/ml IFNγ. All scale bars 10µm. Representative images from 3 
experiments. 
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The recruitment of murine GBPs to the PV has always been thought to be 
necessary for their function in disruption of the parasitophorous membrane and 
subsequent parasite destruction (Yamamoto et al., 2012, Degrandi et al., 2013). In 
this study, it was clear that GBP1 did not recruit to the PV. Therefore, I sought to 
establish whether or not GBP1 still played a role in host restriction of Toxoplasma 
gondii. First, I assessed if the overall survival and viability of parasites was affected 
when in GBP1 deficient epithelial cells. A549 cells that had GBP1 knocked out by 
the CRISPR/Cas9 genome editing technique (made by Barbara Clough) were 
tested by indirect plaque assays alongside their wild type counterparts. Either type I 
or type II Toxoplasma were used to infect A549 cells that had or had not been 
stimulated overnight with IFNγ. The infection was allowed to persist for 6 hours 
before the cells were syringe lysed and the extracellular parasites were plated onto 
confluent, unstimulated HFFs. 3 to 5 days post infection, the plaques were counted 
and normalised to the number of plaques in wild type unstimulated A549s. The 
IFNγ stimulated cells overall produced a much-reduced number of plaques (Figure 
19). Significantly, the A549 ∆GBP1 cells showed an increase of plaque numbers 
with type II parasite compared to the wild type cells. This increase in plaques was 
observed in both the IFNγ stimulated and unstimulated cells, perhaps due to the 
fact that GBP1 is already present and detectable at a basal level in these cells 
(Figure 19). There was no significant difference in the amount of plaques between 
wild type and ∆GBP1 A549 cell when type I parasites were used (Figure 19). These 
results suggest that indeed GBP1 plays a strain dependent role in the restriction of 
Toxoplasma, with type II parasites being more able to survive and replicate in the 
knock out cells. This result indicates that GBPs can have functions on vacuolar 
pathogens at a location away from the vacuole. 
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Figure 19 GBP1 can restrict the growth of type II Toxoplasma in A549 cells, but 
not type I 
Percentage of Toxoplasma plaque growth in A549 wild type and ∆GBP1 cells 
compared to plaque growth in wild type unstimulated cells. A549 cells were 
stimulated or not for 18 hours with 10U/ml IFNγ, before Toxoplasma infection for 6 
hours. 300 or 600 parasites per well were used for type I or type II parasites 
respectively, in a 24-well plate. Results were normalised to 100% in wild type 
unstimulated cells. N=3 independent experiments, carried out in triplicate. 
Significance calculated by 2-way ANOVA, **p<0.001, ****p<0.00001. 
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To ensure that the results were not an artefact due an aberrant clone 
produced by CRISPR, I complemented the knock out cells with GBP1 in order to 
rescue the wild type phenotype. A mCherry-tagged GBP1, or the empty mCherry-
vector as a control, was transfected into the A549 ∆GBP1 cells using the FuGene 
lipid-based transfection method. The toxicity of the transfection seen in these cells 
was less than what was observed in wild type cells, likely resulting from a higher 
tolerance due to absence of endogenous GBP1 protein. The complemented cells 
were stimulated overnight or not, infected with type II Toxoplasma for 6 hours as 
previously described, before being syringe-lysed and plated on to confluent HFFs. 
The plaque numbers were compared to those produced in wild type cells, and 
again were normalised to parasite growth in the wild type unstimulated A549s. 
There was no significant difference between the number of plaques produced in 
wild type cells and those in the complemented knock out cells (Figure 20). 
Similarly, there was no statistically significant difference between the plaques 
produced in the ∆GBP1 cells compared to those that had been transfected with the 
mCherry control vector (Figure 20). 
	  
Figure 20 Complementation of GBP1 rescues control of Toxoplasma growth 
A549 ∆GBP1 cells were transfected or not with mCherryGBP1 or mCherry before 
infecting with Toxoplasma for an indirect plaque assay and compared to plaque 
production in wild type A549 cells. Results were normalised to 100% wild type 
unstimulated cells. Cells were stimulated or not for 18 hours with 10U/ml IFNγ 
before infection with 600 Toxoplasma per well for 6 hours in a 24-well plate. N=3 
independent experiments, carried out in triplicate. Significance calculated by 2-way 
ANOVA, *p<0.01, *p<0.001, ***p<0.0001, ****p<0.00001. 
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These results show that indeed GBP1 is responsible for at least part of the 
restriction of Toxoplasma type II in epithelial cells. This restriction occurs in a strain 
dependent manner and is independent of IFNγ stimulation. 
Toxoplasma is an intracellular parasite with many complex stages of its life 
cycle. During the tachyzoite stage, in order to continue the infection it is necessary 
that the parasites are able to invade, replicate and egress. The restriction of 
Toxoplasma by GBP1 could be affecting any of these vital functions. As A549 cells 
do not have any phagocytic capacity, Toxoplasma relies completely on its own 
ability to invade this cell type. Therefore, I decided to first assess whether or not 
GBP1 played a role that was affecting the levels to which Toxoplasma could invade 
these cells. In order to do this, A549 ∆GBP1 cells, stimulated or not with IFNγ, were 
infected with γ-irradiated tdTomato-expressing Toxoplasma overnight before fixing 
the cells and analysing the populations using FACS. Cells that were fluorescing in 
the PE channel contained the intracellular tdTomato parasites. As the Toxoplasma 
had been γ-irradiated, they were rendered replication-deficient and therefore 
unable to distort the number of parasites known to have invaded. Wild type A549 
cells were shown to be invaded by Toxoplasma at a rate of approximately 50%, as 
shown in Figure 13. When the percentage of A549 ∆GBP1 cells containing 
parasites were compared to wild type cells, there was no difference between the 
rates of invasion (Figure 21). This would suggest that the restriction of Toxoplasma 
by GBP1 is not by mediation of invasion of the parasites; hence GBP1 is able to 
affect the survival of Toxoplasma at a stage later on in the infection. 
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Figure 21 Invasion capacity of Toxoplasma in the absence of GBP1 
Graph showing the percentage of A549 ∆GBP1 cell populations infected with 
irradiated tdTomato expressing type II (Pru) Toxoplasma that fluoresce in the PE 
channel. An isotype control was used to ensure the correct peak was observed. 
MOI 1. Cells were stimulated or not for 18 hours with 10U/ml IFNγ. Representative 
of 3 experiments. 
 
 
In light of GBP1 not playing a role during the invasion of Toxoplasma 
invasion of A549 cells, I determined how the parasites were able to replicate in 
absence of GBP1. In order to do this, eGFP-expressing type-II Toxoplasma were 
seeded on to confluent A549 ∆GBP1 cells plated onto glass coverslips. These cells 
had been stimulated or not overnight with IFNγ. The infection was allowed to 
persist up to 24 hours, with the cells on coverslips being fixed and permeabilised 
ready for staining for immunofluorescence microscopy over a time course. The 
cells on the coverslips were stained with Hoechst to identify the nuclei before being 
mounted onto glass slides. Using a bright-field microscope, vacuoles inside the 
cells were located and the number of parasites within each one was counted. A 
minimum of 100 vacuoles was counted for each condition. The capacity of 
Toxoplasma to replicate in A549 wild type cells has already been determined in 
Figure 14. These data have been shown again to directly compare replication rates 
with those seen in A549 ∆GBP1 cells. The number of replication cycles (measured 
by counting parasites per vacuole) that had occurred was calculated at 12, 18 and 
24 hours post infection. A clear restriction of growth by IFNγ is seen at all time 
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points as expected (Figure 22). At 12 hours, a significant difference between the 
replication in the wild type versus the ∆GBP1 cells was already seen. In the ∆GBP1 
cells, there were significantly more vacuoles containing 2 parasites, indicating more 
Toxoplasma had undergone one replication cycle (Figure 22). By 18 hours post 
infection, ∆GBP1 cells contained significantly more vacuoles that harboured 2 or 4 
parasites, indicating 1 or 2 replication cycles (Figure 22). At the final time point of 
24 hours post infection, the IFNγ stimulated ∆GBP1 cells contained significantly 
more vacuoles that had 8 or more parasites within, indicating 3 or more replication 
cycles (Figure 22). By this time point and without IFNγ, the parasite replication is 
well progressed and there are numerous Toxoplasma in each cell. These results 
show that GBP1 plays a role in restricting the onset of replication of Toxoplasma 
gondii in A549 cells. 
 
 
Figure 22 GBP1 restricts replication of Toxoplasma in A549 cells 
Stacked graph demonstrating the percentage of PVs containing 1, 2, 4 or over 8 
parasites in A549 wild type and ∆GBP1 cells. Cells were stimulated or not for 18 
hours with 10U/ml IFNγ before infection with type II Toxoplasma, MOI 0.5. N=3 
independent experiments, each carried out in triplicate. Significance calculated by 
2-way ANOVA, *p<0.01, ***p<0.0001, ****p<0.00001. 
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show that GBP4 has both cytoplasmic and nuclear localisation in HUVECs (Tripal 
et al., 2007). GTPases in the nucleus are not a common occurrence, with functions 
that usually equate to shuttling of other proteins (Moore, 1998). Interestingly, 
murine Mx1 protein is required to have a nuclear localisation in order to restrict 
influenza virus. Human Mx1 protein is solely cytoplasmic however and still exerts 
an effect against influenza (Zurcher et al., 1992). I first determined the subcellular 
localisation of GBP4 in a steady state cell. As the previous localisation study had 
been carried out using overexpressed tagged GBP4, it was important to confirm the 
location of the endogenous protein. First, I differentiated THP-1 monocytes into 
macrophages by stimulating them with 1µM PMA for 3 days. Following this, the 
cells were stimulated or not with IFNγ overnight. I carried out a subcellular 
fractionation, ran the resulting products on SDS-PAGE and transferred the gel onto 
a nitrocellulose membrane. This membrane was then probed with the anti-GBP4 
peptide polyclonal antibody. Interestingly, GBP4 was found in the nuclear fraction, 
with none visibly present in the cytoplasm (Figure 23).  
 
Figure 23 GBP4 is a nuclear protein in THP-1 macrophages 
Immunoblot of THP-1 macrophages that have undergone subcellular fractionation 
and have been probed for GBP4 with the anti-GBP4 polyclonal peptide antibody. 
10µg of protein was added to each lane for SDS-PAGE. SDS-PAGE was carried 
out on the same gel; blocks have been indicated for demonstration. Cells were 
stimulated or not for 18 hours with 10U/ml IFNγ. Representative of 3 independent 
experiments. For each respective antibody, all samples were exposed to the film 
for equal times before development.  
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To determine the localisation of GBP4 during Toxoplasma infection, another 
subcellular fractionation was carried out, but this time on Toxoplasma-infected 
THP-1 macrophages. As above, the macrophages were stimulated with IFNγ 
overnight before being infected with parasites for 2 hours. After this incubation, the 
cells were subjected to a subcellular fractionation before running on SDS-PAGE. 
The samples were then probed with the anti-GBP4 polyclonal antibody via 
immunoblot after transfer onto a nitrocellulose membrane. The results showed that 
as with the uninfected cells, GBP4 was present in the nucleus in the presence of 
type II Toxoplasma at an MOI of 3. However, when the cells were infected with type 
I parasites at an MOI of 3, GBP4 expression was completely lost. Furthermore, 
when the cells were infected with a combination of type I and II Toxoplasma (both 
MOI 3, resulting in overall MOI 6) GBP4 expression was partially decreased. In this 
double infection some expression can still be seen, implying there is no dominant 
effect by the type I parasites (Figure 24). 
 
Figure 24 Type-I, but not type-II Toxoplasma alters protein expression of GBP4 in 
THP-1 macrophages 
Immunoblot of THP-1 macrophages that were infected with Toxoplasma for 2 hours 
at an MOI of 3 before undergoing subcellular fractionation to be probed for GBP4. 
Cells were stimulated with 10U/ml IFNγ overnight. Representative of 2 independent 
experiments. 10µg of protein was added to each lane for SDS-PAGE. SDS-PAGE 
was carried out on the same gel; blocks have been indicated for demonstration For 
each respective antibody, all samples were exposed to the film for equal times 
before development. 
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 The loss of GBP4 protein was very striking. Within the lab, degradation of 
the protein was not always observed. I determined whether the MOI of type I 
Toxoplasma used was the deciding factor for this phenotype. I infected THP-1 
macrophages with increasing MOI of parasites before lysing the cells at 2 hours 
post infection and analysing protein expression by SDS-PAGE and immunoblot. It 
was clear that the degradation of GBP4 correlated with increased numbers of 
parasites during infection (Figure 25). Additionally, I analysed the band densities of 
GBP4 on the immunoblots using ImageJ software, and plotted the results as a 
percentage of the respective loading control band density in IFNγ-stimulated THP-1 
macrophages (Figure 26). The graph shows very effectively the significant 
decrease of protein expression when THP-1 macrophages are infected with type I 
Toxoplasma parasites. 
 
Figure 25 Effect of increasing type I Toxoplasma MOI on GBP4 protein 
expression 
Immunoblot showing GBP4 protein expression in THP-1 macrophages infected for 
2 hours with type I Toxoplasma using increasing MOIs. 10µg of protein was added 
to each lane for SDS-PAGE. Arrow indicates the GBP4 band. Cells were stimulated 
overnight with 10U/ml IFNγ. Representative of 2 independent experiments.  
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Figure 26 Density of GBP4 protein bands 
Graph showing the density of GBP4 protein bands in immunoblot as compared to 
the respective loading control band. Bands show GBP4 expression in lysate from 
IFNγ-stimulated THP-1 macrophages infected or not for 2 hours with type I 
Toxoplasma at an MOI of 3. Inclusive of 3 independent experiments. Significance 
calculated with unpaired t-test, ****p<0.00001. 
 
The fractionations were carried out at 2 hours post infection, so additionally I 
followed the expression of GBP4 by immunofluorescence to track protein loss. It 
would be interesting if any recruitment of GBP4 to the Toxoplasma vacuole were to 
be observed even though it appears, by immunoblot, to have a solely nuclear 
location in THP-1 macrophages. THP-1 monocytes were plated onto glass 
coverslips before differentiating with PMA to macrophages. When fully 
differentiated, cells were stimulated or not overnight with IFNγ before infecting with 
Toxoplasma at an MOI of 3. The cells on the coverslips were fixed and 
permeabilised periodically over a time course, after which they were stained with 
the anti-GBP4 polyclonal antibody. While there was a relatively high background 
level of staining, it was evident that GBP4 was a nuclear protein. It was also clear 
that, regardless of the time points investigated or parasite strain, the protein did not 
recruit to the Toxoplasma vacuole (Figure 27). During the infection with type I 
parasites, expression of the protein was efficiently depleted between 1 and 2 hours 
(Figure 27A). The GBP4 protein levels on infection with type II parasites did not 
change throughout the time course (Figure 27B). The loss across the population is 
graphically displayed after quantification of GBP4 staining in 100 cells (Figure 28). 
These results show that although GBP4 is found solely in the nucleus in THP-1 
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macrophages, type I Toxoplasma gondii have the ability to eliminate GBP4 protein 
staining very efficiently when using the C-terminal recognising polyclonal peptide 
anti-GBP4 antibody. 
 
Figure 27 GBP4 is not recruited to the PV of Toxoplasma, and protein expression 
is lost during infection with type I parasites 
Immunofluorescence showing the distribution of GBP4 in THP-1 cells at 1 and 2 
hours post infection with type I (A) or type II (B) Toxoplasma at an MOI of 3. Cells 
were stimulated overnight with 10U/ml IFNγ. All scale bars 10µm. Representative 
images from 3 experiments. 
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Figure 28 Staining of GBP4 protein is lost across the cell population upon 
infection with type I Toxoplasma but not type II 
Fluorescence intensity of GBP4 staining in THP-1 cells infected with type I or type 
II Toxoplasma. Intensity was quantified using Image J in a minimum of 20 randomly 
selected cells. Cells were stimulated for 18 hours with 10units/ul IFNγ. Statistical 
analysis determined by unpaired t-test; ****p<0.00001. N=3 independent 
experiments 
  
The loss of protein signal could be attributed to a number of factors. The 
GBP4 protein could be directed for degradation by the type I parasite. There could 
be inhibition of GBP4 transcription or translation. Furthermore, signal could be lost 
due to a modification or truncation of the protein C-terminus, rendering the antibody 
unable to recognise the peptide region against which it was produced. I pursued 
the hypothesis of protein degradation first.  
The degradation of intracellular proteins is a tightly regulated and varied 
process. Originally it was thought that all proteins were degraded via the lysosome- 
a membrane-bound organelle containing acidic, digestive enzymes capable of 
proteolysis (Ciechanover, 2005). However, as it was discovered that lysosome 
deficient cells could degrade proteins in an ATP-dependent manner, it became 
clear that the process was much more complex and diverse (Ciechanover, 2005). 
The discovery of ubiquitin highlighted that different mechanisms were present and 
paved the way to determine the different mechanisms of protein degradation. The 
ubiquitin activating enzyme, E1, activates ubiquitin to be transferred to an ubiquitin-
conjugating enzyme, E2. From here, the ubiquitin is transferred to a protein 
substrate that is bound by the ubiquitin ligase E3. Multiple conjugations of ubiquitin 
molecules suffice as the degradation signal for protein destruction via the ubiquitin-
proteasome proteolytic system (Ciechanover, 2005). The 26S proteasome is a 
protease complex made up of the 19S and 20S proteasome, with the 20S forming 
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a catalytic core. It is this complex that is responsible for degrading the proteins 
conjugated to ubiquitin (Eytan et al., 1989). Furthermore, a number of other 
proteolytic enzymes and systems exist, with one example being the calpain family. 
Calpains are a Ca2+ dependent family of cysteine proteases that reside in the 
cytosol (Khorchid and Ikura, 2002). While the exact mechanism of how calpains 
dictate substrate specificity is not entirely clear, it is thought that amino acid 
preferences and secondary structures, alongside a potential PEST sequence, help 
define targets (Tompa et al., 2004). Another such example of a proteolytic system 
is the caspase family of cysteine proteases. This family gains catalytic ability 
following a long line of signalling events leading to dimerisation and often cleavage 
to induce activity (McIlwain et al., 2015). Caspase family members are activated 
differently, which results in a variation of their final functions. All of these proteolytic 
pathways lead to degradation, destruction or turnover of intracellular proteins.  
 As GBP4 protein expression is lost during infection with type I Toxoplasma, I 
sought to determine how GBP4 is degraded in a steady state cell, as well as how 
this happens in response to the parasite. A vast repertoire of protein-degradation 
inhibitors is commercially available, and from these I took a selection with which to 
test GBP4 degradation.  
 THP-1 macrophages were plated in 6-well plates before being stimulated 
overnight with IFNγ. Following this, the cells were treated as appropriate with the 
individual inhibitors. The macrophages were then infected with type I Toxoplasma 
at MOI 3 for 2 hours, after which cell lysates were run on SDS-PAGE. The resulting 
gels were transferred via Western blot before the membranes were probed with the 
anti-GBP4 peptide antibody. It was clear that when MG132 proteasome inhibitor 
was used in the uninfected samples that GBP4 could be greatly accumulated 
(Figure 29). This indicated that the GBP4 is routinely degraded via the 26S 
proteasome. However, the GBP4 could not be accumulated in the type I infected 
samples, suggesting that however GBP4 is being degraded in response to the 
parasite is through an alternative route. Interestingly, in the type I infected samples 
that were treated with leupeptin, GBP4 protein could once again be detected on the 
immunoblot (Figure 29).  
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Figure 29 GBP4 protein can be accumulated by using protein degradation 
inhibitors 
Immunoblot showing the levels of GBP4 protein with and without protein 
degradation inhibitors in THP1 macrophages that were uninfected or infected for 2 
hours with type I Toxoplasma, MOI 3. 10µg of protein was loaded in to each lane 
for SDS-PAGE. Cells were stimulated for 18 hours with 10U/ml IFNγ. Cells were 
treated with the appropriate inhibitor for 1 hour before infection. Representative of 2 
independent experiments; excluding the calpastatin lane which is N=1. Each panel 
was run on a separate gel, all samples from same experiment. For each respective 
antibody, all samples were exposed to the film for equal times before development. 
 
This implies that the Toxoplasma driven degradation of GBP4 is mediated by 
cysteine, serine and/or threonine peptidases.  
These results show that GBP4 does not recruit to the Toxoplasma PV during 
infection, and that type I Toxoplasma has the ability to direct host or parasite 
cysteine, serine and/or threonine proteases to degrade GBP4 protein in a rapid and 
efficient manner. 
 
4.2 Discussion 
Subcellular localisation of human GBPs 
GBP1 and 4 do not localise to the PV of Toxoplasma, yet GBP1 at least still plays 
an important role in restricting the growth of the parasite (Johnston et al., 2016). 
Interestingly, GBP4 is a nuclear protein whose expression is lost upon infection 
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with the type I Toxoplasma strain, RH. The consequences of this is as yet unclear, 
however, it would suggest that not only are these proteins central in host protection, 
but the parasite has adapted in such a way to begin to avoid their effects.  
 The fact that these proteins are not localised to the PV shows that the 
mechanisms by which they operate vary extensively from their mouse counterparts. 
The recruitment of mGBPs to Toxoplasma was the first indicator that they played a 
role in this parasite infection (Degrandi et al., 2007), with approximately 50% of 
parasite vacuoles coated with members of the GTPase families. This localisation to 
the PV has been a guide for elucidating whether or not to pursue pathogen viability 
assays in bacterial models in murine cells (Haldar et al., 2014, Pilla et al., 2014, 
Meunier et al., 2014, Man et al., 2015). The fact that I did not find a localisation of 
GBPs to the vacuole would have implied they were not relevant during this infection. 
I wonder if other research groups have observed the same phenomenon and 
decided that they could not be important? In 2014 Ohshima et al. showed that 
human GBPs did recruit to the vacuole of Toxoplasma. This occurred at 6 hours 
post infection with a ME49 type II strain of the parasite in human haploid (HAP1) 
cells that are derived from a leukaemia cell line (Ohshima et al., 2014), with only a 
low percentage (approximately 6%) of PVs positive for GBP recruitment. While 
these results do not fall in line with what we have observed, in this study a 
commercial antibody against GBPs 1-5 was used. It is additionally noteworthy that 
the reported 6% recruitment is much less than the usual 30-60% recruitment of 
GBPs observed to pathogen vacuoles in murine cells (Degrandi et al., 2007, 
Virreira Winter et al., 2011, Haldar et al., 2013). However, it could be that family 
members 2, 3 and 5 have some level of recruitment to the vacuole. When staining 
with the anti-pan-GBP antibody that I characterised, I do not see any recruitment of 
protein against either the type I or the type II parasites. Furthermore, the 
accumulation of protein at the parasite did not match the phenotype seen with 
localisation of GBPs in murine cells. In the mouse, a solid ring of protein is acquired 
around the PV membrane, however in the Ohshima study there was a staining 
covering the whole parasite. This difference could arise as a result of a different 
response mechanism across the two host species. There is a chance however that 
the difference is due to an artefact or to unspecific staining of a dead parasite. A 
further explanation could be that these proteins act in a cell specific manner, a 
factor that investigators must take in to consideration in the future. If these 
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experiments were to be repeated in the future, using an anti-GRA antibody would 
prove the Toxoplasma was indeed within a vacuole if dense granule staining co-
localised with the parasite, and would at least reinforce that the parasite has 
successfully invaded. 
 As it appears there is very limited recruitment of human GBPs to the PV of 
Toxoplasma, the question arises whether this is because they are fulfilling an 
entirely different role to mGBPs. Alternatively, would GBPs demonstrate the same 
responses if the same components were present in human cells as in mouse? 
There are many studies that outline the recruitment of mGBPs to the vacuole as 
being potentially dependent on glycine-lysine-serine (GKS)-containing IRGs 
(Yamamoto et al., 2012, Haldar et al., 2015). Humans however possess only 2 
GKS-IRGs, and these are not IFNγ-sensitive (Bekpen et al., 2005). This theory was 
tested using the antibodies produced in this project, when I collaborated with Jörn 
Coers’ laboratory at Duke University, who transfected mouse embryonic fibroblasts 
(MEFs) with human GBP1. These cells were then infected with Toxoplasma before 
staining with my polyclonal anti-GBP1 antibody for immunofluorescence 
microscopy. Interestingly, localisation of the protein to the PV was seen. This could 
imply that the lack of recruitment of GBPs to the PV of Toxoplasma is a result of 
human cells being deficient in IRGs (Johnston et al., 2016). 
Our study continued to determine whether or not GBP1 recruited to 
Salmonella enterica typhimurium or Chlamydia trachomatis (Johnston et al., 2016). 
Furthermore, we looked to see if GBP1 was playing a role in host defence against 
these pathogens. It soon was clear that GBP1 did not recruit to the pathogen 
containing vacuoles (PCVs) of these intracellular bacteria, as elucidated by 
immunofluorescence microscopy (Johnston et al., 2016). These results are in 
contrast to work published previously, which state that GBP1 and GBP2 can recruit 
to the chlamydial vacuole (Tietzel et al., 2009, Al-Zeer et al., 2013). One of these 
studies relied on overexpression of the GBPs, which may have resulted in an 
artefact. Both of these studies focussed on cells that were not epithelial cells, it 
may be that GBP1 is functioning in a cell-specific manner. We concluded that 
GBP1 does not recruit to the PCVs of intracellular pathogens in epithelial cells. 
As these proteins were not localised as expected, I moved to determine 
where they were located within the cell. Previous literature had signified, in an IFNγ 
stimulated cell, GBP1 was found in the cytosol, with a GTPase activity-dependent 
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Golgi association (Modiano et al., 2005, Tripal et al., 2007). The Tripal study also 
showed GBP4 to be found both in the nucleus and in the cytoplasm (Tripal et al., 
2007). These findings were elucidated using an overexpressed GFP tagged 
version of the protein in HUVECs. Therefore, the reason that we do not see GBP4 
in a cytoplasmic localisation could be a caveat due to the overexpression system, 
or a cell-specific phenotype. It would be interesting to see how these findings 
compare to the subcellular localisation of not only mGBP4, but all mGBPs in the 
uninfected cell, but there are very few results outlining the location of murine GBPs 
when vacuolar recruitment is not involved (Degrandi et al., 2007). I believe it is 
important to determine where these proteins are in the cell, as not only may there 
be an observable difference during an infection, it gives clues to the function they 
might be carrying out. This differential location in uninfected cells is another arm of 
evidence that GBPs are playing distinct and non-redundant roles within the cell. 
 
GBP1 in host defence to Toxoplasma gondii 
As GBP1 was not recruited to the PV during Toxoplasma infection, I initially 
questioned whether or not this protein was involved in the host defence to 
Toxoplasma at all. As I began to carry out the Toxoplasma growth assays in A549 
∆GBP1 versus wild type cells, it became clear that indeed GBP1 had the ability to 
restrict the growth and survival of this parasite. By complementing the protein back 
into the ∆GBP1 cells, I could restore the phenotype seen in wild type cells. This 
step proved that GBP1 was the effector of this restriction as opposed to a 
secondary effect introduced during the genetic modification of the cells. Even more 
so, the effects of GBP1 could be seen in a manner that was independent of IFNγ. 
This was fascinating as mGBPs are not present without the stimulation of IFNγ. 
However, it is not the case in human A549 cells, with GBPs showing expression at 
basal level, as demonstrated by immunoblot. This result outlines another important 
difference between mouse and human GBPs. Additionally, it has been 
demonstrated that IFNγ as being necessary for oligomerisation qualities (Britzen-
Laurent et al., 2013). Furthermore, the association of GBP1 to the Golgi is IFNγ 
dependent (Modiano et al., 2005, Tripal et al., 2007). While it is true that GBPs are 
effectors of the IFNγ mediated resistance against a number of pathogens this 
project shows GBP1 can function in an IFNγ independent manner, implying that the 
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mechanism by which this GTPase family member operates does not require 
localisation to the Golgi or oligomerisation with itself or other GBPs.  
 After determining that GBP1 contributed to host defence of Toxoplasma, I 
defined at which stage of infection it was carrying out its effect. I first investigated 
whether the invasion rate of Toxoplasma into epithelial cells was altered in GBP1 
deficient cells. As it was apparent that infection rates were not altered, I next 
determined how the initial replication of the parasite in the cell might be affected. 
This was done using fluorescent microscopy, taking advantage of Toxoplasma that 
heterologously express GFP. By counting how many times the parasite had 
replicated inside the vacuole it was clear even by 6 hours post infection that 
replication was enhanced when GBP1 was absent. This too was IFNγ independent, 
indicating this effect was the same one that resulted in the difference in ability to 
form plaques. This IFNγ-independent method of action opens another line of study 
to investigate how else these proteins can exert their functionality.  
  I was interested to observe that the restriction effects of GBP1 against 
Toxoplasma were exerted in a strain-dependent manner. Traditionally type I 
parasites are classified as virulent, while type II are avirulent. However, this is in 
the context of mice, as the nomenclature is resultant of the fact that one type I 
parasite is sufficient to kill a mouse, while thousands of the type II will be tolerated 
before the mouse succumbs to infection. In humans, there is only recently literature 
describing that the parasites interact differently with the host cell in a strain-
dependent manner. It has been shown that human gene expression and host 
transcriptional responses to Toxoplasma can occur in a strain dependent manner 
(Saeij et al., 2006, Ong et al., 2011). Additionally, a study demonstrating that 
Toxoplasma is restricted by a non-canonical autophagy pathway, as well as my 
published work show that type I parasites largely evade specific host defence 
responses (Selleck et al., 2015, Johnston et al., 2016). This is an exciting area of 
study that should be investigated further. Amongst other things the specific 
virulence factors dictating these responses could be determined.  
 The fact that GBP1 can restrict pathogens falls in line with what is already 
published in the literature, with an effect against vesicular-stomatitis virus, 
encephalomyocarditis virus and C. trachomatis shown (Anderson et al., 1999a, 
Tietzel et al., 2009, Al-Zeer et al., 2013). However, the work published before my 
study regarding human GBPs and Toxoplasma present that they are not involved 
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during infection (Ohshima et al., 2014). When HAP1 cells had the complete GBP 
cluster on chromosome 1 removed using the CRISPR-Cas9 technique, 
Toxoplasma counts did not vary from counts in the wild type cells after 24 hours of 
infection with a type II strain (Ohshima et al., 2014). This could be another cell type 
specific phenotype that is not seen in epithelial cells. Alternatively, some residual 
GBP6 or 7 may be present and active in the cells, as the expression for these have 
not been elucidated. When I immunoblotted lysates from these cells, I noted that 
the levels of GBPs present in the wild type HAP1 cells, even after IFNγ stimulation, 
are very low (data not shown). HAP1 cells are derived from a cell line, KBM-7, that 
has been derived from leukaemia cells and contain only one copy of most human 
chromosomes (Kotecki et al., 1999, Carette et al., 2009). For this reason, they are 
favourable for use in genetic studies and screens, as it is easier to target a gene for 
full knock out when only a single chromosome needs to be effectively manipulated. 
However, these cells are not very biologically relevant in studies with infection 
models. As a result, it is a possibility that there is no difference seen after GBP 
deletion due to an insufficient GBP response in the wild type cells. It remains to be 
seen when the system used in my project is transferred to another cell type, 
whether a striking GBP1-dependent restriction of parasite growth is still present.  
 To determine whether or not GBP1 plays a role in the restriction of other 
pathogens, I worked with collaborators to determine the effect of this protein on S. 
enterica typhimurium and C. trachomatis. Both of these bacterial pathogens are 
intracellular, and furthermore reside within a PCV inside the cell. In this regard, 
they are comparable to Toxoplasma gondii. When pathogen viability assays were 
carried out after infection of epithelial cells that had either GBP1 intact or deleted, 
we saw no difference in bacteria growth for either S. enterica typhimurium or C. 
trachomatis (Johnston et al., 2016). This result suggests that GBP1 can act in a 
host defence role in a pathogen-specific manner. While other studies have been 
published demonstrating GBP1 restricts C. trachomatis growth, the work was 
carried out in either in HeLa cells or macrophages (Tietzel et al., 2009, Al-Zeer et 
al., 2013). Again, this suggests that GBPs may be functioning in a cell-specific 
manner, which needs to be taken into consideration by others looking to study this 
protein family.  
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GBP4 characteristics during Toxoplasma gondii infection 
I initially chose GBP4 as a prioritised candidate for study due to the fact it was 
reported to have a cyto-nuclear localisation in the literature (Tripal et al., 2007). My 
results have shown that in THP-1 macrophages the localisation of GBP4 is solely 
nuclear. As the work done by Tripal et al. was performed in endothelial cells, we 
come again to hypothesise that GBPs are functioning in a cell-specific manner 
(Tripal et al., 2007). It is possible however, that the slight difference in subcellular 
localisation was an artefact due to the fact that overexpressed GFP-tagged GBP4 
was used to determine the subcellular localisation. GTPases in the nucleus are 
most often found to be Ran proteins, which are responsible for trafficking RNA and 
proteins between the cytosol and nucleus (Moore, 1998). There are a few other 
GTPases in the nucleus that are carrying out functions in that location, for example 
PI-3Kinase Enhancer (PIKE) which interacts with nuclear PI3K to stimulate its lipid 
kinase activity (Ye et al., 2000). The most relevant nuclear GTPase to this study is 
the myxovirus resistant protein (Mx)-1 that is found in mouse. Mx proteins are part 
of the same large dynamin-like family of interferon-inducible GTPases as GBPs 
and IRGs. They are known to have important anti-viral properties, and are well-
conserved between a number of species (Verhelst et al., 2013), with MxA and MxB 
present in humans and two versions of the MxA protein in mouse, Mx1 and Mx2 
(Haller et al., 2015). These GTPases play vital roles against a broad range of both 
DNA and RNA viruses including influenza A and hepatitis B (Verhelst et al., 2013, 
Haller et al., 2015). As a result, Mx proteins can interact with the target viruses in 
both the nucleus and the cytoplasm. Interestingly, rodent Mx1 requires nuclear 
localisation to exert its functions (Zurcher et al., 1992). Conversely, the human Mx 
proteins are found solely in the cytoplasm, however can still exert full anti-viral 
mechanisms by inhibiting viral mRNA synthesis (Haller et al., 2015). This 
comparison is intriguing, as even within a family of highly identical proteins, Mx 
proteins seem to be playing different and necessary functions in murine versus 
human cells. This seems to also be the case with GBPs. The fact that, with GBP4, 
another member of this large-interferon inducible family has been located to the 
nucleus is striking, as so few GTPases are found in this cell compartment. 
Furthermore, GBPs and Mx proteins are GTPases that are highly conserved yet 
operating with diverse mechanisms across species.  
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 The loss of GBP4 expression upon infection with type I, yet not type II 
Toxoplasma was intriguing, as no parasite virulence factors in humans have been 
defined yet. Only examples of Toxoplasma proteins manipulating mouse cell 
components have been described (Fentress et al., 2010, Steinfeldt et al., 2010, 
Virreira Winter et al., 2011, Jensen et al., 2013, Franco et al., 2014, Bougdour et al., 
2014). The mechanism by which the parasite is manipulating GBP4 could be 
occurring at a transcriptional, translational or protein degradation level. By using 
inhibitors of protein degradation, I was able to accumulate the protein during 
infection. I ensured to use inhibitors that target varying aspects of protein 
degradation, to highlight the process by which this is happening. MG-132 is used to 
inhibit the 26S proteasome, as well as leupeptin that can inhibit cysteine/ serine/ 
threonine peptidases. Via these different reagents I was able to highlight while the 
protein is degraded in a 26S proteasome dependent manner in an uninfected cell, 
type I parasite infection results in GBP4 being degraded by cysteine, serine and/or 
threonine peptidases. Interestingly, it has been shown previously that type I 
Toxoplasma also effects protein levels in MEFs by a mechanism that can be 
inhibited when leupeptin is added to the culture (Carmen and Sinai, 2011). This 
study showed that degradation of BH3 interacting-domain death agonist (BID), a 
pro-apoptotic member of the B-cell lymphoma-2 (Bcl-2) family, is manipulated by 
the type I parasite in a leupeptin dependent manner (Carmen and Sinai, 2011). 
While the Toxoplasma virulence factor responsible for this host-protein 
manipulation has not been identified, it appears that type I parasites potentially 
possess a component that can modify both mouse and human cell proteins. Other 
inhibitors such as calpastatin to target the non-lysosomal calpain proteases, 
lactacystin for 20S proteasome inhibition and Z-VAD-FMK that is a specific 
caspase inhibitor were also preliminarily tested (data not shown). While I saw no 
accumulation of protein during infection when these inhibitors were used, a more 
thorough investigation is required.   
For this reason, I conclude that the parasite is acting on the protein product. 
In order to formally rule out an effect on GBP4 transcript, however, it would be 
prudent to conduct a qPCR analysis on samples taken over a time course during 
Toxoplasma infection. A potential effect on protein translation could be analysed by 
the observing stability of GBP4 protein, with and without the protein translation 
inhibitor cycloheximide. By using this method in infected and uninfected cells one 
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can determine the half-life of the protein, and can demonstrate whether the parasite 
has an effect on protein translation or degradation. It is furthermore a possibility 
that modification or truncation of GBP4 results in the antibody being unable to 
recognise its target. Due to the fact I can inhibit the loss of protein recognition, it is 
unlikely that this is the case. However, the way to fully identify whether an epitope-
masking post-translational modification or a truncation had occurred would be to 
utilise an antibody targeted to an epitope in a completely separate, N-terminal 
location. As no other specific GBP4 antibodies have been identified this not a 
possible course of action at the moment. Alternatively, if the endogenous protein 
was tagged using CRISPR-Cas9 at the N-terminus it may be possible to 
indisputably confirm this.  
 The disappearance of GBP4 in a parasite strain-specific fashion indicates it 
might be playing an important function during Toxoplasma infection. Whether or not 
the loss of expression is a host or Toxoplasma driven phenomenon is unclear. 
However, it is unlikely to be a host-driven mechanism due to the fact that the 
observation occurs with the type I parasite as opposed to the type II. This is due to 
the fact that traditionally type I is the ‘virulent’ parasite strain, and that some studies 
in human have already demonstrated that this may be true to a certain respect in 
man as well (Saeij et al., 2006, Ong et al., 2011, Selleck et al., 2015, Johnston et 
al., 2016). Cysteine, serine and threonine peptidases are activated by the cleavage 
of a pro-domain from their active sites (Di Cera, 2009, Verma et al., 2016). In the 
case of cysteine peptidases, a low pH or glycosaminoglycan polysaccharides can 
potentially disrupt salt bridges within this pro-domain and results in exposure of the 
active site (Verma et al., 2016). Many serine and threonine peptidases are 
activated in a calcium dependent manner, with an increasing calcium concentration 
resulting in an unmasked active site (Di Cera, 2009). Whether or not Toxoplasma 
can manipulate host factors to result in the activation of these proteases, or can 
release factors to induce exposure of the protease active site remains to be seen. 
Therefore it is likely that type I parasites actively function to circumvent control by 
GBP4.  
 The next step is to fully define the role that GBP4 plays against Toxoplasma. 
This can be achieved in the same way as with GBP1, using cells that have had the 
protein knocked-out using CRISPR-Cas9. Within the lab, preliminary results with 
A549 ∆GBP4 cells show that indeed the growth of Toxoplasma is enhanced when 
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GBP4 is not present (Joseph Wright, unpublished). While this result alone is 
exciting, it is interesting to note that this GBP4-mediated restriction is dependent on 
IFNγ stimulation. This difference in IFNγ dependence between GBP1 and GBP4 is 
another example of how the GBP family members appear to be playing their own 
unique roles and can function differently to each other. This IFNγ dependence 
could be due to a number of factors. Perhaps there is not a sufficient residual basal 
level of GBP4 in epithelial cells that is able to restrict pathogens. It may also be that 
the activation of the GTPase activity requires this cytokine, and in turn the 
activation is necessary for restriction. Alternatively, the mechanism by which GBP4 
exerts its function maybe be dependent on an interaction partner or component that 
requires IFNγ stimulation. These partners could even be other GBPs, and as IFNγ 
is required for oligomerisation (Britzen-Laurent et al., 2010) it could be an assembly 
process that cannot occur. If an assembly process is required, there is a chance 
that other GBP family members can be found in the nucleus also. For example, 
overexpressed GBP2 has already been observed in the nucleus of endothelial cells 
(Tripal et al., 2007). I carried out subcellular fractionations followed by 
immunoblotting, and did not observe GBP2 in the nucleus of epithelial cells. 
However, this could be another cell specific phenomenon, or GBP2 may only be 
located in the nucleus under specific conditions. Alternatively, GBP4 could have a 
cytoplasmic location and role in specific conditions that may also require the GBP 
oligomerisation process. This project has resulted in an anti-GBP4 antibody that 
has the capacity for immunoprecipitation. This means it is possible to retrieve the 
protein from cells that were subjected to a number of different conditions, including 
stimulated and unstimulated, and infected and uninfected. Following isolation of 
protein interacting complexes, the identity of the samples could be determined by 
mass spectrometry in order to identify the candidate interaction partners and thus 
define the pathway by which GBP4 functions. 
 GBP4 is an interesting GBP candidate due to the fact that it is the 
least similar to the other GBP family members in terms of sequence, showing less 
than 60% similarity to all family members except GBPs 6 and 7 (Olszewski et al., 
2006). Furthermore, when I analysed the sequence to determine if a nuclear 
localisation signal (NLS) was present, there were both monopartite and bipartite 
NLS motifs predicted, with relatively low prediction scores that suggest the protein 
is localised both in the nucleus and cytoplasm (Figure 30). Monopartite and 
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bipartite sequences are classical NLS motifs that have either one or two clusters of 
basic amino acids respectively (Lange et al., 2010). These NLS sequences are 
found towards the C-terminal end of the GTPase binding domain, and therefore 
would not be cleaved to induce relocalisation. Traditionally, a NLS motif would be 
determined and then mutated to observe the effects on protein expression and 
trafficking. Until we identify the site that is responsible for nuclear location, that step 
cannot be taken.  
 
Figure 30 Predicted nuclear localisation signals within GBP4 amino acid 
sequence 
Predicted monopartite and bipartite NLS signals within GBP4 protein, as 
determined using the cNLS Mapper tool (http://nls-mapper.iab.keio.ac.jp/cgi-
bin/NLS_Mapper_form.cgi). 
 
The sequence of GBP4 is additionally interesting as there is a 21 amino acid 
long extended N-terminal region that has two methionines, leading to a dispute as 
to which is the correct protein translation start site (Olszewski et al., 2006). 
Additionally, there is a chance that the N terminus is subject to modification and as 
a result might affect protein function. In this project, I was able to show that when 
GBP4 was tagged at the N-terminus, cleavage and accumulation of the tag 
occurred up to a few hours post-expression of the protein. While this is useful to 
know for the production of tools in the future, it was apparent that something 
interesting was occurring. This cleavage occurred in IFNγ-stimulated cells and 
during deliverance of GBP4 DNA into the cell by Vaccinia virus. It is a possibility 
that the truncation of GBP4 is required for the activation and anti-pathogen 
response. In order to address this question, it would be prudent to 
immunoprecipitate GBP4 before N terminal sequencing the to compare the N 
terminus protein of GBP4 in the nucleus. Once this has been identified, we would 
have a clue as to the N terminal start site and potential cleavage sites. If these sites 
Predicted monopartite motif
240 RHFFRKRKCFVF
242 FFRKRKCFV
Predicted bipartite motif
196 RDFTLELKLDGNPITEDEYLENALKIPGKNPKI
223 PGKNPKIQNSNMPRECIRHFFRKRKFC
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could be mutated, assays could be carried out to study the effect of the N terminus 
on GBP4 function. The problem lies in the fact that it has been proven unsuccessful 
to overexpress these GTPases in human cells. This presents a problem that is 
prudent for mutation of either the N terminus or the NLS motifs. Here again is a 
hurdle that could be solved by CRISPR-Cas9. This system allows not only for DNA 
to be mutated to delete translation of a protein, but can also introduce site-directed 
mutations that lead to insertion of a tag, or a single nucleotide change (Ran et al., 
2013). Therefore, employing CRISPR-Cas9, one could generate clonal cell lines in 
which the endogenous GBP4 is mutated as described at specific regions.  
 The interaction between pathogens and their hosts is complicated and 
variable. There are many examples of pathogens that can manipulate host features 
that result in increased virulence and pathology and thus promote their own 
survival. Numerous bacteria that can cause disease in humans have been shown 
to covalently modify host response GTPases, including Vibrio cholera, Escherichia 
coli, L. pneumophilia and Stapylococcus aureus (Aktories, 2011), so the 
modification of GBP GTPases would be a plausible virulence strategy for 
Toxoplasma. Other bacterial pathogens have the ability to exert transcriptional 
control. Listeria monocytogenes interferes with the SUMOylation machinery that is 
responsible for transcriptional regulation (Cossart, 2011). Furthermore Listeria and 
other bacteria including Mycobacterium tuberculosis, Shigella flexinuri and 
Heliobacter pylori can epigenetically control expression of genes at the mRNA level, 
via the modification of histone expression and/ or chromatin structure (Hamon and 
Cossart, 2008, Cossart, 2011). Toxoplasma is also capable of manipulating a 
number of features in the murine host. The Rop18 kinase of Toxoplasma can 
directly phosphorylate IRGs so that there is reduced PV recruitment, with Rop16 
hypothesised to work similarly on GBPs (Fentress et al., 2010, Steinfeldt et al., 
2010, Virreira Winter et al., 2011). Rop16 kinase and Gra15 also are responsible 
for interrupting the Jak-STAT and NFκB pathways in order to promote pathogen 
survival (Jensen et al., 2013). Furthermore, Toxoplasma manipulates the cell to 
specifically induce the transcription factor c-myc. This results in the upregulation of 
c-myc dependent products that play roles in mechanisms including cell cycle 
progression, apoptosis, cell differentiation, and metabolism (Franco et al., 2014). 
Gra16 and Gra24 are secreted dense granule proteins that both contain nuclear 
localisation signals, and have been shown to alter host genome expression via the 
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regulation of p53 and p38α signalling pathways respectively (Bougdour et al., 2014). 
As GBP4 is found within the nucleus, it is possible that it is intercepting parasite 
responses that aim to modify cell genetic responses. Alternatively, perhaps GBP4 
is involved in regulating transcription in response to infection, possibly due to 
specific interactions with important components to this pathway. Therefore 
Toxoplasma could be affecting transcriptional defence processes indirectly via 
GBP4.  
 GBPs that have been best characterised in the literature, GBP1 and 5 
(Tietzel et al., 2009, Shenoy et al., 2012, Al-Zeer et al., 2013, Johnston et al., 2016) 
sit on an entirely different branch of the GBP phylogenetic tree to GBP4 (Figure 31). 
Therefore, the fact that the GBP4 sequence differs the most compared to these 
other family members would infer that it would be most likely to play a unique role 
in infection. GBP4 has not been intensively studied in the literature. There is one 
paper by Hu et al. that focuses on mouse GBP4 as a negative regulator of Sendai 
virus-induced IFN-alpha (IFNα). This downregulation of IFN occurs as a result of 
IFN-regulatory factor 7 (IRF7) inhibition. Sendai virus was used to infect cells that 
had mGBP4 silenced, as well as wild type cells; after which the supernatant from 
these cultures was added to cells infected with VSV. The VSV was observed to 
replicate less efficiently when supernatant from the mGBP4 silenced culture was 
used (Hu et al., 2011). This suggests that a higher level of IFNα is secreted from 
cells in response to Sendai virus when mGBP4 is not functional. Perhaps mGBP4 
is targeted specifically by Sendai virus, and manipulated to enhance viral survival 
via negative regulation of IFN. Alternatively, perhaps it is playing a vastly different 
role to other mGBP family members, and does not restrict viral replication in cells. It 
would be interesting to see if mouse GBP4 reacts in a similar manner across 
different viral infections, and to investigate whether human GBP4 shows a similar 
phenotype during viral infection.  
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Figure 31 The phylogenetic tree showing distribution of GBP family members 
The phylogenetic tree, created using amino acid sequences for GBP family 
members, with the ClustalW Phylogeny software. 
 
Murine versus human cells as models of infection 
Mouse models are an invaluable tool and have been used to study innumerable 
processes that have benefitted medical research. It is possible to engineer genome 
modifications, and interbreed them to become genetically identical to limit variability 
in results. From mice, it is straightforward to obtain primary cells that in most cases 
will provide a biologically relevant result. These are features that are obviously 
impossible or near impossible in the process of studying human biology. While it is 
possible to obtain primary cells, the range is limited and often difficult to acquire, 
especially if a large number of cells are required over a long time period. For this 
reason, human cell lines that have been adapted for in vitro culture are generally 
utilised. I ensured the cell lines I worked with expressed GBPs and were IFNγ-
responsive. However, these lines are often adapted from a cancerous sample, or 
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are immortalised with cancer or viral genes to survive in a culture dish; both A549 
and THP-1 cells are adapted from cancerous samples. A wide variety of cell types 
exist, including endothelial cells, epithelial cells, fibroblasts and monocyte cells. 
These cell lines are not always the most biologically relevant to an infection and 
can represent only single cell results rather than a whole animal response. 
Therefore, many studies will still move to identify pathways and component 
functions in the mouse, or other animal models, before describing a comparison in 
human cells. While this is a successful strategy in many studies, this project has 
highlighted that the animal model is not always going to show characteristics that 
are reproducible in, or representative of, human responses.  
 For many years, the host response to Toxoplasma by interferon-inducible 
GTPases, the IRGs and GBPs, have been intensively studied. As mentioned 
previously, the human genome comprises only 2 copies of GKS-IRG genes, and 
these are not IFNγ-sensitive (Bekpen et al., 2005). As the GBP family is much 
better conserved, it seemed prudent to understand GBP responses in mice so that 
there was a likely chance to determine responses that were also replicated in a 
human host. While looking to determine whether or not GBP1 or 4 played a role in 
defence against Toxoplasma infection, the first priority was to determine whether or 
not these proteins localised to the PV. As it quickly became clear that this was not 
the case, I wondered if GBPs could play a role at all. This is because mouse GBPs 
play a specific role in disrupting the PV, and hence leading to death of the parasite 
(Yamamoto et al., 2012, Meunier et al., 2014, Pilla et al., 2014). Furthermore, 
mGBPs have been shown to interact extensively with IRGs in order to carry out 
their defensive capacities (Haldar et al., 2013). However, it is now clear that in stark 
contrast to in mice, human GBPs play an important role in a location away from the 
parasite itself and in the absence of canonical IRG GTPases.  
 The subcellular locations of human GBPs have been described in the 
literature previously (Modiano et al., 2005, Tripal et al., 2007) and have been more 
specifically described in my Results chapter 2. No report has located murine GBPs 
to the nucleus. While it may be the case that the finding is yet to occur, it would be 
interesting that human and mouse GBPs have potentially evolutionarily diverged so  
that the roles they play are totally separate. GBPs 1 and 5 have also been reported 
to have a localisation to the golgi (Modiano et al., 2005, Tripal et al., 2007), 
indicating there may be a role of these GTPases related to golgi-mediated protein 
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modification or vesicular trafficking. Whether or not GBP1 and 5 are fulfilling the 
same function at the golgi is unknown. However, seeing these two family members 
specifically localise at the organelle could imply that the GBPs that are not localised 
to the golgi upon IFNγ stimulation may be performing a different role.  
 Determining the subcellular localisation of proteins gives key clues as to the 
functions they carry out, and can elude to potential interaction partners. We are 
speculating that GBP4 could play a role in transcription, while GBP1 and 5 may be 
involved in post-transcriptional protein modifications considering their association 
with the golgi apparatus (Modiano et al., 2005, Tripal et al., 2007). I have 
postulated that mouse and human GBPs have very different characteristics, but 
perhaps mouse GBPs are actually capable of carrying out the same functions as 
their human counterparts. Mouse GBPs are not all found at the vacuole during 
Toxoplasma infection. The murine GBPs 8, 10 and 11 are found distributed in 
vesicles throughout the cytoplasm, and do not relocalise to the PV upon infection 
with the parasite (Degrandi et al., 2007). This could mean that the PV-absent family 
members are not functional during infection, or alternatively they could be playing a 
separate role altogether maybe in line with human GBPs. This project underlines 
that it is important to look at the functions of all GBPs at a location away from the 
pathogen vacuole.  
 In functionality experiments in the mouse, it is now known that the mGBP 
cluster located on chromosome 3 is responsible for the activation of the 
inflammasome, in turn leading to activation of caspase-11 (Pilla et al., 2014, 
Meunier et al., 2014). Humans do not possess caspase-11 and instead have the 
homologs caspase-4 and -5. It will be interesting to see how these studies progress, 
and if it can be shown that GBPs are capable of activating human caspase-4 and -
5 to cause cell death. A relatively high level of GBP conservation exists across 
species (Li et al., 2009), and already GBPs have been implicated in inflammasome 
activation in zebrafish (Tyrkalska et al., 2016). It will be exciting to see if GBPs 
across multiple species are able to induce inflammasome activation in response to 
infection.  
 The human versus mouse host reactions to Toxoplasma has recently been 
appreciated to be different not only on the level of parasite restriction, but also for 
parasite recognition by the host cell. It is known that in mice, host cell invasion by 
the parasite is not required for IL-12 release and instead Toxoplasma profilin, a 
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soluble endotoxin, is required for simulating high levels of this cytokine from DCs 
(Yarovinsky et al., 2005). This stimulation of DCs requires recognition of the profilin 
by TLR11 and 12, with mice deficient in these genes succumbing quickly to 
Toxoplasma infection (Yarovinsky et al., 2005, Koblansky et al., 2013). What is 
interesting is that humans lack a functional TLR11 gene and are completely 
deficient in the TLR12 gene (Roach et al., 2005), but still mount an effective 
response to the infection and do not succumb to it. As a result, when this same 
mechanism of IL-12 was investigated in DCs derived from primary peripheral blood 
monocytes a completely different mechanism was observed. Instead of responding 
to profilin, the response was dependent on the phagocytosis of live tachyzoite 
parasites, while actively invading live parasites were not sufficient (Tosh et al., 
2016). In mouse, CD8α+ DCs are principally responsible for IL-12 release in the 
spleen (Reis e Sousa et al., 1997, Mashayekhi et al., 2011), with CD11b+ CD8α- 
being the main producer of IL-12 at the site of infection (Goldszmid et al., 2012). 
However, Tosh et al. show that the human counterpart of CD11b+ CD8α- DCs, the 
CD1c+ DCs, produce some IL-12, and the human equivalent of CD8α+ DCs are 
unresponsive. Instead, CD16+ monocytes are a main producer of this vital cytokine; 
further highlighting differences in host responses dependent on species (Tosh et al., 
2016). Findings like these suggest that when studying host defence mechanisms 
against Toxoplasma using a mouse model may not provide results that are 
transferrable to human.  
 Mice are a natural intermediate host for Toxoplasma, so it is logical that 
these two species have evolved alongside each other, resulting in a specialised 
host-parasite relationship (Gazzinelli et al., 2014). Selective pressure has led to a 
significant alteration in the immune system. It is hypothesised that this coevolution 
has led to the emergence of highly specialised mechanisms of defence including 
the varying TLR responses and the maintenance of IRG function (Gazzinelli et al., 
2014). Perhaps in the absence of this selection pressure, human GBPs have 
developed an entirely different set of qualities against this pathogen and others. 
Investigators should bear this in mind when studying the roles of these large 
GTPases, particularly with Toxoplasma infection. 
 As it is becoming clear that mouse models will not provide all the answers 
regarding human responses to this parasite, the scientific community is requiring a 
more biologically relevant tool with which to study human host defence. As I 
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mentioned above, human cell lines can only provide an approximation of true 
situations during an in vivo infection. Macrophages would be the cell of choice with 
which to study host response to Toxoplasma, as these cells are probably 
preferentially infected by the parasite (Zhao et al., 2014). A number of human 
macrophage cell lines exist, including THP-1 cells, AML-193, U-937 and HL-60 
cells. All of these cell lines were derived from patients with either monocytic 
leukaemia or histiocytic, non-Hodgkin lymphoma. THP-1s are the most commonly 
used human macrophage line, however these cells, as with the other cell lines, 
require activation to differentiate from monocytes to macrophages. This means 
they are already in an activated immune state that may affect the process of 
infection by Toxoplasma or other pathogens. DCs play such an important role 
during Toxoplasma infection that they are another cell type that would be very 
interesting to be able to study in vitro. While THP-1 monocytes can be carefully 
cultured to differentiate to DCs (Berges et al., 2005) this again is a very artificial 
system. To study human DCs, it is required to isolate them from human blood 
samples, which of course presents a large limiting factor to biochemical analysis.  
 An additional problem arises when we consider that these cell lines may not 
have all of the immunoregulatory pathways intact. The most extreme example of 
cells used for immune studies that are arguably not biologically relevant is perhaps 
the use of HeLa cells. HeLa cells were isolated in 1951 from a cervical cancer 
sample, which upon inspection contained 76-80 heavily mutated chromosomes, 
compared to a normal 46 chromosomes. Additionally, almost 2000 genes are 
expressed more highly than the physiological range of 16 human tissue samples, 
with these genes duplicated up to six times (Landry et al., 2013). This is due to the 
effects of the human papilloma virus that was the origin of the cancer, as a result of 
its ability to inactivate p53. Because of this aberrant chromosome number and 
irregular genetic makeup, the cells may possess an unbalanced set of immune 
modulatory molecules. However, while this is one of the most severe examples, the 
cells used in this project are also not without caveats. THP-1 cells have been 
analysed to have better response mechanisms to stimuli other than human-
macrophage cell lines, for example U937 cells, however they respond much less 
than macrophages that have been differentiated from primary peripheral blood 
monocytes (Sharif et al., 2007, Chanput et al., 2010, Chanput et al., 2014). There is 
evidence too that the TLR expression levels in THP-1 cells can be variable 
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dependent on the concentration of PMA induction used during the macrophage-
differentiation step. This means there may be caveats in the analysis of a response 
to a pathogen that relies on a specific TLR expression pattern. A549 are epithelial 
cells that were isolated from lung adenocarcinoma. Upon analysis they were shown 
to have 13 abnormal chromosomes with half of the abnormalities deriving from 
deletions and amplifications of genes (Peng et al., 2010). While I ensured that the 
GBPs I was interested in were present in these cells, there is a possibility that 
interaction partners or up- and down-stream effectors are not present or functional. 
This would result in non-biologically relevant results, with the potential of missing a 
GBP function altogether. For these reasons, it is important that we begin to move 
our studies into cells that are more likely to mimic natural responses.  
 To this end, I began working with induced pluripotent stem cells (iPSCs). 
These are cells that are taken from a human sample and reprogrammed to become 
pluripotent progenitors of monocytes and other cell types. These cells can provide 
researchers with primary cells that can survive in tissue culture that have not been 
adapted from cancerous tissue, or that have been adapted over such a long time 
that they do not recognise as natural cells. The iPSCs that I handled were re-
programed at the Sanger Institute in Cambridge to become monocyte precursors. I 
obtained these cells from the Sanger and became competent in their culture and 
maintenance. During my PhD I focussed on learning to maintain and culture these 
iPSCs, with the aim to carry out CRISPR-Cas9 GBP deletion on the monocytes 
progenitors. Once this would be achieved, it would be possible to differentiate the 
cells to primary macrophages that were deficient in specific GBPs. Other lab 
members can now employ CRISPR gene manipulation before differentiating them 
into primary macrophages. This would provide a very biologically relevant tool with 
which to study human responses to infection- a tool that would potentially 
revolutionise our understanding of cell autonomous reaction to pathogens. To 
repeat the experiments in these cells would give the most biologically relevant 
insight into how GBPs function in vivo, particularly in the context of a Toxoplasma 
infection. 
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Chapter 5. Results gathered to be used for 
continuation of GBP work in the Frickel Lab 
5.1 Results  
5.1.1 Protein interaction partners of GBP2 
As I began to unravel the characteristics of human Guanylate Binding Proteins and 
their functions during infection with Toxoplasma, I used the antibodies I generated 
to identify specific GBP interaction partners. I obtained data that could not be fully 
investigated at the time. However, I will discuss the raw data produced in this 
chapter. Based on my findings and analysis, additional work remains that can be 
mined to continue this line of research. A number of projects will be able to begin 
and to be continued within the Frickel lab.  
 Mass spectrometry of immunoprecipitated GBP1 and 2 in collaboration with 
Bram Snijders within the Francis Crick Institute led to the generation of the data set 
of potential GBP interacting partners. The anti-GBP2 peptide polyclonal antibody 
produced in rabbits was very effective at retrieving GBP2 from A549 lysates. In this 
application, the antibody cross-reacted with GBP1, therefore immunoprecipitating 
this family member also (Chapter 3, Figure 7). A549 cells were stimulated overnight 
with IFNγ before being infected or not with type I or type II Toxoplasma. The 
infection was allowed to persist for 2 hours before the cells were lysed using lysis 
buffer containing the mild detergent 0.5% NP-40. This was to ensure that 
interactions between proteins were maintained. The lysates were subjected to a 
pre-clearing step, during which they were incubated with the preimmune serum that 
was obtained during the antibody production process, followed by an incubation of 
this mixture with Protein Sepharose G beads. This stage limits the number of non-
specific interactions with the beads. After this step, the anti-GBP2 antibody was 
allowed to mix with the pre-cleared cell lysate before the complex was added to 
fresh Protein Sepharose G beads. The beads were then spun down from the 
suspension, isolating GBP2, GBP1 and their potential interaction partners. The 
protein complexes were removed from the beads by boiling in SDS loading buffer 
and the resulting product was run on SDS-PAGE. The gel was only permitted to 
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run for a very short distance to ensure a dense concentration of protein that would 
be then analysed by mass spectrometry.  
 At this stage, the samples were given to Bram Snijders and Vesela Encheva 
who ran the experiment and gave me back a data-set containing gene identities of 
the proteins isolated. Briefly, they carried out the analysis by excising the protein 
piece and destained it using 50% acetonitrile, 50mM ammonium bicarbonate, 
reduced with 10mM dithiothretiol, alkylated with 55mM iodoacetamine. The proteins 
were then digested with 6ng/ml trypsin overnight at 37˚C before the peptides were 
extracted in formic acid and 1% acetonitrile. These peptides were loaded on to an 
Easy Spray column (Thermo Fisher). Reverse phase chromatography was 
performed using the RSLC nano U3000 (Thermo Fisher). The in-gel digested 
samples were run on a linear gradient of 80 % acetonitrile, 0.1 % formic acid from 2 
to 40% over 35 minutes. The Q exactive was operated in a data dependent mode 
on the most abundant ions. They created the list of 908 proteins by searching the 
parent ion and tandem mass spectra against Homo sapiens and Toxoplasma 
gondii databases. Furthermore the Max Quant software added a list of 247 
common laboratory contaminants to the database. The datasets were filtered on a 
posterior error probability to achieve a 1% false discovery rate on protein and 
peptide levels. Finally, they used the Max Quant matching function to increase 
overlap between experiments.  
 I received the information in the form of a Perseus software file. Importantly, 
we retrieved GBP1 and GBP2 proteins in the experiment demonstrating that the 
immunoprecipitation protocol had worked. Using this software, I analysed the 
potential protein interactions that had the lowest false discovery rates and which 
occurred in a Toxoplasma infection specific manner. I was interested in proteins 
that were identified during infection with the parasite as compared to the uninfected 
control (Table 7).  
 Other members of the lab can further mine this dataset. The next step with 
this information would be to carry out another immunoprecipitation with the GBP2 
antibody before probing an immunoblot with an antibody against one of potential 
protein partners. It is true that GBP1 was retrieved with this antibody and therefore 
the list contains potential interaction partners of this protein too.  
 Based upon this list, there a large number of possible mechanisms by which 
GBP1/2 exert their function in terms of a Toxoplasma infection. Mouse GBPs have 
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been implicated in both canonical and non-canonical inflammasome induction. One 
wonders whether or not human GBPs can play a similar role. One of the potential 
interaction partners that I identified from the mass spectrometry run was 
transmembrane protein 214 (TMEM214), which is a known interactor of caspase-4, 
the human equivalent of mouse caspase-11 (Li et al., 2013). This candidate was 
found in a type II infection-dependent manner. This is interesting as GBP1 can 
restrict type II parasites, but not type I. TMEM214 acts an anchor for procaspase-4 
at the endoplasmic reticulum outer membrane (Li et al., 2013). As GBP1 is 
isoprenylated and membrane targeted, there is a possibility that it interacts with 
TMEM214 to ensure cleavage of procaspase-4 to caspase-4.  
 The data obtained from the mass spectrometry analysis leaves room to 
speculate that metabolic functions could be driven by GBP1/2. This is because 
proteins like Lon protease homolog, Vacuolar ATPase assembly integral 
membrane protein (VMA21) and major vault protein (MVP) were co-
immunoprecipitated from the sample in an infection dependent manner. VMA21 
and MVP were retrieved from samples in a strain-independent manner. This would 
suggest that they do not play a role in the GBP1 strain-dependent restriction of 
Toxoplasma. Instead a more general role could be carried out, or potentially these 
are protein interaction partners with GBP2 and result in an un-yet identified host 
defence function. VMA21 is of particular interest as it is an assembly chaperone of 
the mammalian proton pump complex in the endoplasmic reticulum. When levels of 
VMA21 are manipulated, autophagy is blocked leading to a deficient mTORC1 
pathway, resulting in ineffective autolysosomes that can cause vacuoles in the cell 
(Ramachandran et al., 2013). Lon protease homolog is a mitochondrial protease 
that plays a vital function in the degradation of damaged, oxidised and mis-folded 
proteins. Additionally, some proteins may be degraded by Lon protease homolog in 
normal conditions (Quiros et al., 2015). This protease has also been implicated in 
regulation of mitochondrial gene expression and in chaperoning membrane 
complex components (Bota and Davies, 2002). MVP is highly conserved between 
species and has functions that are not yet fully understood. However, it is known 
that MVP is involved in a number of cellular signal transduction pathways, including 
STAT1 and MAPK activation, and is thought to result in a cell survival response 
(Berger et al., 2009). Rab-18 was also retrieved. This protein is found in 
endosomes and lipid droplets, and is implicated in membrane trafficking between 
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the endoplasmic reticulum and the golgi apparatus (Dejgaard et al., 2008). As 
GBP1 and 2 are isoprenylated for targeting to membranes and to enhance protein-
protein interactions, it would be logical that they could be involved in trafficking 
other proteins to specific areas in the cell.  
 Table 8 displays potential interaction partners of GBP1/2 that were retrieved 
in all conditions (unless otherwise stated). GBP1/2, or any GBP, may play a role in 
the cell that is independent of infection. In this case, the relevant interaction 
partner(s) would be retrieved in all conditions. While this would be a more difficult 
route to follow up, it is an interesting line of investigation that could be considered 
in the future. A large number of candidates that suggest a function in translation 
were identified (Table 2), with almost the complete ribosomal complex being 
retrieved. Ribosomes are abundant in cells, thus this result could potentially be an 
artefact, but it is worth taking note of this finding. Furthermore, a significant 
selection of initiation of translation factors was isolated. These proteins bind to the 
ribosome complex and trigger the beginning of the biosynthesis. There is a 
possibility that GBPs interact with these proteins to induce the synthesis of a 
certain product to mediate host defense. Elongation factors were also identified as 
potential interaction partners (Table 8). These are a set of proteins that enable the 
elongation from the first binding site on the ribosome, to the last. 
 These candidates present a large number of opportunities to determine 
interaction partners of GBP1/2 that may result in identifying a mechanistic pathway 
for these proteins. It appears that these proteins could play a role in translation, 
metabolic pathways and/or inflammasome induction. 
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Table 7 Protein interaction candidates for GBP1 and 2 identified in a Toxoplasma 
strain-dependent manner 
Table showing possible protein interaction partners of GBP1/2 as identified by 
immunoprecipitation of GBP1/2 from A549 cells followed by mass spectrometry 
analysis. The candidates common to both type I and type II infection highlighted in 
blue. Cells were stimulated for 18 hours with 10U/ml IFNγ. Infection persisted for 2 
hours, MOI 3. 
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Table 8 Protein interaction candidates of GBP1 and 2 that implicate roles in 
translation. 
Table showing possible protein interaction partners of GBP1/2 as identified by 
immunoprecipitation of GBP1/2 from A549 cells followed by mass spectrometry 
analysis. Candidates that are implicated in translation have been listed. The 
candidates are common to uninfected, and type I and type II infected samples, 
excepting candidate highlighted in yellow that was detected in the uninfected 
sample only. Cells were stimulated for 18 hours with 10U/ml IFNγ. Infection 
persisted for 2 hours, MOI 3. 
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5.2 Discussion 
Throughout this project, I have continuously developed tools that I could use to 
characterise GBPs, but also that other people could use. I have not only designed 
and characterised antibodies and cells, I have optimised experiments and collated 
a large dataset that can be mined to identify protein interaction partners of GBP1 
and 2. The antibodies I have designed and characterised, with the cells that are 
being developed in the lab, are invaluable tools that can be used to determine GBP 
function in a wide array of pathogen types.  
During, this project I have highlighted that there are relatively basic 
questions regarding the GBP family members that still need to be addressed. While 
the GTPase activity of GBP1 has been extensively studied in vitro (Praefcke et al., 
1999, Praefcke et al., 2004, Kunzelmann et al., 2005, Ghosh et al., 2006, Abdullah 
et al., 2009, Vopel et al., 2010, Abdullah et al., 2010, Wehner et al., 2012), the 
properties and characteristics of the other GBPs are widely unknown. The GTPase 
activity of GBP4 and other family members has not been elucidated. The 
requirements for the activation of GTPase activity or activation of other cellular 
components still remain largely unknown. There could be underlying differences 
here that could account for the differences observed between the characteristics of 
and the roles played by both human GBP family members, and GBPs across 
species. It is apparent also that some functions of GBP1 occur in a GTPase 
independent manner. The inhibition of endothelial cell invasion and proliferation 
occurs regardless of the GTPase nucleotide bound state (Guenzi et al., 2001, 
Guenzi et al., 2003). The fact that GBP1 can restrict type II Toxoplasma in an IFNγ-
independent manner would suggest that this mechanism too occurs by GTPase-
independent means. Therefore it is still important to take into account GBP function 
when IFNγ is not present. 
On a similar note, there are many basic aspects of protein turnover and 
principles that have not been investigated. For GBP4, parasite infection clearly 
impacts on protein levels observed. The synthesis and degradation rates, and the 
routes of degradation are generally unknown. Using the protein synthesis inhibitor 
cycloheximide coupled with protein expression quantification, characterisation of 
protein production can be achieved. The samples will be incubated with inhibitor 
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before washing the cycloheximide off and tracking the rate that protein expression 
can once again be detected in an immunoblot. This will be possible using the 
antibodies that I have produced throughout the project. Conversely, the route of 
degradation for each GBP can be determined by using inhibitors of specific 
degradation pathways. The rate of degradation can be calculated by incubating the 
sample with a protease inhibitor, after which this inhibitor will be washed off and 
protein expression will be quantified by immunoblot. Cycloheximide must be used 
in these experiments too to ensure the degraded protein is not being replaced by 
freshly synthesised product.  
The antibodies I have designed and characterised, with the cells that are 
being developed in the lab, are important tools that can be used to determine GBP 
function in a wide array of pathogen types. To show that GBP1 is able to restrict 
Toxoplasma replication in a location away from the parasitophorous vacuole 
changes the way we should think about these proteins. While the discovery is 
groundbreaking, there is no further clarification as to the mechanism by which 
GBP1 conducts this function. The above results demonstrating potential interaction 
partners of GBP1 present a very real possibility to narrow down the area in which 
this GBP family member, at least, exerts its function. The mass spectrometry data 
that I have collated and prioritised can be mined in many different ways to discover 
interacting partners and hopefully identify mechanisms by which this GBP family 
member functions. GBP1 has been implicated in cell remodelling and endothelial 
cell proliferation (Schnoor et al., 2009, Ostler et al., 2014) in humans, as well as in 
inflammatory responses (Shenoy et al., 2012, Pilla et al., 2014, Meunier et al., 2014, 
Meunier et al., 2015, Man et al., 2015). However metabolic or translational 
functions would be completely novel. With the discovery of ‘off-site’ GBP responses, 
this opens the possibility for never before considered roles of this protein family that 
do not involve the pathogen vacuole. 
 I have shown in this dataset that there are a vast number of potential 
mechanisms by which GBP1 could be functioning against Toxoplasma infection. 
These include inflammasome responses via the identification of TMEM214, an 
interaction partner of caspase-4 (Li et al., 2013). Also a role in trafficking of proteins 
is possible after the retrieval of proteins such as Rab-18, a protein required for 
trafficking between the endoplasmic reticulum and golgi apparatus. As GBP1 is 
isoprenylated (Nantais et al., 1996) and has been localised to the golgi (Modiano et 
Continuation of GBP investigation 
 
127 
 
al., 2005, Tripal et al., 2007), this is one exciting prospect to follow, as there may 
be a role in regulating post-translational modification or packaging of proteins. 
Identifying translational-activator-GCN1 along with a vast array of ribosomal 
proteins and initiation of translation factors points to a function in mediating 
translation. Translational functions are further implicated with the identification of a 
large number of elongation factors, which are responsible for forming the initial 
peptide bond to the ribosome complex. If GBP1 truly does interact with 
components such as Lon protease homolog, VMA21 and MVP then a metabolic 
function can be implicated (Berger et al., 2009, Quiros et al., 2015, Ramachandran 
et al., 2013). VMA21 is implicated in autophagy and cell death, an important cell 
defence mechanism (Ramachandran et al., 2013). GBP1 can restrict Toxoplasma 
in a strain-dependent manner, however the interaction with VMA21 occurs in a 
strain-independent manner. This would suggest that if the interaction between 
GBP1 and VMA21 was real, it is not a dominant mechanism of protection against 
Toxoplasma. However, there could be a general function of GBP1 that is 
dependent on this interaction. Alternatively, as GBP2 is also a bait protein in this 
mass spectrometry experiment, VMA21 may interact with this family member. As 
the function of GBP2 against Toxoplasma is not yet characterised, there is a 
possibility that a role is fulfilled by this interaction. MVP is another protein 
interaction candidate that is immunoprecipitated in a strain-independent manner. 
This protein is implicated in cellular signal transduction pathways, thought to result 
in increased cell survival responses (Berger et al., 2009). As GBP expression has 
generally been associated with cell death responses it could be that GBP1 
negatively regulated MVP, or vice versa. If GBP1/2 were proven to interact with 
Lon protease homolog, a function in degradation of misfolded or damaged proteins 
would be likely (Quiros et al., 2015). This again would be an interesting line of 
study to investigate, considering the relationship between GBP1 and the golgi, with 
potential for protein modification and regulation. 
 All of the above interactions can be confirmed or discounted by repeating 
the immunoprecipitation with the GBP antibodies before probing an immunoblot 
with antibodies against the candidate proteins. To distinguish between GBP1 and 
GBP2 specific antibodies, one could immunoprecipitate from A549 ∆GBP1 cells 
and verify which interactions are missing or still present. The missing interactions 
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would signify a GBP1-specific interaction partner, and remaining candidates would 
denote GBP2-specific proteins.  
These results are definitely exciting, and open numerous doors in the 
challenge of outlining mechanistic function of these large GTPases.  
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Chapter 6. Conclusion 
Overall this project has made progress in developing the tools that are necessary 
to fully elucidate the functions played by human guanylate binding proteins. I have 
shown that GBP1 works to restrict Toxoplasma during vacuolar replication. GBP4 
is a nuclear GTPase that loses expression upon infection with type I Toxoplasma 
parasites. I have highlighted the importance of looking at functions of GBPs at a 
location away from the PV. This project underlines that breakthroughs made in 
mice are not always transferrable across species. While the mouse may not be the 
most suitable model to study GBPs with regards to their functions in humans, I 
have shown it is possible to move studies into a human system and that research 
in primary cells is becoming more accessible. I have demonstrated that GBPs are 
playing specific and relevant roles during infection, and have provided a great 
number of tools that will be used to further our understanding of these interesting 
and important GTPases. I firmly believe that research should be built on each 
other’s successes, and that sharing reagents and knowledge is key - I hope the 
work done during my PhD will contribute to this. 
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Chapter 7. Appendix 
Table 9 Primer lists for GBP cloning 
Primer name Vector Restriction 
sites 
Sequence 
GBP3 For C1 GFP/ 
mCherry 
BamHI/ 
BspEI 
GGATCCTCCGGAATGGCTCCAGAG
ATCCACATGACA 
GBP3 Rev BamHI/ SacI GGATCCCTCGAGTTAGATCTTTAAG
CTTATATGCGACAT 
GBP5 For C1 GFP/ 
mCherry 
BamHI/ 
BspEI 
GGATCCTCCGGAATGCTTTAGAGAT
CCACATGTCA 
GBP5 Rev BamHI/ SacI GGATCCCTCGAGTTAGAGTAAAACA
CATGGATCATCG 
GBP6 For C1 GFP/ 
mCherry 
HindIII/ 
BspEI 
AAGCTTTCCGGAATGGAATCTGGAC
CCAAAATGT 
GBP6 Rev HindIII/ SacI AAGCTTCTCGAGTTAAAAGGGGAGC
TTATGCTTT 
GBP 7 For C1 GFP/ 
mCherry 
BamHI/ 
BspEI 
GGATCCTCCGGAATGGCATCAGAG
ATCCACATG 
GBP7 Rev BamHI/ SacI GGATCCCTCGAGTCAGCTTATAATT
TTCTTACCAGGA 
GBP4 For pcDNA3 
FlagHA 
BamHI/ KpnI GGATCCGGTACCATGGGTGAGAGA
ACTCTTCACGCT 
GBP4 Rev BamHI/ 
XhoI 
GGATCCGAGCTCTTAAATACGTGAG
CCAAGATATTTTGT 
GFP/mCherry 
GBP3 For 
pGene  BamHI/ 
BspEI 
GGATCCTCCGGAATGGCTCCAGAG
ATCCACATGACA 
GFP/mCherry 
GBP3 Rev 
BamHI/ SacI GGATCCCTCGAGTTAGATCTTTAAG
CTTATATGCGACAT 
GFP/mCherry 
GBP5 For 
pGene BamHI/ 
BspEI 
GGATCCTCCGGAATGCTTTAGAGAT
CCACATGTCA 
GFP/mCherry 
GBP5 Rev 
BamHI/ SacI GGATCCCTCGAGTTAGAGTAAAACA
CATGGATCATCG 
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GFP/mCherry 
GBP6 For 
pGene  HindIII/ 
BspEI 
AAGCTTTCCGGAATGGAATCTGGAC
CCAAAATGT 
GFP/mCherry 
GBP6 Rev 
HindIII/ SacI AAGCTTCTCGAGTTAAAAGGGGAGC
TTATGCTTT 
GFP/mCherry 
GBP7 For 
pGene 
GFP 
BamHI/ 
BspEI 
GGATCCTCCGGAATGGCATCAGAG
ATCCACATG 
GFP/mCherry 
GBP7 Rev 
BamHI/ SacI GGATCCCTCGAGTCAGCTTATAATT
TTCTTACCAGGA 
GFP GBP4 
For 
pGene BamHI/ KpnI GGATCCGGTACCATGGGTGAGAGA
ACTCTTCACGCT 
GFP GBP4 
Rev 
BamHI/ 
XhoI 
GGATCCGAGCTCTTAAATACGTGAG
CCAAGATATTTTGT 
GFP GBP4 
For 
pJS4 AscI AAGCTTGGCGCGCCATGGTGAGCA
AGGGCGAGGAGCT 
GFP GBP4 
Rev 
PacI AAGCTTTTAATTAATTAAATACGTGA
GCCAAGATATT 
GFP GBP4 
For 
pLVX-
Tight-
Puro 
MluI AAGCTTACGCGTATGGTGAGCAAG
GGCGAGGAGCTG 
GFP GBP4 
Rev 
NotI AAGCTTGCGGCCGCTTAAATACGTG
AGCCAAGATATT 
 
 
Table 10 PCR Amplification of GBP for C1/ pcDNA3/ pGene vectors 
Temperature (˚C) Time Cycles 
95 2 minutes 1 
95 30 seconds  
35 Tm-5 30seconds 
72 1 minute/ kb 
72 5 minutes 1 
4 Pause 1 
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Table 11 PCR amplification of GBP4 for pJS4 and pLVX-Tight-Puro 
 Temperature (˚C) Time  Cycles 
95 1 minute 1 
95 15 seconds  
35 60 15 seconds 
72 5 seconds 
72 5 minutes 1 
4 pause 1 
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Figure 32 mCherry-C1 vector map 
  
pmCherry-C1 Vector Information   PT3975-5
 Cat. No. 632524
(060412) 
* The XbaI site is methylated in the DNA provided by Clontech. If you wish to digest the vector with XbaI 
enzyme, you will need to transform the vector into a dam - host and make fresh DNA.  
 
pmCherry-C1 Restriction Map and Multiple Cloning Site (MCS).
Description
pmCherry-C1 is a mammalian expression vector designed to express a protein of interest 
fused to the C-terminus of mCherry, a mutant fluorescent protein derived from the 
tetrameric Discosoma sp. red fluorescent protein, DsRed (1). The excitation and emission 
maxima of the native mCherry protein are 587 nm and 610 nm, respectively. Expression 
of fusion proteins that retain the fluorescent properties of the unmodified mCherry protein 
can be monitored by flow cytometry and their localization in vivo can be determined by 
fluorescence microscopy. 
The multiple cloning site (MCS) in pmCherry-C1 is positioned downstream of the mCherry 
coding sequence. A Kozak consensus sequence is located immediately upstream of 
the mCherry gene to enhance translational efficiency in eukaryotic systems (2). SV40 
polyadenylation signals downstream of the mCherry gene and the MCS direct proper 
processing of the 3' end of the mCherry (or fusion gene) mRNA. 
The vector backbone contains an SV40 origin for replication in mammalian cells expressing 
the SV40 large T antigen, a pUC origin of replication for propagation in E. coli, and an f1 
origin for single-stranded DNA production. A neomycin-resistance cassette (Neor) allows 
stably transfected eukaryotic cells to be selected using G418. This cassette consists of 
the SV40 early promoter (PSV40 e), the Tn5 neomycin/kanamycin resistance gene, and 
polyadenylation signals from the herpes simplex virus thymidine kinase (HSV TK) gene. 
A bacterial promoter (PKanr) upstream of the cassette confers kanamycin resistance in E. 
pmCherry-C1
4722 bp
Kanr/Neor
mCherry
HSV TK
poly A+
PCMV IE
SV40
  ori
pUC
 ori
f1 
 ori
PSV40 e
MCS
 SV40
poly A+
PKanr
  PstI 
(1360)
 PstI 
(969)
 AgeI 
 (601)
1315 TAC AAG TCC GGA CTC AGA TCT CGA GCT CAA GCT TCG AAT TCT GCA GTC
SacI
SalIXhoI
AccIBglIIBspEI EcoRIHindIII
1363 GAC GGT ACC GCG GGC CCG GGA TCC ACC GGA TCT AGA TAA CTG ATC ATA
KpnI XmaI
SacII SmaI
ApaIAsp718 BamHI BclIXbaI*
End mCherry
SalI
AccI
STOP STOP STOP
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Figure 33 eGFP-C1 vector map 
(PR29971; published 03 October 2002)
Restriction Map and Multiple Cloning Site (MCS) of pEGFP-C1. All restriction sites shown are unique. The Xba I and
Bcl I sites (*) are methylated in the DNA provided by BD Biosciences Clontech. If you wish to digest the vector with these
enzymes, you will need to transform the vector into a dam– host and make fresh DNA.
Description
pEGFP-C1 encodes a red-shifted variant of wild-type GFP (1–3) which has been optimized for
brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 488 nm;
emission maximum = 507 nm.) pEGFP-C1 encodes the GFPmut1 variant (4) which contains the
double-amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the
EGFP gene contains more than 190 silent base changes which correspond to human codon-usage
preferences (5). Sequences flanking EGFP have been converted to a Kozak consensus translation
initiation site (6) to further increase the translation efficiency in eukaryotic cells. The MCS in pEGFP-
C1 is between the EGFP coding sequences and the SV40 poly A. Genes cloned into the MCS will
be expressed as fusions to the C-terminus of EGFP if they are in the same reading frame as EGFP
and there are no intervening stop codons. SV40 polyadenylation signals downstream of the EGFP
gene direct proper processing of the 3' end of the EGFP mRNA. The vector backbone also contains
an SV40 origin for replication in mammalian cells expressing the SV40 T-antigen. A neomycin
resistance cassette (Neor), consisting of the SV40 early promoter, the neomycin/kanamycin
resistance gene of Tn5, and polyadenylation signals from the Herpes simplex virus thymidine kinase
(HSV TK) gene, allows stably transfected eukaryotic cells to be selected using G418. A bacterial
promoter upstream of this cassette expresses kanamycin resistance in E. coli. The pEGFP-C1
backbone also provides a pUC origin of replication for propagation in E. coli and an f1 origin for single-
stranded DNA production.
pEGFP-C1 Vector Information  PT3028-5
GenBank Accession #: U55763 Catalog #6084-1
pEGFP-C1
4.7 kb
Mlu I (1642)
Dra III (1872)
ApaL I 
  (4360)
Stu I
(2577)
Ase I
(8)
Nhe I (592)
    Eco47 III (597)
              Age I (601)
EcoO109 I
           (3854)
SnaB I 
  (341)
BsrG I (1323)
 MCS
  (1330–1417)
pUC
 ori 
HSV TK
poly A
f1
ori 
SV40
poly A
EGFP  
PCMV  IE
PSV40e
SV40 ori
P
  Kanr/
        Neor
TAC AAG TCC GGA CTC AGA TCT CGA GCT CAA GCT TCG AAT TCT GCA GTC GAC GGT ACC GCG GGC CCG GGA TCC ACC GGA TCT AGA TAA CTG ATC A
1340
•
1330
•
1350
•
1360
•
1370
•
1390
•
1380
•
1400
•
Hind III Xho I   Apa I
Bsp120 I
   Kpn I
Asp718 I
BamH I
EGFP
 Xba I*
  Xma I
  Sma I  Sac II
   Sal I
   Acc I  Sac IEcl136 II
EcoR I   Pst IBspE I  Bgl II
STOPs
 Bcl I*
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Figure 34 pGene vector map 
  
Appendix 
 
136 
 
 
Figure 35 pJS4 vector map 
  
Appendix 
 
137 
 
 
 
Figure 36 pLVX-Tight-Puro vector map 
  
(PR063561; published 30 June 2010)
pLVX-Tight-Puro Vector Information  PT3996-5
 Catalog Nos. 632162
 632163
pLVX-Tight-Puro Vector Map and Multiple Cloning Site (MCS).
Description
pLVX-Tight-Puro is a tetracycline (Tet)-inducible, lentiviral expression vector designed to 
express a gene of interest under the control of PTight, a modified Tet-responsive promoter. PTight 
consists of a modified minimal CMV promoter, and seven direct repeats of a 36 bp regulatory 
sequence that contains the 19 bp tet operator sequence (tetO; 1). This vector is designed to 
be used with our Lenti-XTM Tet-On® Advanced and Tet-Off® Advanced Inducible Expression 
Systems (Cat. Nos. 632162 and 632163). These systems provide the inducible gene expression 
strategy of Gossen & Bujard, with major improvements described by Urlinger, et al. (2-6), in 
a lentiviral format.
pLVX-Tight-Puro contains all of the viral processing elements necessary for the production 
of replication-incompetent lentivirus, as well as elements to improve viral titer, transgene 
expression, and overall vector function. The woodchuck hepatitis virus posttranscriptional 
regulatory element (WPRE) promotes RNA processing events and enhances nuclear export 
of viral and transgene RNA (7), leading to increased viral titers from packaging cells, and 
enhanced expression of your gene of interest in target cells. In addition, the vector includes 
a Rev-response element (RRE), which further increases viral titers by enhancing the transport 
of unspliced viral RNA out of the nucleus (8). Finally, pLVX-Tight-Puro also contains a central 
polypurine tract (cPPT) element that increases nuclear importation of the viral genome during 
target cell infection, resulting in improved vector integration and more efficient transduction (9).
pLVX-Tight-Puro
7791 bp
Ampr
5' LTR
3’ LTR
RRE
PBS

cPPT
WPRE
PPGK 
Puror
MCS
PTight
pUC Ori
  SalI
(7424)
  SalI
(5239)
 XhoI
(2204)
pLentiX TREtight PGK Puro PT5
2521 TGGAGAAGGA TCCGCGGCCG CGCCGGCTCT AGATCGCGAA CGCGTGAATT CTACCGGGTA
ACCTCTTCCT AGGCGCCGGC GCGGCCGAGA TCTAGCGCTT GCGCACTTAA GATGGCCCAT
Xba I site (*) is methylated in the DNA provided by Clontech Laboratories, Inc. If you wish to digest the vector with Xba I enzyme, 
you will need to transform the vector into a dam- host and make fresh DNA. 
BamHI MluI
EcoRINotI XbaI*
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Table 12 Peptide sequences for polyclonal antibody production 
Human GBP Peptide Sequence 
1 QDLQTKMRRRKAC  
2 QKDIWDIQMRSKSLE  
3 KTLKKKTKRYMSHKLKI  
4 QLNKEINQLKEKIEST  
5 NLFIQKTEELKAKYYRE  
6 QFKRMIDTTKNDDTPW  
7 LKEQIEAAENEEPSVF  
 
Table 13 Peptide sequences for monoclonal antibody production 
Human GBP Peptide Sequence 
2 KEGFENESKRLQKDIWDIQMRSKSLE 
4 KEEFQKKSEQLNKEINQLKEKIEST 
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Table 14 GBP antibodies produced 
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Buffer recipes 
Blotto 
5% skim milk powder (Sigma # 70166) 
0.05% Tween 20 (Sigma # P1379) 
PBS 
 
 
Perm/ Quench 
50mM NH4Cl 
0.2% Saponin  
PBS 
 
 
PGAS 
0.2% Gelatin, porcine (Sigma #G-7765) 
0.02% Saponin 
0.02% NaN3 
PBS 
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Breaking Report
Human GBP1 does not localize to pathogen vacuoles but
restricts Toxoplasma gondii
Ashleigh C. Johnston,1 Anthony Piro,2
Barbara Clough,1 Malvin Siew,1
Sebastian Virreira Winter,3 Jörn Coers2 and
Eva-Maria Frickel1*
1Host-Toxoplasma Interaction Laboratory, The Francis
Crick Institute, Mill Hill Laboratory, London NW7 1AA,
United Kingdom.
2Departments of Molecular Genetics and Microbiology
and Immunology, Duke University Medical Center,
Durham, NC 27710, USA.
3Max Planck Institute for Infection Biology, Charitéplatz
110117 Berlin, Germany.
Summary
Guanylate binding proteins (GBPs) are a family of
large interferon-inducible GTPases that are
transcriptionally upregulated upon infection with
intracellular pathogens. Murine GBPs (mGBPs)
including mGBP1 and 2 localize to and disrupt
pathogen-containing vacuoles (PVs) resulting in
the cell-autonomous clearing or innate immune
detection of PV-resident pathogens. Human GBPs
(hGBPs) are known to exert antiviral host defense
and activate the NLRP3 inflammasome, but it is
unclear whether hGBPs can directly recognize and
control intravacuolar pathogens. Here, we report
that endogenous or ectopically expressed hGBP1
fails to associate with PVs formed in human cells
by the bacterial pathogens Chlamydia trachomatis
or Salmonella typhimurium or the protozoan
pathogen Toxoplasma gondii. While we find that
hGBP1 expression has no discernible effect on
intracellular replication of C. trachomatis and S.
typhimurium, we observed enhanced early
Toxoplasma replication in CRISPR hGBP1-deleted
human epithelial cells. We thus identified a novel
role for hGBP1 in cell-autonomous immunity that is
independent of PV translocation, as observed for
mGBPs. This study highlights fundamental
differences between human and murine GBPs and
underlines the need to study the functions of GBPs
at cellular locations away from PVs.
Introduction
The cytokine Interferon gamma (IFNγ) is an important
mediator of host response against an array of intracellular
pathogens (MacMicking, 2012). Such infections include
the apicomplexan parasite Toxoplasma gondii, in which
case IFNγ drives effector mechanisms to eliminate the fast
replicating acute phase tachyzoite stage. The
intravacuolar bacteria Chlamydia trachomatis and Salmo-
nella typhimurium are likewise targeted by IFNγ-driven
host responses in the acute stages of infection, resulting in
C. trachomatis reticulate bodies forming an aberrant
non-dividing form, and in S. typhimurium clearance (Kazar
et al., 1971; Pie et al., 1997). In response to infection, IFNγ
upregulates a vast number of proteins, with a family of
large GTPases, the Guanylate Binding Proteins (GBPs),
being among the most highly induced (Cheng et al., 1983).
GBPs have been studied in vitro or in murine models and
are important in immune activation and restricting intra-
cellular pathogens, including viruses, bacteria and proto-
zoan parasites (MacMicking, 2012).
In mice, mGBPs accumulate around pathogen-
containing vacuoles (PV) of intracellular pathogens such
as Toxoplasma (Degrandi et al., 2007; Virreira Winter
et al., 2011; Haldar et al., 2013; Selleck et al., 2013), C.
trachomatis (Coers et al., 2008; Haldar et al., 2013),
Mycobacterium bovis BCG (Kim et al., 2011) and S.
typhimurium (Meunier et al., 2014). At PVs mGBPs act
cooperatively to assemble host defense responses that
include an oxidative burst, the delivery of antimicrobial
peptides and the induction of autophagy (Kim et al., 2011).
Additionally, mGBPs promote the disintegration of
Salmonella-containing vacuoles thereby exposing
bacteria to the cytosol where they can activate the
cytosolic LPS sensor caspase-11 (Meunier et al., 2014).
Rapid activation of caspase-11 in response to infections
with Legionella pneumophila or Chlamydia muridarum
requires additional lysis-independent function of mGBPs
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that are poorly characterized (Pilla et al., 2014; Finethy
et al., 2015). In addition to their association with PVs
mGBPs also co-localize with the cytosolic bacterial
pathogens Listeria monocytogenes and Francisella
novicida (Kim et al., 2011; Man et al., 2015; Meunier
et al., 2015). The association of mGBPs with F. novicida
prompts bacteriolysis and the activation of the cytosolic
DNA sensor AIM2 (Man et al., 2015; Meunier et al., 2015).
Human GBPs are much less well understood, and their
functional significance remains largely unknown. hGBP5
promotes NLRP3 inflammasome assembly and conse-
quently IL-1β production in response to LPS and nigericin
(Shenoy et al., 2012). hGBP1 can mediate the inhibition of
endothelial cell proliferation (Guenzi et al., 2001) and has
been shown to exhibit anti-viral properties. When hGBP1
expression is silenced using small hairpin RNAs, Dengue
virus burden increases (Pan et al., 2012). hGBP1 also
mediates an antiviral effect against vesicular stomatitis
v i rus and encepha lomyocard i t i s v i rus when
overexpressed in HeLa cells (Anderson et al., 1999).
While these studies indicate that human GBPs have
relevance during pathogenic infection, we do not under-
stand which microbes they target and how the endoge-
nous proteins act.
The structure and biochemical properties of GBPs have
been studied in detail, with the structure of hGBP1
revealing a globular GTPase domain connected to an
arm-like extension, and revealing the very fast GTP
hydrolysis rate of 95min!1 (Prakash et al., 2000). Some
hGBPs also have the ability to perform two consecutive
hydrolysis steps from GTP to GMP (Schwemmle and
Staeheli, 1994). hGBP 1, 2 and 5 contain a ‘CaaX’
prenylation motif at their C-terminus, implying a capacity to
target membranes.
In agreement with their biophysical properties and
observations made for mGBPs, hGBPs have been
postulated to recognize PVs formed by type II Toxoplasma
vacuoles as well as C. trachomatis PVs, also known as
inclusions (Tietzel et al., 2009; Al-Zeer et al., 2013;
Ohshima et al., 2014). It has been reported that
interference with hGBP1 and 2 expression in IFNγ-
primed cells led to increased C. trachomatis inclusions
size, indicating better growth of the bacteria in absence of
these proteins (Tietzel et al., 2009). Many of these studies
have relied on heterologously expressed proteins or an
antibody recognizing several GBP family members. A
recent study on Toxoplasma postulates no effect on
parasite restriction by hGBPs (Ohshima et al., 2014). It
thus remains unclear which, if any, hGBPs target
Toxoplasma PVs, and whether endogenous hGBPs can
target and restrict C. trachomatis.
Here, we demonstrate that hGBP1, in contrast to its
closest murine orthologues mGBP1 and 2 fails to
recognize PV formed by C. trachomatis, S. typhimurium
or Toxoplasma in human epithelial cells. Our data indicate
that hGBP1 is not essential for the execution of cell-
autonomous control of the replication of these pathogens
in unprimed and IFNγ-primed human epithelial cells.
However, in a similar manner to mGBPs, hGBP1 is able
to restrict Toxoplasma early after host cell infection. This
restriction cannot be attributed to an invasion mechanism,
but rather hGBP1 is responsible for delaying the onset of
parasite replication. GBPs have only been reported to play
a role in cell-autonomous control of infections if they
accumulated around the pathogen-containing vacuole.
Here we show that this is not the case for hGBP1. We thus
define a novel role for hGBP1 with its capacity to restrict
Toxoplasma in early infection without targeting to the PV.
Results
hGBP1 does not localize to intracellular pathogen
vacuoles in epithelial cells
Several mGBPs recruit to PVs in an IFNγ-dependent
manner, disrupt PV integrity and facilitate pathogen
destruction. We explored whether hGBP1 was able to
target intracellular vacuoles formed by the bacterial
pathogens C. trachomatis and S. typhimurium or the
parasite Toxoplasma. Human GBP1 is the closest
orthologue of mGBP2 previously shown to associate with
vacuolar C. trachomatis, S. typhimurium and Toxoplasma
in murine fibroblasts, epithelial cells, macrophages and
spleen tissue (Degrandi et al., 2007; Tietzel et al., 2009;
Virreira Winter et al., 2011; Al-Zeer et al., 2013; Haldar
et al., 2013; Selleck et al., 2013; Meunier et al., 2014). To
this end, we produced a specific peptide antibody that
could distinguish hGBP1 from all other hGBPs by
immunoblot, and additionally a pan-hGBP antibody that
recognized hGBPs 1, 2, 3 and 5 (Fig. S1A). While we
could not overexpress hGBP4, this family member is least
identical to hGBP1 so we are confident the antibody will
not cross react. We show that A549 cells express GBPs
including hGBP1 at steady state level and further
upregulate the protein in response to IFNγ (Fig. S1B).
To further characterize this newly generated anti-
hGBP1 antibody, we employed CRISPR/Cas9 technology
to generate a lung epithelial A549-derived cell line
lacking hGBP1 expression. A region 5′ to the GTPase
domain of Gbp1 was targeted for disruption, and deletion
was confirmed by sequencing and immunoblot (Fig. S1C
and D). The cells were further analysed by the pan-hGBP
antibody, demonstrating that other hGBPs are still intact
with normal protein expression (Fig. S1D). Using anti-
hGBP1 for immunofluorescence staining we found that
both naïve and IFNγ-primed and ΔhGBP1 cells exhibited
low background immunofluorescence intensity. In con-
trast, parental A549 cells showed a robust increase in the
anti-hGBP1 immunofluorescence signal when primed with
hGBP1 restricts Toxoplasma away from the vacuole 1057
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IFNγ (Fig. S1E), demonstrating that anti-hGBP1 specifi-
cally detects endogenous hGBP1 in situ.
Having confirmed the specificity of theanti-hGBP1antibody
we asked whether hGBP1 associated with PVs. To do so, we
infected IFNγ-primed A549 cells with three representative
vacuolar pathogens. Immunofluorescent microscopy showed
that hGBP1 does not recruit around the PVs formed by C.
trachomatis (Fig. 1A),S. typhimurium (Fig. 1B) orToxoplasma
(Fig. 1C). This lack of recruitment was observed at all time
points tested (data not shown) and not affected by the
absence of presence of IFNγ priming (Fig. S2A to C).
In order to associate with membranes hGBPs first
transition into an active GTP-bound state and following
hydrolysis hGBPs in the GDP-bound state form tetramers
that can attach to membranes (Syguda et al., 2012). We
therefore considered that the anti-hGBP1 antibody failed
to detect hGBP1 in the active, membrane-associated
state. To test for this, we ectopically expressed hGBP1
N-terminally fused to mCherry. We observed that mCherry-
hGBP1 heterologously expressed in mouse embryonic
fibroblast (MEFs) localized to Toxoplasma PVs (Fig S3A).
Staining with anti-hGBP1 overlapped with the mCherry-
hGBP1 signal showing that anti-hGBP1 can detect hGBP1
in its active, membrane-associated state and indicating that
hGBP1 fails to associate with PVs in human A549 cells. We
stained IFNγ induced MEFs with anti-hGBP1 to ensure our
antibody did not overlap with mGBPs at the PV (Fig S3B).
Last, we expressed mCherry-hGBP1 in A549 cells and
failed to observe any association of mCherry-hGBP1
Toxoplasma PVs (data not shown), further corroborating
our finding that in striking contrast to mGBP1 and 2, hGBP1
is not recruited to intact vacuolarmembranes of intracellular
pathogens in infected human cells.
hGBP1 restricts Toxoplasma, but not the intravacuolar
bacterial pathogens C. trachomatis and S. typhimurium
As the subcellular location of hGBP1 was not consistent
with observations made with mGBPs and the roles they
play during intracellular pathogen infection, we were
interested to determine whether hGBP1 could still play a
role in controlling these particular infections. We assessed
the ability of the pathogens to replicate in the absence of
hGBP1 in comparison to their wild-type cells. For C.
trachomatis and S. typhimurium infections, inclusion
forming unit (IFU) or colony forming unit (CFU) assays
were employed, respectively, in the presence or absence
of IFNγ. Priming cells with IFNγ restricted the replication
and growth of both C. trachomatis and S. typhimurium
Fig. 1. hGBP1 does not localize to the intracellular pathogen vacuole.
A. Immunofluorescent confocal image of C. trachomatis vacuoles 20hpi in mCherry-hGBP1 expressing A549 cells primed with 200 U/ml IFNγ. N = 2.
B. Immunofluorescent confocal image of S. typhimurium vacuoles 4hpi in A549 cells primed with 50 U/ml IFNγ stained for endogenous hGBP1. N = 3.
C. Immunofluorescent confocal image of Toxoplasma vacuoles in A549 cells primedwith 10 U/ml IFNγ at the indicated time points post infection.N = 3.
All scale bars 10 μm.
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(Fig. 2A and B). However, the ability of bacteria to sustain
themselves via replication in the presence or absence of
immune pressure was the same regardless of the
presence of hGBP1 (Fig. 2A and B). We then determined
whether Toxoplasma replication was influenced by the
absence of hGBP1. We compared the capacity of the
parasite to replicate and form plaques in fibroblasts after
an initial infection in A549 cells primed or not with IFNγ.
Type I or type II Toxoplasma were incubated in A549 cells
for 6 h, a time period too short for replication to occur,
meaning potential differences in plaque number would be
a result of parasite killing or early restriction. Twice as
many type II Toxoplasma were able to survive when the
infection took place in ∆hGBP1 cells, while type I parasites
remained unaffected (Fig. 2C). Intriguingly, this was still
true in cells that were not primed with IFNγ. An
immunoblot confirmed the presence of hGBP1 even at
basal steady state level (Fig. S1B). In accordance, the
number of viable Toxoplasma parasites was largely
reduced to levels seen in parental A549 cells when
∆hGBP1 A549 cells were complemented with hGBP1
(Fig. 2C). Thus hGBP1 does not restrict replication of the
bacterial pathogens C. trachomatis and S. typhimurium,
but does promote restriction of type II Toxoplasma.
hGBP1 mediates early replication of Toxoplasma infection
As we determined that Toxoplasma underwent early
restriction by hGBP1, our next move was to identify the
stage at which parasites were limited. We excluded
differential invasion as a reason for the enhanced recovery
of parasites from ∆hGBP1 cells. FACS analysis of A549
cells infected with fluorescent parasites showed that
regardless of genotype of the cell, type II parasites invaded
around 50% of A549 cells when an MOI of 4 was used
(Fig. 3A). Immunofluorescence microscopy was used to
ensure that individual cells of each genotype were infected
with low and equivalent numbers of parasites (Fig. 3B). We
used immunofluorescence microscopy to assess the early
replication status of Toxoplasma in A549 cells. At 24 h post
infection (hpi) it was evident that ∆hGBP1 cells contained
more vacuoles filled with 2 or more parasites than co-
isogenic wildtype cells did (Fig. 3C). By counting the
number of parasites per vacuole over an infection time
course, we quantified the replication efficiency of Toxo-
plasma (Fig. 3D). At 12hpi significantly more vacuoles
contained parasites that had replicated once in the
∆hGBP1 cells as compared to the wild-type counterpart,
regardless of IFNγ priming. By 18hpi, numbers of vacuoles
6h 
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Fig. 2. hGBP1 restricts growth of Toxoplasma gondii but not C. trachomatis or S. typhimurium
A. C. trachomatis IFUassayscarriedout inA549cells primedor notwith 200U/ml IFNγ, 40hpi.N = 2.Error bars represent standard error of themean (STEM).
B.S. typhimuriumCFUassays carried out in A549 cells primed or notwith 50 U/ml IFNγ, 6 and 25hpi.N = 3. Significancewas analysed by 2wayANOVA.
C. Plaqueassaysshowingviability ofToxoplasma incubated for6 h inWT,∆hGBP1,∆hGBP1+ hGBP1or∆hGBP1+ cherryA549cellsprimedornotwith10U/
ml IFNγ before seeding onto HFF. Counts were taken 4 days after HFF infection.N=5, ComplementationN= 3. Significance was analysed by 2way ANOVA.
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containing 2 or 4 parasites, indicating 1 or 2 replication
cycles, respectively, were significantly increased in the
IFNγ primed ∆hGBP1 (Fig. 3D). Finally, counts taken at
24 h show a significantly increased number of vacuoles that
hold parasites that have undertaken 3 or more replication
cycles in the IFNγ primed ∆hGBP1 A549 cells.
Our observations suggest that hGBP1 can delay the
onset of parasite replication. We concluded that type II
Toxoplasma is restricted early after invasion in A549 cells
by a yet unknown mechanism driven by hGBP1 without
the protein targeting to the vacuole.
Discussion
We find that hGBP1 mediates an initial attenuation of type
II Toxoplasma early post-infection, without impacting
subsequent replication of Toxoplasma, C. trachomatis or
S. typhimurium in human epithelial cells. The observed
early Toxoplasma attenuation is not because of a defect in
parasite invasion in the presence versus absence of
hGBP1. Rather, we hypothesize that hGBP1 either
mediates early killing or slows down early replication of
the parasite, as at 12, 18 and 24hpi the ∆hGBP1 cells
Fig. 3. hGBP1 mediates early replication of Toxoplasma gondii.
A. FACS analysis determined the number of A549 cells that had been invaded by Toxoplasma 1hpi. Cells had been primed or not with 10 U/ml IFNγ.
Representative of 3 independent experiments.
B. Immunofluorescence confocal images taken at 1hpi show the same numbers of parasites enter individual cells.
C. Immunofluorescence confocal images of A549 cells primed or not with 10 U/ml IFNγ.
D. Replicating parasites were determined by counting the number of parasites within vacuoles at specified times post infection. N = 2. Significance
was analysed using 2way ANOVA.
All scale bars 10 μm.
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contain significantly more parasites that have undergone
replication. To our knowledge this is the first report
demonstrating that an IFN-inducible GTPase can restrict
growth of an intracellular PV-resident pathogen indepen-
dently of any detectable association of the GTPase with
the PV itself.
Cell-autonomous restriction pathways for intracellular
pathogens driven by host resistance proteins often see the
protein localize to PVs. For example, ubiquitin-driven
autophagy and galectin-mediated control of Salmonella
relies on a pathogen-localization step of ubiquitin and
galectin (Perrin et al., 2004; Thurston et al., 2012).
Additionally in mouse, Immunity Related GTPases (IRGs)
and GBPs mediate cell-autonomous killing by directly
localizing and disrupting PVs (Martens et al., 2005; Ling
et al., 2006). We clearly define that endogenous hGBP1 is
not targeted to C. trachomatis, S. typhimurium or
Toxoplasma. We do, however, show that hGBP1
possesses the ability to recruit to Toxoplasma PVs when
heterologously expressed in mouse fibroblasts (Fig. S3A).
These results suggest that human cells lack a cellular
pathway for the delivery of GBPs to PVs that is present in
mouse cells. In support of this model, we recently
demonstrated that the translocation of mGBP1 and
mGBP2 to PVs in mouse cells requires GKS proteins, a
subset of IRG protein found in mouse but not in human
cells (Haldar et al., 2015). Therefore, it appears likely that
the deficiency of hGBP1 recruitment to PVs in human cells
is due in part to the absence of GKS encoding genes from
the human genome.
Conflicting reports attributed hGBPs to have a function
in intracellular C. trachomatis, but not Toxoplasma control
in non-hematopoietic cells (Tietzel et al., 2009; Ohshima
et al., 2014). Both reports find hGBPs localized to PVs
24hpi. Reduction of bacterial inclusions upon ectopic
expression of hGBP1 and 2 was observed in HeLa cells.
Curiously the demonstrated localization of hGBP1 is
observed for wild type, GTPase-deficient and helical-
domain-only protein. We, and others, have previously
shown that GTPase-activity deficient mouse GBP1 does
not recruit to PVs (Kim et al., 2011; Virreira Winter et al.,
2011). It is conceivable that detecting overexpressed
hGBP1 with antibody staining presents with different
results than detection of endogenous hGBP1. Equally,
overexpressed hGBP1 might exert a different effect than
endogenous hGBP1 and HeLa cells may present with a
different restriction pathway than other epithelial cells.
Ohshima et al. successfully knocked out the entire GBP
locus in haploid fibroblast-like human cancer cells, with
the resulting cells showing no defect in IFNγ-induced cell-
autonomous control of Toxoplasma at 24hpi. The early
restriction of the parasite by hGBP1 we observe may have
been missed or may not exist in fibroblasts. They also
demonstrate that a low percentage of Toxoplasma PVs
were decorated with hGBPs at 6hpi. The staining was
carried out using an antibody against hGBP1-5, so it is
conceivable that the protein present at that location
comprises another family member(s). In contrast to our
findings, hGBP1 has been shown to localize to the
bacterial inclusion in THP1 macrophages and restrict C.
trachomatis as demonstrated by shRNA knockdown
(Al-Zeer et al., 2013). It remains to be investigated if
human GBPs can localize to PVs of other pathogens in
macrophages. Combined with our results, this leads us to
speculate that hGBP1 may restrict select pathogens in a
cell type- and localization-dependent manner.
hGBPs are highly upregulated in all stages of infection
with intracellular pathogens and are often found in
transcriptional analysis of patient samples. Combined
with knowledge acquired from murine studies, it is almost
certain that hGBPs have an impact on the control of these
infections. We find that hGBP1 plays a role in mediating
early restriction of Toxoplasma soon after infection without
directly localizing to the pathogen. Previous definitions of
how this host restriction factor family is acting against
vacuolar intracellular pathogens were reliant on the
protein being present at the vacuole. Clearly, we have to
rethink this rather simplistic assessment as a proxy for
potential functions especially for the human GBPs. Early
restriction of pathogens directly after invasion is the first
step a cell takes to combat the invading foreign agent.
These early restriction mechanisms have to act in a rapid
and precise manner in order to start the cascade of
intracellular defense mechanisms. Because hGBP1 is
expressed at steady state level and we observe its
defense activity even in absense of interferon priming, it
most likely interacts with and directs specific cellular
machineries that do not require induction. Future work will
elucidate the mechanism by which hGBP1 can mediate
early restriction of Toxoplasma.
Experimental procedures
Cell culture
A549 lung epithelial cells were grown in DMEM with glutamine
(Life Technologies) supplemented with 10% FBS and cultured at
37 °C in 5% CO2. Where appropriate, cells were stimulated
overnight by addition of human IFNγ (R&D Systems) to growth
media. Human foreskin fibroblasts (HFF) were maintained in
DMEM with glutamine supplemented with 1% FBS and cultured at
37 °C in 5% CO2.
Bacteria culture and infection
C. trachomatis serovar L2 434/Bu containing a GFP expression
vector (Wang et al., 2011) was propagated in Vero cells.
Elementary Bodies (EBs) were purified by sequential density
gradients (Saka et al., 2011), and MOI was determined for purified
EBs through infection of confluent Vero cells. For infections,
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purified EBs were diluted in cell culture medium (DMEM+FBS),
and then added to tissue culture dishes containing cells. Infection
was facilitated by spinning for 30min at 1560 ×g at 10 °C.
Finally, infection was allowed to continue to the desired time
point at 37 °C and 5% CO2. S. typhimurium WT strain 22023S
(received from David Holden) was cultured in Luria-Bertani (LB)
broth and grown overnight at 37 °C in a shaking incubator. To
allow invasive properties of S. typhimurium, a further culture was
produced in anaerobic conditions, gently shaking for 2 h before
infection. An optical density reader was used to measure the
absorbance at 600 nm wavelength (OD600). The multiplicity of
infection (MOI) was calculated using 1.0164/OD600 = μl contain-
ing 1 × 106 bacteria and the bacteria were spun at 1000 rpm for
5min to synchronously infect cells. At 1hpi, cells were washed
with PBS and new DMEM medium was added containing
100 μg/ml gentamycin and 10mM HEPES. At 2hpi cells were
washed twice and 10 μg/ml gentamycin was added into new
DMEM medium.
Parasite culture and infection
Toxoplasma expressing luciferase/eGFP or tdTomato (RH type I
or Prugniaud type II) were maintained in vitro by serial passage
on monolayers of HFF cells. For infection, Toxoplasma were
syringe lysed from HFF cultures and added to cell cultures at an
MOI 2 for type I parasites, and MOI 5 for type II parasites. The
cultures were centrifuged at 1000 rpm for 5min to synchronize
infection, before being maintained at 37 °C in 5% CO2. Where
appropriate, parasites were irradiated in HFF cells with
15 000rads.
Antibodies
A unique sequence for hGBP1 was selected (QDLQTKMRRRKAC)
and the peptide conjugated to keyhole limpet haemocynin was
ordered from BioMatik Corporation, Canada. Rabbits were inocu-
lated with these peptides, and final bleeds taken after 11weeks
(APS, Cambridge).
Fixed immunofluorescent microscopy
For Toxoplasma and S. typhimurium infections, A549 cells were
plated on coverslips (Thermo Fisher) and cultured and infected as
above. The cells were fixed in 3% paraformaldehyde (PFA) and
permeabilized in Perm Quench (see Supporting Information)
before incubating sequentially with primary and secondary
antibodies diluted in PGAS (see Supporting Information) for 1 h
at room temperature. Coverslips with cells were washed in PBS,
with the final wash containing 1 μg/ml Hoechst. Coverslips were
mounted on glass slideswithMowiol 4-88. Slides were viewed on a
Zeiss Axioplan II Epifluorescence microscope or on an SP5-
inverted Confocal microscope and analysed using LAS-AF software.
Imageswere further formatted using ImageJ software. ForChlamydial
microscopy, A549 and MEF cells ectopically overexpressing
mCherry-hGBP1 were infected, as above. At 20hpi, cells were fixed
with 4% PFA, before being stained with Hoechst in PBS+300mM
Glycine. After thorough washing in PBS, slides were mounted with
Mowiol containing 0.01% p-phenylenediamine (PPD). Slides were
visualized using a Zeiss 510 Inverted Confocal Microscope, and
analysed using Zen Blue software.
Pathogen viability assays
An IFU assay was used to assess C. trachomatis replication. WT
and hGBP1-deficient A549 cells were plated to confluence in 12-
well plates and stimulated for approximately 16 h with 200U/ml
human IFNγ. Cells were infected with C. trachomatis, as above, at
an MOI of 1. At 40hpi, bacteria were harvested by lysing cells in
water for 10min at 37 °C with frequent mixing, and 5X sucrose-
phosphate-glutamic acid buffer (SPG) was added to a final
concentration of 1X. Bacteria-containing lysates were then added
to cell culture medium (DMEM+10% FBS), and 10-fold serial
dilutions were performed. These dilutions were used to infect
confluent Vero cells in black-walled 96-well plates, as above. At
24hpi, infected Vero cells were fixed and permeabilized for 5min
on ice with ice-cold Methanol, and blocked with 2% BSA in PBS.
Wells were stained with a mouse monoclonal anti-Chlamydia LPS
antibody, followed by goat anti-mouse IgG AlexaFluor 488 and
Hoechst. For each well, 10 images were taken on a Zeiss
Obzerver.Z1 scope using a 20X objective, and the number of
Chlamydia inclusions/field was enumerated and averaged across
the 10 images. The number of infectious units/well of A549 cells
was calculated, taking into account the well area represented by
each field and accounting for dilution. For each condition,
infections were performed in triplicate (3 wells of A549 cells) for
a single experiment. S. typhimurium CFU assays were performed
by infecting cells for desired period of time before washing twice
with ice-cold PBS and lysing with 0.5% Sodium deoxycholate
(NaDOC) (Sigma-Aldrich) in PBS. Each sample was mechanically
scraped and pipetted up and down. The lysates were diluted
appropriately in LB and spread on a pre-warmed 10 cm2 agar
plate, incubated overnight at 37 °C followed by colony counting.
Parasite viability was assessed by indirect plaque assay. A549
cells were infected with 300 type I parasites or 600 type II
parasites in 24 well plates for the desired length of time before
scraping and syringe lysing the cell layer to release the
Toxoplasma. This suspension was then plated onto confluent
HFF in a 24 well plate in serial dilutions of 1:2. This infection was
allowed to persist at 37 °C at 5% CO2 for 4 days, after which
plaques were counted using a microscope.
Parasite invasion assay using Flow cytometry
A549 cells were infected with irradiated type II Pru parasites for
1 h before washing twice in PBS. Cells were lifted with 2X Trypsin,
before quenching in DMEM. The cell pellet was washed twice in
PBA (see Supporting Information) before fixing with 4% PFA for
20min on ice. PBA was added to quench reaction before
suspension was centrifuged at 1500 rpm for 3min at 4 °C, after
which cell pellet was resuspended in PBA and analysed on a BD
LSR-II. Results were analysed using FlowJo software.
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Overexpression of mCherry-hGBP1
The mCherry or mCherry-hGBP1 plasmids were transfected into
A549 ∆hGBP1 or SV40 T-antigen immortalized Mouse Embryonic
Fibroblasts using lipid transfection.
CRISPR/Cas9 mediated deletion of Gbp1
The guide RNA sequence hGBP1 guide1, 5′ cattacacagcctatggtgg
3′ to human Gbp1 was selected using the optimized CRISPR
design site crispr.mit.edu. Oligonucleotides were synthesized
(Sigma-Aldrich) and annealed and cloned into the CRISPR vector
p48139 containing a puromycin selection cassette (Ran et al.
2013. pSpCas9 (BB)-2A-Puro (pX459)was a gift fromFengZhang.
Addgene plasmid no 48139), using the BbsI restriction site,
according to the Addgene CRISPR Genome Engineering Toolbox
(Zhang Lab) www.addgene.org/crispr/zhang/. Transfection of
A549 cells with hGBP1 guide RNA-containing p48139 plasmid
was performed using FuGENE6 reagent (Promega) according to
themanufacturer’s instructions. Selection using 2 μg/ml puromycin
was commenced 30–36 h post transfection and continued for 48 h.
The puromycin was then removed and the cells allowed to recover
before selecting individual clones. To confirm disruption of hGBP1,
clones were cultured and either lysed with cell lysis buffer
containing 1% Triton X100 (Sigma) for SDS-PAGE and immuno-
blotting with hGBP1-specific antibody or lysed with DNAreleasy
(Anachem Ltd) for subsequent DNA sequence analysis.
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